ATE517992T1 - Funktionelle und hyperfunktionelle sirna - Google Patents

Funktionelle und hyperfunktionelle sirna

Info

Publication number
ATE517992T1
ATE517992T1 AT03786798T AT03786798T ATE517992T1 AT E517992 T1 ATE517992 T1 AT E517992T1 AT 03786798 T AT03786798 T AT 03786798T AT 03786798 T AT03786798 T AT 03786798T AT E517992 T1 ATE517992 T1 AT E517992T1
Authority
AT
Austria
Prior art keywords
functional
hyperfunctional sirna
gene silencing
silencing
sirna
Prior art date
Application number
AT03786798T
Other languages
English (en)
Inventor
Anastasia Khvorova
Angela Reynolds
Devin Leake
William Marshall
Stephen Scaringe
Original Assignee
Dharmacon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dharmacon Inc filed Critical Dharmacon Inc
Application granted granted Critical
Publication of ATE517992T1 publication Critical patent/ATE517992T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/12—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of one atom of oxygen (internal monooxygenases or internal mixed function oxidases)(1.13.12)
    • C12Y113/12007—Photinus-luciferin 4-monooxygenase (ATP-hydrolysing) (1.13.12.7), i.e. firefly-luciferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1048—SELEX
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y502/00—Cis-trans-isomerases (5.2)
    • C12Y502/01—Cis-trans-Isomerases (5.2.1)
    • C12Y502/01008—Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
AT03786798T 2002-11-14 2003-11-14 Funktionelle und hyperfunktionelle sirna ATE517992T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42613702P 2002-11-14 2002-11-14
US50205003P 2003-09-10 2003-09-10
PCT/US2003/036787 WO2004045543A2 (en) 2002-11-14 2003-11-14 Functional and hyperfunctional sirna

Publications (1)

Publication Number Publication Date
ATE517992T1 true ATE517992T1 (de) 2011-08-15

Family

ID=32329096

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03786798T ATE517992T1 (de) 2002-11-14 2003-11-14 Funktionelle und hyperfunktionelle sirna

Country Status (9)

Country Link
US (52) US8090542B2 (de)
EP (7) EP2314691A3 (de)
JP (2) JP2006507841A (de)
AT (1) ATE517992T1 (de)
AU (1) AU2003295600A1 (de)
DK (1) DK2284266T3 (de)
ES (1) ES2440284T3 (de)
PT (1) PT2284266E (de)
WO (1) WO2004045543A2 (de)

Families Citing this family (1479)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050053976A1 (en) * 1996-06-06 2005-03-10 Baker Brenda F. Chimeric oligomeric compounds and their use in gene modulation
US20080119427A1 (en) * 1996-06-06 2008-05-22 Isis Pharmaceuticals, Inc. Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US6841539B1 (en) * 1998-05-21 2005-01-11 Isis Pharmaceuticals, Inc. Compositions and methods for topical delivery of oligonucleotides
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US7098192B2 (en) * 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
US20040157327A1 (en) * 1999-10-22 2004-08-12 Wyeth Pablo, a polypeptide that interacts with BCL-XL, and uses related thereto
DE10100586C1 (de) 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
ATE450621T2 (de) 2000-03-30 2009-12-15 Whitehead Biomedical Inst Mediatoren von rns-interferenz, die rns- sequenzspezifisch sind
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
KR100872437B1 (ko) 2000-12-01 2008-12-05 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
US7423142B2 (en) 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US7767802B2 (en) * 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
EP1390383B1 (de) * 2001-05-11 2012-02-29 Isis Pharmaceuticals, Inc. Antisense-permeationsverstärker
US20050164968A1 (en) * 2001-05-18 2005-07-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of ADAM33 gene expression using short interfering nucleic acid (siNA)
US20070173473A1 (en) * 2001-05-18 2007-07-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of proprotein convertase subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA)
US20050196767A1 (en) * 2001-05-18 2005-09-08 Sirna Therapeutics, Inc. RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA)
WO2008030239A1 (en) * 2006-09-05 2008-03-13 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF HISTONE DEACETYLASE (HDAC) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20050119212A1 (en) * 2001-05-18 2005-06-02 Sirna Therapeutics, Inc. RNA interference mediated inhibition of FAS and FASL gene expression using short interfering nucleic acid (siNA)
US20050019915A1 (en) * 2001-06-21 2005-01-27 Bennett C. Frank Antisense modulation of superoxide dismutase 1, soluble expression
US20030144221A1 (en) * 2001-07-17 2003-07-31 Isis Pharmaceuticals Inc. Antisense modulation of BCL2-associated X protein expression
US7425545B2 (en) * 2001-07-25 2008-09-16 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression
US20050043256A1 (en) * 2001-07-30 2005-02-24 Isis Pharmaceuticals, Inc. Antisense modulation of stearoyl-CoA desaturase expression
US7442781B2 (en) * 2001-08-16 2008-10-28 Urifer Ltd. Diagnosis, prevention and treatment of cancer
DE10154163A1 (de) 2001-11-03 2003-05-22 Advanced Med Tech Vorrichtung zum Aufrichten und Stabilisieren der Wirbelsäule
WO2003064621A2 (en) * 2002-02-01 2003-08-07 Ambion, Inc. HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
EP3415625A1 (de) 2002-02-01 2018-12-19 Life Technologies Corporation Doppelsträngige oligonukleotide
US7405292B2 (en) * 2002-02-19 2008-07-29 The Children's Hospital Of Philadelphia Cellular genes regulated by HIV-1 infection and methods of use thereof
US8067575B2 (en) * 2002-02-20 2011-11-29 Merck, Sharp & Dohme Corp. RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
US7662952B2 (en) * 2002-02-20 2010-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acid (siNA)
JP5578388B2 (ja) * 2002-04-18 2014-08-27 オプコ ファーマシューティカルズ、エルエルシー 中枢神経システム及び／若しくは眼の細胞及び組織中の遺伝子の特異的阻害のための手段と方法
US7199107B2 (en) 2002-05-23 2007-04-03 Isis Pharmaceuticals, Inc. Antisense modulation of kinesin-like 1 expression
US20040248094A1 (en) * 2002-06-12 2004-12-09 Ford Lance P. Methods and compositions relating to labeled RNA molecules that reduce gene expression
US7582058B1 (en) * 2002-06-26 2009-09-01 Nuvasive, Inc. Surgical access system and related methods
US6793678B2 (en) 2002-06-27 2004-09-21 Depuy Acromed, Inc. Prosthetic intervertebral motion disc having dampening
WO2004008949A2 (en) 2002-07-19 2004-01-29 Triage Medical, Inc. Method and apparatus for spinal fixation
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
EP1532248B1 (de) * 2002-07-26 2009-04-01 Novartis Vaccines and Diagnostics, Inc. Modifizierte kleine irns moleküle und methoden zu deren anwendung
US20080274989A1 (en) 2002-08-05 2008-11-06 University Of Iowa Research Foundation Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
WO2004014933A1 (en) 2002-08-07 2004-02-19 University Of Massachusetts Compositions for rna interference and methods of use thereof
US20040029275A1 (en) * 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
KR101117673B1 (ko) * 2002-08-21 2012-03-07 더 유니버시티 오브 브리티쉬 콜롬비아 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브
EP2277551B1 (de) 2002-09-06 2013-05-08 Cerulean Pharma Inc. Polymere auf basis von cyclodextrin zur verabreichung von an diese kovalent gebundene arzneimittel
AU2003278957A1 (en) 2002-09-26 2004-04-23 Amgen, Inc. Modulation of forkhead box o1a expression
US20060160759A1 (en) * 2002-09-28 2006-07-20 Jianzhu Chen Influenza therapeutic
US20050259483A1 (en) * 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Genes and polypeptides relating to prostate cancers
US7892793B2 (en) 2002-11-04 2011-02-22 University Of Massachusetts Allele-specific RNA interference
US9827263B2 (en) 2002-11-05 2017-11-28 Ionis Pharmaceuticals, Inc. 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations
US20060009410A1 (en) * 2002-11-13 2006-01-12 Crooke Rosanne M Effects of apolipoprotein B inhibition on gene expression profiles in animals
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US7405289B2 (en) * 2002-11-13 2008-07-29 Metabolex, Inc. Pancreatic islet transcription factor and uses thereof
US9719092B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting CNTD2
US7781575B2 (en) 2002-11-14 2010-08-24 Dharmacon, Inc. siRNA targeting tumor protein 53 (p53)
US20100113307A1 (en) * 2002-11-14 2010-05-06 Dharmacon, Inc. siRNA targeting vascular endothelial growth factor (VEGF)
JP2006507841A (ja) * 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ
US7691998B2 (en) * 2002-11-14 2010-04-06 Dharmacon, Inc. siRNA targeting nucleoporin 62kDa (Nup62)
US9839649B2 (en) 2002-11-14 2017-12-12 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7619081B2 (en) * 2002-11-14 2009-11-17 Dharmacon, Inc. siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)
US7977471B2 (en) * 2002-11-14 2011-07-12 Dharmacon, Inc. siRNA targeting TNFα
US9771586B2 (en) 2002-11-14 2017-09-26 Thermo Fisher Scientific Inc. RNAi targeting ZNF205
US20080268457A1 (en) * 2002-11-14 2008-10-30 Dharmacon, Inc. siRNA targeting forkhead box P3 (FOXP3)
US7951935B2 (en) 2002-11-14 2011-05-31 Dharmacon, Inc. siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
US8198427B1 (en) 2002-11-14 2012-06-12 Dharmacon, Inc. SiRNA targeting catenin, beta-1 (CTNNB1)
US10011836B2 (en) 2002-11-14 2018-07-03 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9719094B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting SEC61G
US7635770B2 (en) * 2002-11-14 2009-12-22 Dharmacon, Inc. siRNA targeting protein kinase N-3 (PKN-3)
US7592442B2 (en) * 2002-11-14 2009-09-22 Dharmacon, Inc. siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US7612196B2 (en) 2002-11-14 2009-11-03 Dharmacon, Inc. siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
US9879266B2 (en) 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US20090227780A1 (en) * 2002-11-14 2009-09-10 Dharmacon, Inc. siRNA targeting connexin 43
CN101914532A (zh) * 2002-11-22 2010-12-15 生物智囊团株式会社 Rna干扰的目标碱基序列的搜索方法
US7829694B2 (en) 2002-11-26 2010-11-09 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US20060257851A1 (en) * 2002-11-26 2006-11-16 Itzhak Bentwich Bioinformatically detectable group of novel viral regulatory genes and uses thereof
US7605249B2 (en) 2002-11-26 2009-10-20 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US7618948B2 (en) * 2002-11-26 2009-11-17 Medtronic, Inc. Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
JP3792655B2 (ja) * 2003-01-20 2006-07-05 日本電気株式会社 新規な癌遺伝子、該癌遺伝子由来の組換えタンパク質、およびそれらの用途
US7994149B2 (en) 2003-02-03 2011-08-09 Medtronic, Inc. Method for treatment of Huntington's disease through intracranial delivery of sirna
US7732591B2 (en) * 2003-11-25 2010-06-08 Medtronic, Inc. Compositions, devices and methods for treatment of huntington's disease through intracranial delivery of sirna
WO2004071453A2 (en) 2003-02-13 2004-08-26 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of pouchitis
WO2004076664A2 (en) * 2003-02-21 2004-09-10 University Of South Florida Vectors for regulating gene expression
WO2004078940A2 (en) * 2003-03-05 2004-09-16 Senesco Technologies, Inc. USE OF ANTISENSE OLIGONUCLEOTIDES OR siRNA TO SUPPRESS EXPRESSION OF eIF-5A1
EP1606305A4 (de) * 2003-03-12 2009-06-24 Vasgene Therapeutics Inc Nukleinsäureverbindungen für die inhibierung von angiogenese und tumorwachstum
AU2003225410A1 (en) * 2003-03-21 2004-10-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
US20040185559A1 (en) * 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
EP1615658A1 (de) * 2003-03-25 2006-01-18 The Board Of Trustees Of The University Of Illinois Hemmung der tumorzellproliferation mittels foxm1b-hemmer
EP1469070A1 (de) * 2003-04-15 2004-10-20 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Livinspezifische SiRNAs zur Behandlung von therapie-resistente Tumoren
EP1615943A4 (de) * 2003-04-18 2006-08-16 Univ Pennsylvania Zusammensetzung und verfahren for sirna-inhibierung von angiopoietin 1 und 2 und deren rezeptor tie2
US20070042979A1 (en) * 2003-05-30 2007-02-22 Junichi Yano Oligonucleic acid-bearing composite and pharmaceutical composition containing the composite
EP2251039A3 (de) * 2003-05-30 2010-12-08 Nippon Shinyaku Co., Ltd. Doppelsträngige Oligo-RNA zum Hemmen der Expression von BCL-2 und sie enthaltende pharmazeutische Zusammensetzung
ES2712695T3 (es) * 2003-06-02 2019-05-14 Univ Massachusetts Métodos y composiciones para controlar la eficacia de la silenciación del ARN
AU2004252442B2 (en) * 2003-06-02 2010-04-08 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of FNAi
US7750144B2 (en) 2003-06-02 2010-07-06 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of RNA silencing
CA2542232A1 (en) * 2003-06-09 2005-01-20 Alnylam Pharmaceuticals, Inc. Method for treating neurodegenerative disease by inhibiting alpha-synuclein
US7595306B2 (en) * 2003-06-09 2009-09-29 Alnylam Pharmaceuticals Inc Method of treating neurodegenerative disease
US8575327B2 (en) 2003-06-12 2013-11-05 Alnylam Pharmaceuticals, Inc. Conserved HBV and HCV sequences useful for gene silencing
EP1646357A4 (de) * 2003-06-27 2007-01-10 Diadexus Inc Pro104 antikörper-zusammensetzungen und anwendungsverfahren
FR2857013B1 (fr) * 2003-07-02 2005-09-30 Commissariat Energie Atomique Petits arn interferents specifiques des sous-unites alpha, alpha prime et beta de la proteine kinase ck2 et leurs applications
US20060280725A1 (en) * 2003-07-02 2006-12-14 Barrie Bode Compositions and methods of treating and diagnosing hepatoma
CA2531069A1 (en) * 2003-07-03 2005-01-27 The Trustees Of The University Of Pennsylvania Inhibition of syk kinase expression
WO2005019422A2 (en) * 2003-08-13 2005-03-03 The Board Of Trustees Of The University Of Illinois Silencing of tgf-beta receptor type ii expression by sirna
US7888497B2 (en) * 2003-08-13 2011-02-15 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
US7825235B2 (en) * 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
EP1666593A4 (de) * 2003-08-18 2009-07-15 Japan Health Science Found Verbessertes sirna-molekül und verfahren zur hemmung der genexpression unter verwendung davon
US8501705B2 (en) * 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
US7901874B2 (en) * 2003-09-11 2011-03-08 Hubit Genomix, Inc. Methods for identifying agents for preventing or treating proliferative diseases, and for inhibiting extracellular matrix or α1 type IV collagen
US8680063B2 (en) 2003-09-12 2014-03-25 University Of Massachusetts RNA interference for the treatment of gain-of-function disorders
WO2005027980A1 (en) * 2003-09-12 2005-03-31 University Of Massachusetts Rna interference for the treatment of gain-of-function disorders
SG146682A1 (en) 2003-09-18 2008-10-30 Isis Pharmaceuticals Inc Modulation of eif4e expression
US8722637B2 (en) * 2003-09-22 2014-05-13 The Board Of Trustees Of The University Of Illinois Methods and compositions of IG20 and DENN-SV splice variants
CN1890382A (zh) * 2003-09-24 2007-01-03 肿瘤疗法科学股份有限公司 检测、诊断和治疗肝细胞癌(hcc)的方法
AR041407A1 (es) * 2003-09-26 2005-05-18 Nestor Alberto Kerner Oligonucleotidos antiandrogenos utilizables en el tratamiento de patologias dermatologicas relacionadas con el metabolismo de los androgenos, sus composiciones farmaceuticas y sus usos y metodos de tratamiento
WO2005038013A1 (en) 2003-10-07 2005-04-28 Isis Pharmaceuticals, Inc. Artisense oligonucleotides optimized for kidney targeting
JP4486928B2 (ja) * 2003-10-09 2010-06-23 タカラバイオ株式会社 ヒトＦｌｔ３の機能を抑制するための組成物
US20080227733A1 (en) * 2003-10-30 2008-09-18 Immune Disease Institute, Inc. Method for Treating and Preventing Ischemia-Reperfusion Injury Using Rna Interfering Agent
US20050191653A1 (en) * 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
WO2005056021A1 (en) 2003-12-04 2005-06-23 University Of South Florida Polynucleotides for reducing respiratory syncytial virus gene expression
SE0303397D0 (sv) * 2003-12-17 2003-12-17 Index Pharmaceuticals Ab Compounds and method for RNA interference
US20060134787A1 (en) 2004-12-22 2006-06-22 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA
CA2553211A1 (en) * 2004-01-12 2005-07-21 Genesense Technologies Inc. Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in combination therapies for the treatment of cancer
US7642066B2 (en) * 2004-01-15 2010-01-05 Washington University High throughput pharmaceutical screening using drosophila
EP1726313A4 (de) * 2004-01-16 2008-04-09 Takeda Pharmaceutical Arzneimittel zur prävention und behandlung von arteriosklerose
WO2005071080A2 (en) * 2004-01-20 2005-08-04 Isis Pharmaceuticals, Inc. Modulation of glucocorticoid receptor expression
US7468431B2 (en) * 2004-01-22 2008-12-23 Isis Pharmaceuticals, Inc. Modulation of eIF4E-BP2 expression
US8778900B2 (en) * 2004-01-22 2014-07-15 Isis Pharmaceuticals, Inc. Modulation of eIF4E-BP1 expression
WO2005090606A2 (en) * 2004-01-23 2005-09-29 Dharmacon, Inc. Identification of toxic nucleotide sequences
US8491914B2 (en) * 2004-02-13 2013-07-23 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for delivery of interference RNA
AU2005214904B2 (en) 2004-02-13 2011-07-21 Rockefeller University Anti-microRNA oligonucleotide molecules
GB0404209D0 (en) * 2004-02-25 2004-03-31 Uws Ventures Ltd Materials and methods for treatment of allergic disease
US20060058255A1 (en) * 2004-03-01 2006-03-16 Jianzhu Chen RNAi-based therapeutics for allergic rhinitis and asthma
DE102004010547A1 (de) * 2004-03-03 2005-11-17 Beiersdorf Ag Oligoribonukleotide zur Behandlung von irritativen und/oder entzündlichen Hauterscheinungen durch RNA-Interferenz
ES2423060T3 (es) * 2004-03-12 2013-09-17 Alnylam Pharmaceuticals, Inc. Agentes iRNA que tienen como diana al VEGF
US8084599B2 (en) 2004-03-15 2011-12-27 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
CA2560269A1 (en) * 2004-03-19 2005-09-29 The Penn State Research Foundation Combinatorial methods and compositions for treatment of melanoma
TW200600785A (en) * 2004-03-23 2006-01-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancer
JP2005312428A (ja) * 2004-03-31 2005-11-10 Keio Gijuku Ｓｋｐ−２発現抑制を利用した癌の治療
KR101147147B1 (ko) 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
US7416842B2 (en) * 2004-04-05 2008-08-26 The Rockefeller University DNA virus microRNA
JP2007531794A (ja) 2004-04-05 2007-11-08 アルニラム ファーマスーティカルズ インコーポレイテッド オリゴヌクレオチドの合成および精製に使用する方法および反応試薬
US20050244869A1 (en) * 2004-04-05 2005-11-03 Brown-Driver Vickie L Modulation of transthyretin expression
US8088902B2 (en) * 2004-04-05 2012-01-03 The Rockefeller University DNA virus microRNA and methods for inhibiting same
JP4761389B2 (ja) 2004-04-09 2011-08-31 株式会社ジーンケア研究所 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤
US7365058B2 (en) 2004-04-13 2008-04-29 The Rockefeller University MicroRNA and methods for inhibiting same
WO2005117938A2 (en) * 2004-04-13 2005-12-15 Regents Of The University Of Minnesota Methods of treating ocular conditions
US20050261233A1 (en) * 2004-04-21 2005-11-24 Sanjay Bhanot Modulation of glucose-6-phosphatase translocase expression
WO2005103254A1 (en) * 2004-04-22 2005-11-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem UNIVERSAL TARGET SEQUENCES FOR siRNA GENE SILENCING
WO2006078278A2 (en) 2004-04-27 2006-07-27 Alnylam Pharmaceuticals, Inc. Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety
CA2562833A1 (en) * 2004-04-27 2005-11-03 Galapagos N.V. Methods, agents, and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts
CA2562151C (en) 2004-04-30 2016-09-06 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a c5-modified pyrimidine
US20050287558A1 (en) 2004-05-05 2005-12-29 Crooke Rosanne M SNPs of apolipoprotein B and modulation of their expression
US7605250B2 (en) * 2004-05-12 2009-10-20 Dharmacon, Inc. siRNA targeting cAMP-specific phosphodiesterase 4D
WO2005111211A2 (en) 2004-05-14 2005-11-24 Rosetta Genomics Ltd. Micronas and uses thereof
US20090253770A1 (en) * 2004-05-18 2009-10-08 Kurume University Target gene mimitin of myc
US7563885B1 (en) * 2004-05-24 2009-07-21 Isis Pharmaceuticals, Inc. Modulation of Tudor-SN expression
US8101350B1 (en) * 2004-05-24 2012-01-24 Isis Pharmaceuticals, Inc. Modulation of exportin 5 expression
US20100152280A1 (en) * 2004-05-24 2010-06-17 Isis Pharmaceuticals, Inc. Modulation of sid-1 expression
US7795419B2 (en) * 2004-05-26 2010-09-14 Rosetta Genomics Ltd. Viral and viral associated miRNAs and uses thereof
US7575863B2 (en) 2004-05-28 2009-08-18 Applied Biosystems, Llc Methods, compositions, and kits comprising linker probes for quantifying polynucleotides
US20060015264A1 (en) * 2004-06-02 2006-01-19 Mcshea Andrew Interfering stem-loop sequences and method for identifying
US8394947B2 (en) * 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
EP1602926A1 (de) 2004-06-04 2005-12-07 University of Geneva Neue Mittel und Verfahren zur Behandlung von Gehörverlust oder Tinnitus
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
US20060156421A1 (en) * 2004-06-18 2006-07-13 Cagan Ross L High throughput screening methods for anti-metastatic compounds
EP2298896A1 (de) * 2004-06-22 2011-03-23 The Board of Trustees of the University of Illinois Verfahren zur Inhibierung von Tumorzellwachstum mit FOXM1 siRNS
US20060051815A1 (en) * 2004-06-25 2006-03-09 The J. David Gladstone Institutes Methods of treating smooth muscle cell disorders
PL1766010T3 (pl) 2004-06-28 2011-07-29 Univ Western Australia Antysensowne oligonukleotydy do indukcji pominięcia egzonu i sposoby ich zastosowania
JP2008504840A (ja) 2004-06-30 2008-02-21 アルニラム ファーマスーティカルズ インコーポレイテッド 非リン酸骨格結合を含むオリゴヌクレオチド
US20060004398A1 (en) * 2004-07-02 2006-01-05 Binder Lawrence J Jr Sequential dilator system
JP2006031308A (ja) * 2004-07-15 2006-02-02 Mitsubishi Space Software Kk 核酸配列設計装置、核酸配列設計方法、核酸配列設計プログラム、機能阻害効果算出装置、機能阻害効果算出方法、機能阻害効果算出プログラム、機能阻害影響度算出装置、機能阻害影響度算出方法および機能阻害影響度算出プログラム。
CA2574086A1 (en) * 2004-07-21 2006-02-23 Medtronic, Inc. Medical devices and methods for reducing localized fibrosis
WO2006093526A2 (en) 2004-07-21 2006-09-08 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a modified or non-natural nucleobase
US7514548B2 (en) * 2004-08-02 2009-04-07 University Of Iowa Research Foundation Methods of inhibiting COX-2
CA2574603C (en) 2004-08-04 2014-11-04 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase
US20060223147A1 (en) * 2004-08-05 2006-10-05 Kyowa Hakko Kogyo Co., Ltd., Process for producing glycoprotein composition
JP4468989B2 (ja) 2004-08-16 2010-05-26 クアーク・ファーマスーティカルス、インコーポレイテッド Ｒｔｐ８０１阻害剤の治療への使用
WO2006017932A1 (en) * 2004-08-18 2006-02-23 Genesense Technologies Inc. Small interfering rna molecules against ribonucleotide reductase and uses thereof
US20110313024A1 (en) * 2004-08-20 2011-12-22 Leonid Beigelman RNA INTERFERENCE MEDIATED INHIBITION OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
HUE033977T2 (en) 2004-08-23 2018-02-28 Sylentis Sau Treatment of eye disorders with siRNAs characterized by increased intraocular pressure
CN100395335C (zh) * 2004-08-24 2008-06-18 暨南大学 抑制bcl-2基因表达的siRNA双链
CN1324136C (zh) * 2004-08-24 2007-07-04 暨南大学 抑制bc1－2基因表达的siRNA双链及其应用
CN100410373C (zh) * 2004-08-24 2008-08-13 暨南大学 抑制bcl-2基因表达的siRNA双链
RU2410430C2 (ru) * 2004-08-31 2011-01-27 Силентис С.А.У. Способы и композиции для ингибирования экспрессии рецептора p2х7
ES2375995T3 (es) 2004-09-17 2012-03-08 University Of Massachusetts Composiciones y sus usos para deficiencias de enzima lisosomal.
GB0420977D0 (en) * 2004-09-21 2004-10-20 Keymed Medicals & Ind Equip An instrument for use in a medical simulator
EP1799867A2 (de) * 2004-09-23 2007-06-27 Vasgene Therapeutics, Inc. Zusammensetzungen und verfahren zur erkennung und behandlung von tumoren
NZ572403A (en) 2004-09-24 2010-03-26 Alnylam Pharmaceuticals Inc Rnai modulation of apob and uses thereof
CN101291948B (zh) * 2004-09-28 2012-05-30 夸克医药公司 寡核糖核苷酸以及其用于治疗脱发、肾衰竭和其它疾病的方法
AU2005288522B2 (en) * 2004-09-28 2012-06-28 Quark Pharmaceuticals, Inc. Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
EP1799826B1 (de) * 2004-09-29 2009-08-12 Children's Memorial Hospital siRNA-VERMITTELTES GEN-SILENCING VON ALPHA-SYNUKLEIN
EP1796732B1 (de) * 2004-10-01 2013-10-30 Novartis Vaccines and Diagnostics, Inc. Modifizierte, kleine, interferierende rna-moleküle und verwendungsverfahren dafür
US8765704B1 (en) 2008-02-28 2014-07-01 Novartis Ag Modified small interfering RNA molecules and methods of use
US20090186353A1 (en) * 2004-10-04 2009-07-23 Rosetta Genomics Ltd. Cancer-related nucleic acids
US7825229B2 (en) * 2005-03-25 2010-11-02 Rosetta Genomics Ltd. Lung cancer-related nucleic acids
US20060089325A1 (en) * 2004-10-13 2006-04-27 Sanjay Bhanot Antisense modulation of PTP1B expression
US20060110440A1 (en) * 2004-10-22 2006-05-25 Kiminobu Sugaya Method and system for biasing cellular development
US7790878B2 (en) * 2004-10-22 2010-09-07 Alnylam Pharmaceuticals, Inc. RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
US8080420B2 (en) 2004-10-22 2011-12-20 University Of Central Florida Research Foundation, Inc. Methods and products for biasing cellular development
JP2008519861A (ja) * 2004-11-12 2008-06-12 マサチューセッツ・インスティテュート・オブ・テクノロジー 細胞増殖性疾患を治療するための方法および組成物
US8440610B2 (en) 2004-11-12 2013-05-14 Massachusetts Institute Of Technology Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells
US20060134189A1 (en) * 2004-11-17 2006-06-22 Protiva Biotherapeutics, Inc siRNA silencing of apolipoprotein B
KR101330229B1 (ko) * 2004-11-19 2013-11-15 가부시키가이샤 진케어켄큐쇼 암세포 특이적 세포증식 억제제
US7923207B2 (en) 2004-11-22 2011-04-12 Dharmacon, Inc. Apparatus and system having dry gene silencing pools
US20060166234A1 (en) 2004-11-22 2006-07-27 Barbara Robertson Apparatus and system having dry control gene silencing compositions
US7935811B2 (en) 2004-11-22 2011-05-03 Dharmacon, Inc. Apparatus and system having dry gene silencing compositions
US9944713B2 (en) 2004-11-24 2018-04-17 Medicinal Bioconvergence Research Center Antibody specific to the AIMP2-DX2
US8003780B2 (en) * 2004-11-24 2011-08-23 Neomics Co., Ltd. AIMP2-DX2 gene and SiRNA targeting AIMP2-DX2
EP1814597A4 (de) * 2004-11-24 2009-04-22 Alnylam Pharmaceuticals Inc Rnai-modulation des bcr-abl-fusionsgens und dessen verwendungen
WO2006063164A2 (en) * 2004-12-08 2006-06-15 Wisconsin Alumni Research Foundation Compositions and methods for treating neuroendocrine tumors
US20090155904A1 (en) * 2004-12-08 2009-06-18 Bioneer Corporation Method of inhibiting expression of target mrna using sirna consisting of nucleotide sequence complementary to said target mrna
JP4981681B2 (ja) * 2004-12-09 2012-07-25 アルナイラム ファーマシューティカルズ， インコーポレイテッド 哺乳類における免疫応答誘導組成物および方法、ならびに短鎖干渉ｒｎａなどのオリゴヌクレオチド剤に対する免疫応答の回避方法
EP1819346A4 (de) * 2004-12-09 2009-07-15 Centocor Inc Oxytocin-rezeptorantagonisten und deren verwendung zur behandlung von lungenkrankheiten
WO2006066158A2 (en) * 2004-12-14 2006-06-22 Alnylam Pharmaceuticals, Inc. Rnai modulation of mll-af4 and uses thereof
US7332591B2 (en) * 2004-12-21 2008-02-19 The University Of Iowa Research Foundation Bardet-Biedl susceptibility gene and uses thereof
DE602005027747D1 (de) * 2004-12-22 2011-06-09 Alnylam Pharmaceuticals Inc Zum gen-silencing geeignete konservierte hbv- und hcv-sequenzen
TWI401316B (zh) * 2004-12-23 2013-07-11 Alcon Inc 用於治療青光眼之血清澱粉樣蛋白Ａ的ＲＮＡｉ抑制作用
US20060166920A1 (en) * 2005-12-27 2006-07-27 Regents Of The University Of Michigan Oligonucleotide based therapeutics
CN101119734B (zh) 2005-01-07 2012-05-09 阿尔尼拉姆医药品有限公司 RSV的RNAi调节及其治疗应用
DE102005003788A1 (de) * 2005-01-19 2006-07-20 Eberhard-Karls-Universität Tübingen Universitätsklinikum siRNA-Moleküle zur Behandlung von Blutgefäßen
WO2006081192A2 (en) * 2005-01-24 2006-08-03 Alnylam Pharmaceuticals, Inc. Rnai modulation of the nogo-l or nogo-r gene and uses thereof
US7879992B2 (en) * 2005-01-31 2011-02-01 Isis Pharmaceuticals, Inc. Modification of MyD88 splicing using modified oligonucleotides
TW200639253A (en) * 2005-02-01 2006-11-16 Alcon Inc RNAi-mediated inhibition of ocular targets
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
JP2008544742A (ja) 2005-02-25 2008-12-11 アイシス ファーマシューティカルズ， インコーポレーテッド ＩＬ４Ｒ−αに対する組成物およびその使用
DE602006009234D1 (de) * 2005-03-02 2009-10-29 Nat Inst Immunology Hemmung der expression von spag9 mit sirnas
US20070185044A1 (en) * 2005-03-08 2007-08-09 Dobie Kenneth W Modulation of ace2 expression
JP2008533050A (ja) 2005-03-11 2008-08-21 アルコン，インコーポレイテッド 緑内障を処置するためのフリッツルド関連蛋白質―１のｒｎａｉ媒介性阻害
GB0505081D0 (en) * 2005-03-14 2005-04-20 Genomica Sau Downregulation of interleukin-12 expression by means of rnai technology
ATE524546T1 (de) * 2005-03-25 2011-09-15 Medtronic Inc Verwendung von anti-tnf oder anti-il1-rnai zur unterdrückung der wirkung entzündungsfördernder cytokine zur lokalen schmerzbehandlung
JP4131271B2 (ja) * 2005-03-30 2008-08-13 ソニー株式会社 情報処理装置および方法、並びにプログラム
ATE541928T1 (de) * 2005-03-31 2012-02-15 Calando Pharmaceuticals Inc Inhibitoren der untereinheit 2 der ribonukleotidreduktase und ihre verwendungen
US20070213293A1 (en) * 2005-04-08 2007-09-13 Nastech Pharmaceutical Company Inc. Rnai therapeutic for respiratory virus infection
JP2008538355A (ja) * 2005-04-08 2008-10-23 アイシス ファーマシューティカルズ， インコーポレーテッド アセチル−ＣｏＡカルボキシラーゼに関する組成物およびそれらの用途
MX2007012766A (es) 2005-04-12 2008-10-01 Intradigm Corp Composición y métodos de terapéuticos de arni para el tratamiento de cáncer y otras enfermedades de neovascularización.
US20090117539A1 (en) * 2005-04-12 2009-05-07 Larry Gilbertson DNA sequences for gene suppression
WO2006112239A1 (ja) * 2005-04-15 2006-10-26 National University Corporation Tottori University ｈＴＥＲＴ発現調節遺伝子
US20090203055A1 (en) * 2005-04-18 2009-08-13 Massachusetts Institute Of Technology Compositions and methods for RNA interference with sialidase expression and uses thereof
US20060253068A1 (en) * 2005-04-20 2006-11-09 Van Bilsen Paul Use of biocompatible in-situ matrices for delivery of therapeutic cells to the heart
EP1714970A1 (de) * 2005-04-22 2006-10-25 Universität des Saarlandes Anwendung von Inhibitoren von Enzymen der RNAse-A Genfamilie zur Stabilisierung von Oligonukleotiden mit RNA interferierender Aktivität
AU2006242225B2 (en) 2005-04-29 2012-01-12 Rockefeller University Human microRNAs and methods for inhibiting same
US7902352B2 (en) * 2005-05-06 2011-03-08 Medtronic, Inc. Isolated nucleic acid duplex for reducing huntington gene expression
EP1885854B1 (de) * 2005-05-06 2012-10-17 Medtronic, Inc. Verfahren und sequenzen zur unterdrückung der expression des huntington-gens in primaten
KR20060119412A (ko) * 2005-05-20 2006-11-24 아주대학교산학협력단 ＩＬ-6 발현 억제를 위한 ｓｉＲＮＡ 및 이를 함유하는조성물
EP1888083B1 (de) * 2005-05-24 2011-12-28 Isis Pharmaceuticals, Inc. Zusammensetzungen und ihre verwendungen gegen niedermolekulare ptpase
EP1728514A1 (de) * 2005-06-03 2006-12-06 Immunotech S.A. Verwendungen von Oligonukleotiden welche mesenchymale Stammzellen Proliferation verursachen
CA2609206A1 (en) * 2005-06-06 2006-12-14 Gen-Probe Incorporated Compositions, methods and kits for determining the presence of chlamydophila pneumoniae in a test sample
US20100266574A1 (en) * 2005-06-10 2010-10-21 Orna Mor Oligoribonucleotides and Methods of Use Thereof for Treatment of Fibrotic Conditions and Other Diseases
EP1734118A1 (de) * 2005-06-15 2006-12-20 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Genom-weites RNAi-Screening zur Identifizierung von Genen die das JAK/STAT Pathway modulieren
FI20050640A0 (fi) * 2005-06-16 2005-06-16 Faron Pharmaceuticals Oy Yhdisteitä amiinioksidaasista riippuvien sairauksien tai häiriöiden hoitoon tai estoon
ES2397113T3 (es) * 2005-06-23 2013-03-04 Isis Pharmaceuticals, Inc. Composiciones y procedimientos para modular el corte y empalme de SMN2
EP1896084A4 (de) * 2005-06-27 2010-10-20 Alnylam Pharmaceuticals Inc Rnai-modulation von hif-1 und therapeutische anwendungen davon
US9133517B2 (en) 2005-06-28 2015-09-15 Medtronics, Inc. Methods and sequences to preferentially suppress expression of mutated huntingtin
US20080280843A1 (en) * 2006-05-24 2008-11-13 Van Bilsen Paul Methods and kits for linking polymorphic sequences to expanded repeat mutations
CA2607668A1 (en) * 2005-07-21 2007-02-01 Alnylam Pharmaceuticals, Inc. Rnai modulation of the rho-a gene and uses thereof
WO2007010628A1 (ja) * 2005-07-22 2007-01-25 Japanese Foundation For Cancer Research 癌の予防・治療剤
CN101273144B (zh) * 2005-07-27 2011-12-28 肿瘤疗法科学股份有限公司 诊断食道癌的方法
AU2006275810A1 (en) * 2005-07-28 2007-02-08 University Of Massachusetts Glucose transport-related genes, polypeptides, and methods of use thereof
JP2009504782A (ja) 2005-08-18 2009-02-05 アルナイラム ファーマシューティカルズ インコーポレイテッド 神経疾患を治療するための方法および組成物
ATE532878T1 (de) * 2005-08-24 2011-11-15 Life Technologies Corp Verfahren zur quantifizierung von sirnas, mirnas und polymorphen mirnas
US20070054873A1 (en) * 2005-08-26 2007-03-08 Protiva Biotherapeutics, Inc. Glucocorticoid modulation of nucleic acid-mediated immune stimulation
MX348513B (es) * 2005-09-16 2017-06-16 Devgen Nv Metodos para controlar plagas utilizando arni.
CA2623772A1 (en) * 2005-09-19 2007-03-29 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Modulation of glucocorticoid receptor expression
US20080311552A1 (en) * 2005-09-20 2008-12-18 London Health Sciences Centre Research, Inc. Use of Sirnas in Organ Storage/Reperfusion Solutions
US20120164730A1 (en) * 2005-10-11 2012-06-28 Ben-Gurion University Of The Negev Research And Development Authority Ltd. Compositions for silencing the expression of vdac1 and uses thereof
EP2395076A1 (de) 2005-10-14 2011-12-14 MUSC Foundation For Research Development Targeting von PAX2 zur Induktion der DEFB1-vermittelten Tumorimmunität und Krebstherapie
GB0521351D0 (en) * 2005-10-20 2005-11-30 Genomica Sau Modulation of TRPV expression levels
WO2007047913A2 (en) * 2005-10-20 2007-04-26 Isis Pharmaceuticals, Inc Compositions and methods for modulation of lmna expression
CA2624221A1 (en) * 2005-10-24 2007-05-03 Takeda Pharmaceutical Company Limited Preventives/remedies for cancer
GB0521716D0 (en) * 2005-10-25 2005-11-30 Genomica Sau Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases
US7723314B1 (en) * 2005-10-28 2010-05-25 Transderm, Inc. Methods and compositions for treating pachyonychia congenita
AU2006305886C1 (en) 2005-10-28 2011-03-17 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of huntingtin gene
EP1948680A4 (de) * 2005-10-28 2010-01-13 Univ California Verfahren und verbindungen zum nachweis und zum isolieren von lymphomzellen
US20080090775A1 (en) * 2005-10-31 2008-04-17 Chong Huang Antagonist of TEB4 and Methods of Use
WO2007051303A1 (en) 2005-11-02 2007-05-10 Protiva Biotherapeutics, Inc. MODIFIED siRNA MOLECULES AND USES THEREOF
WO2007056326A2 (en) * 2005-11-04 2007-05-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of nav1.8 gene
WO2007056331A2 (en) * 2005-11-09 2007-05-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of factor v leiden mutant gene
US8066730B2 (en) * 2005-11-14 2011-11-29 Scapa Flow, Llc Medical dilator system or dilator device
US8067558B2 (en) 2005-12-19 2011-11-29 New York University Constitutively active fragments of eukaryotic heat shock RNA
US7919603B2 (en) * 2005-12-19 2011-04-05 New York University Heat shock RNA
US20070270366A1 (en) * 2005-12-20 2007-11-22 Karras James G Double stranded nucleic acid molecules targeted to il-4 receptor alpha
US8258287B2 (en) * 2005-12-21 2012-09-04 Centre de Cooperation Internationale en Recherche Agronomique pour le Developpment (CIRAD) Interfering RNAs targeting the morbillivirus nucleoprotein gene
US20070178068A1 (en) * 2005-12-22 2007-08-02 Reich Samuel J Compositions and methods for regulating complement system
AR057252A1 (es) * 2005-12-27 2007-11-21 Alcon Mfg Ltd Inhibicion de rho quinasa mediada por arni para el tratamiento de trastornos oculares
US8673873B1 (en) 2005-12-28 2014-03-18 Alcon Research, Ltd. RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders
TW200731980A (en) 2005-12-29 2007-09-01 Alcon Mfg Ltd RNAi-mediated inhibition of HIF1A for treatment of ocular angiogenesis
US7444453B2 (en) * 2006-01-03 2008-10-28 International Business Machines Corporation Address translation device
EP1984400B1 (de) 2006-01-05 2012-11-28 Immune Disease Institute, Inc. Regulatoren von nfat
US20090060921A1 (en) * 2006-01-17 2009-03-05 Biolex Therapeutics, Inc. Glycan-optimized anti-cd20 antibodies
ES2395842T3 (es) * 2006-01-17 2013-02-15 Synthon Biopharmaceuticals B.V. Composiciones y métodos para la humanización y optimización de N-glicanos en plantas
WO2007084954A2 (en) * 2006-01-19 2007-07-26 The Board Of Trustees Of The University Of Illinois Selective inhibition of ig20 splice variants to treat cancers
UY30097A1 (es) 2006-01-20 2007-08-31 Atugen Ag Usos terapeuticos de inhibidores de rtp801
US7825099B2 (en) 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
SI2161038T1 (sl) 2006-01-26 2014-05-30 Isis Pharmaceuticals, Inc. Sestavki in njihove uporabe, usmerjeni proti huntingtinu
US8229398B2 (en) * 2006-01-30 2012-07-24 Qualcomm Incorporated GSM authentication in a CDMA network
WO2008048342A2 (en) * 2006-02-08 2008-04-24 Dharmacon, Inc. Microarray for detecting and quantifying microrna
CN105385679B (zh) * 2006-02-13 2020-05-26 孟山都技术有限公司 选择和稳定dsRNA构建体
JP4961549B2 (ja) * 2006-02-16 2012-06-27 国立大学法人愛媛大学 アンドロゲン受容体遺伝子に特異的なｓｉＲＮＡ
US7910566B2 (en) 2006-03-09 2011-03-22 Quark Pharmaceuticals Inc. Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
WO2007109097A2 (en) * 2006-03-16 2007-09-27 Alnylam Pharmaceuticals, Inc. RNAi MODULATION OF TGF-BETA AND THERAPEUTIC USES THEREOF
FI20060246A0 (fi) 2006-03-16 2006-03-16 Jukka Westermarck Uusi kasvua stimuloiva proteiini ja sen käyttö
AU2007230995B2 (en) * 2006-03-24 2011-08-11 Alnylam Pharmaceuticals, Inc. dsRNA compositions and methods for treating HPV infection
CA2647728C (en) 2006-03-31 2014-12-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of eg5 gene
US8076306B2 (en) * 2006-04-12 2011-12-13 Isis Pharmaceuticals, Inc. Compositions and their uses directed to hepcidin
TW200808360A (en) 2006-04-13 2008-02-16 Alcon Mfg Ltd RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
WO2007121156A2 (en) 2006-04-13 2007-10-25 Alcon Research, Ltd Rnai-mediated inhibition of histamine receptor h1-related conditions
WO2007123391A1 (en) * 2006-04-20 2007-11-01 Academisch Ziekenhuis Leiden Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
KR20090015073A (ko) * 2006-04-21 2009-02-11 인터벤셔널 스파인, 인코포레이티드 척추 고정을 위한 방법 및 기구
WO2007127919A2 (en) * 2006-04-28 2007-11-08 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a gene from the jc virus
DK2021472T3 (da) * 2006-05-05 2011-09-19 Isis Pharmaceuticals Inc Forbindelser og fremgangsmåder til modulering af genekspression
EP2023936A4 (de) * 2006-05-05 2010-11-24 Isis Pharmaceuticals Inc Zusammensetzungen und ihre verwendungen in bezug auf ptpr-alpha
CN101484588B (zh) * 2006-05-11 2013-11-06 阿尔尼拉姆医药品有限公司 抑制pcsk9基因表达的组合物和方法
TWI322690B (en) * 2006-05-11 2010-04-01 Flysun Dev Co Ltd Short interference ribonucleic acids for treating allergic dieases
US8243715B2 (en) * 2006-05-15 2012-08-14 Oracle Israel Ltd. Delivering sip-based call services to circuit-switched terminals
US20090130212A1 (en) * 2006-05-15 2009-05-21 Physical Pharmaceutica, Llc Composition and improved method for preparation of small particles
BRPI0711950A2 (pt) * 2006-05-19 2011-12-13 Scripps Research Inst tratamento para o dobramento inadequado da proteìna
CA2650416A1 (en) 2006-05-19 2007-11-29 Alcon Research, Ltd. Rnai-mediated inhibition of tumor necrosis factor .alpha.-related conditions
AU2012201409B2 (en) * 2006-05-19 2014-06-12 Arrowhead Research Corporation RNAi-Mediated inhibition of tumor necrosis factor alpha-related conditions
CA2652770A1 (en) * 2006-05-19 2007-11-29 Alnylam Pharmaceuticals, Inc. Rnai modulation of aha and therapeutic uses thereof
EP1857548A1 (de) * 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Mittel und Verfahren zur Induktion von Exon-skipping
WO2007136758A2 (en) * 2006-05-19 2007-11-29 Board Of Regents, The University Of Texas System Sirna inhibition of p13k p85, p110, and akt2 and methods of use
CA2653451C (en) * 2006-05-22 2015-12-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of ikk-b gene
US9273356B2 (en) 2006-05-24 2016-03-01 Medtronic, Inc. Methods and kits for linking polymorphic sequences to expanded repeat mutations
US8430813B2 (en) 2006-05-26 2013-04-30 Depuy Spine, Inc. Illuminated surgical access system including a surgical access device and integrated light emitter
US8598333B2 (en) * 2006-05-26 2013-12-03 Alnylam Pharmaceuticals, Inc. SiRNA silencing of genes expressed in cancer
AR061168A1 (es) * 2006-06-02 2008-08-06 Alcon Mfg Ltd Inhibicion mediada por arni de blancos relacionados con factor 1 derivado de celulas de estroma para el tratamiento de enfermedades relacionadas con neovascularizacion
WO2007141796A2 (en) * 2006-06-09 2007-12-13 Quark Pharmaceuticals, Inc. Therapeutic uses of inhibitors of rtp801l
US7915399B2 (en) * 2006-06-09 2011-03-29 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
EP2412805B1 (de) * 2006-06-09 2014-04-30 Kabushiki Kaisha Yakult Honsha An der Verewigung menschlicher Krebszellen beteiligtes Gen und Verwendung dafür
JP2009540011A (ja) * 2006-06-12 2009-11-19 エクセジェニックス、インク．ディー／ビー／エー オプコ ヘルス、インク． 血管新生のｓｉＲＮＡ阻害のための組成物及び方法
KR100794705B1 (ko) * 2006-06-13 2008-01-14 (주)바이오니아 선택적 스플라이싱을 고려한 ｓｉＲＮＡ를 이용하여 표적ｍＲＮＡ의 발현을 억제하는 방법
GB0612342D0 (en) 2006-06-21 2006-08-02 Glaxosmithkline Biolog Sa Method
WO2008005769A2 (en) * 2006-06-30 2008-01-10 Immusol, Incorporated Methods of inhibiting hcv replication
WO2008008719A2 (en) * 2006-07-10 2008-01-17 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the myc gene
JP4756271B2 (ja) * 2006-07-18 2011-08-24 独立行政法人産業技術総合研究所 ガン細胞の老化、アポトーシス誘導剤
EP1884569A1 (de) 2006-07-31 2008-02-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Sensibilisierung von Krebszellen für eine Therapie unter der Verwendung von siNA gerichtet gegen Gene aus der 1p und 19q chromosomalen Region
US8138160B2 (en) 2006-08-03 2012-03-20 Warsaw Orthopedic, Inc. Reagents, methods and systems to suppress pro-inflammatory cytokines
JP2010500290A (ja) * 2006-08-04 2010-01-07 アイシス ファーマシューティカルズ， インコーポレーテッド Ｊｎｋタンパク質を調節するための組成物および方法
EP2057177B1 (de) 2006-08-04 2012-11-21 Isis Pharmaceuticals, Inc. Zusammensetzungen und ihre verwendung in bezug auf diacylglycerol-acyltransferase 1
SI2056845T1 (en) 2006-08-08 2018-02-28 Rheinische Friedrich-Wilhelms-Universitaet Bonn STRUCTURE AND USE 5 'PHOSPHATE OF OLIGONUCLEOTES
US20080039415A1 (en) * 2006-08-11 2008-02-14 Gregory Robert Stewart Retrograde transport of sirna and therapeutic uses to treat neurologic disorders
JP6047270B2 (ja) 2006-08-11 2016-12-21 バイオマリン テクノロジーズ ベー．フェー． Ｄｎａリピートの不安定性に関連した遺伝的障害を治療するための方法及び手段
JPWO2008029790A1 (ja) * 2006-09-04 2010-01-21 協和発酵キリン株式会社 新規核酸
US7872118B2 (en) * 2006-09-08 2011-01-18 Opko Ophthalmics, Llc siRNA and methods of manufacture
US7737266B2 (en) * 2006-09-18 2010-06-15 Board Of Regents, The University Of Texas System RNAi modulation of SCAP and therapeutics uses thereof
WO2008035692A1 (fr) * 2006-09-19 2008-03-27 Jcr Pharmaceuticals Co., Ltd. Marqueur d'identification de cellule cancéreuse et inhibiteur de prolifération de cellule cancéreuse
AR055648A1 (es) * 2006-09-21 2007-08-29 Gen Med Sa Un oligonucleotido de rna de doble cadena una composicion farmaceutica o cosmetica que lo comprende y uso del mismo enla preparacion de un medicamento para el tratamiento de enfermedades relacionadas con el metabolismo de androgenos
WO2008036933A2 (en) 2006-09-21 2008-03-27 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the hamp gene
US8809514B2 (en) 2006-09-22 2014-08-19 Ge Healthcare Dharmacon, Inc. Tripartite oligonucleotide complexes and methods for gene silencing by RNA interference
WO2008063760A2 (en) * 2006-10-18 2008-05-29 The University Of Texas M.D. Anderson Cancer Center Methods for treating cancer targeting transglutaminase
AU2007310982A1 (en) * 2006-10-18 2008-04-24 Marina Biotech, Inc. Nicked or gapped nucleic acid molecules and uses thereof
JP2010507387A (ja) * 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のｓｉＲＮＡおよびその使用方法
US8324367B2 (en) 2006-11-03 2012-12-04 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
US9375440B2 (en) * 2006-11-03 2016-06-28 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
AU2006350507A1 (en) * 2006-11-09 2008-05-15 Unibioscreen S.A. Targeting of alpha-1 or alpha-3 subunit of Na+, K+-ATPase in the treatment of proliferative diseases
WO2008060478A2 (en) * 2006-11-09 2008-05-22 The Board Of Regents Of The University Of Texas System Hedgehog signaling pathway proteins and uses thereof
CA2669520C (en) * 2006-11-13 2016-07-26 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Methods of treating cancer using sirna molecules directed against cd24
USD631962S1 (en) 2006-11-14 2011-02-01 Scapa Flow, Llc Medical dilator
US7819842B2 (en) 2006-11-21 2010-10-26 Medtronic, Inc. Chronically implantable guide tube for repeated intermittent delivery of materials or fluids to targeted tissue sites
US7988668B2 (en) * 2006-11-21 2011-08-02 Medtronic, Inc. Microsyringe for pre-packaged delivery of pharmaceuticals
US8034921B2 (en) * 2006-11-21 2011-10-11 Alnylam Pharmaceuticals, Inc. IRNA agents targeting CCR5 expressing cells and uses thereof
EP2455471A3 (de) * 2006-11-27 2012-09-12 Isis Pharmaceuticals, Inc. Verfahren zur Behandlung von Hypercholesterinämie
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
US20080171719A1 (en) * 2006-11-28 2008-07-17 Alcon Manufacturing, Ltd. RNAi-MEDIATED INHIBITION OF AQUAPORIN 1 FOR TREATMENT OF IOP-RELATED CONDITIONS
US8105382B2 (en) 2006-12-07 2012-01-31 Interventional Spine, Inc. Intervertebral implant
US8979931B2 (en) 2006-12-08 2015-03-17 DePuy Synthes Products, LLC Nucleus replacement device and method
WO2008084319A2 (ja) * 2006-12-18 2008-07-17 Kyowa Hakko Kirin Co., Ltd. 新規核酸
US20100015627A1 (en) * 2006-12-22 2010-01-21 Vincent Beuger Selection method
US8476243B2 (en) 2006-12-29 2013-07-02 Transderm, Inc. Methods and compositions for treating keratin hyperproliferative disorders
US7754698B2 (en) * 2007-01-09 2010-07-13 Isis Pharmaceuticals, Inc. Modulation of FR-alpha expression
AU2007344641B2 (en) 2007-01-16 2014-05-22 The University Of Queensland Method of inducing an immune response
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
WO2008094860A2 (en) 2007-01-30 2008-08-07 Allergan, Inc. Treating ocular diseases using peroxisome proliferator-activated receptor delta antagonists
AR065083A1 (es) 2007-02-02 2009-05-13 Amgen Inc Hepcidina, antagonistas de la hepcidina y metodos de uso
US20080188433A1 (en) * 2007-02-07 2008-08-07 Academia Sinica Methods of diagnosis of spinal muscular atrophy and treatments thereof
WO2008101087A1 (en) * 2007-02-14 2008-08-21 Ontherex Llc Compositions and methods for modulation of pdx-1
EP2137205A2 (de) * 2007-02-26 2009-12-30 Quark Pharmaceuticals, Inc. Inhibitoren von rtp801 und ihre verwendung bei der behandlung von krankheiten
WO2008104978A2 (en) * 2007-02-28 2008-09-04 Quark Pharmaceuticals, Inc. Novel sirna structures
US20100105134A1 (en) * 2007-03-02 2010-04-29 Mdrna, Inc. Nucleic acid compounds for inhibiting gene expression and uses thereof
WO2008109449A1 (en) * 2007-03-02 2008-09-12 Mdrna Inc. Nucleic acid compounds for inhibiting bcl2 gene expression and uses thereof
WO2008109362A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting vegf gene expression and uses thereof
JP2010519912A (ja) * 2007-03-02 2010-06-10 エムディーアールエヌエー，インコーポレイテッド Ｒａｓ遺伝子の発現を抑制するための核酸化合物およびその使用
US20080287383A1 (en) * 2007-03-02 2008-11-20 Nastech Pharmaceutical Company Inc. Nucleic acid compounds for inhibiting erbb gene expression and uses thereof
US20090018099A1 (en) * 2007-03-02 2009-01-15 Hitto Kaufmann Protein production
EP2126081A2 (de) * 2007-03-02 2009-12-02 MDRNA, Inc. Nukleinsäureverbindungen zur hemmung der hif1a-genexpression und ihre verwendung
US20100112687A1 (en) * 2007-03-02 2010-05-06 Mdrna, Inc. Nucleic acid compounds for inhibiting erbb family gene expression and uses thereof
WO2008109357A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting apob gene expression and uses thereof
WO2008109518A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting wnt gene expression and uses thereof
JP5467415B2 (ja) * 2007-03-02 2014-04-09 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト タンパク質製造の改良
WO2008109377A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting vegf family gene expression and uses thereof
WO2009029293A2 (en) * 2007-03-02 2009-03-05 Mdrna, Inc. Nucleic acid compounds for inhibiting myc gene expression and uses thereof
US20080293136A1 (en) * 2007-03-02 2008-11-27 Nastech Pharmaceutical Company Inc. Nucleic acid compounds for inhibiting akt gene expression and uses thereof
CA2680058C (en) * 2007-03-08 2019-04-16 University Health Network Induction of apoptosis and inhibition of cell proliferation through modulation of carnitine palmitoyltransferase 1c activity
CA2680589A1 (en) * 2007-03-14 2008-09-18 Universita' Degli Studi Di Milano - Bicocca Modulator compounds of the drug resistance in epithelial tumour cells
JP5103621B2 (ja) * 2007-03-20 2012-12-19 国立大学法人愛媛大学 ＡＤＡＴ１遺伝子に特異的なｓｉＲＮＡ
US7812002B2 (en) * 2007-03-21 2010-10-12 Quark Pharmaceuticals, Inc. Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer
RU2559536C2 (ru) 2007-03-24 2015-08-10 Джензим Корпорейшн Введение антисмысловых олигонуклеотидов, комплементарных человеческому аполипопротеину в
PE20090064A1 (es) * 2007-03-26 2009-03-02 Novartis Ag Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
JP5350360B2 (ja) * 2007-03-29 2013-11-27 アルナイラム ファーマシューティカルズ， インコーポレイテッド エボラ由来の遺伝子の発現を阻害するための組成物および方法
GB0707069D0 (en) * 2007-04-12 2007-05-23 Medical Res Council Methods and uses
WO2008124927A1 (en) * 2007-04-13 2008-10-23 Vincent Research & Consulting Inc. Sirna against thymidylate synthase and uses thereof in cancer treatment regimens
WO2008143774A2 (en) * 2007-05-01 2008-11-27 University Of Massachusetts Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy
WO2008132234A2 (en) * 2007-05-01 2008-11-06 Santaris Pharma A/S Rna antagonist compounds for the modulation of beta-catenin
JP5346923B2 (ja) * 2007-05-04 2013-11-20 インデックス・ファーマシューティカルズ・アクチエボラーグ 腫瘍増殖阻害化合物及びそれらの使用方法
AU2008251037A1 (en) * 2007-05-15 2008-11-20 Johnson & Johnson Research Pty Limited Suppression of viruses involved in respiratory infection or disease
DE202007007322U1 (de) * 2007-05-23 2008-10-02 Baumgart, Rainer, Prof. Dr.med., Dipl.-Ing. Instrumentensatz zur minimal invasiven Vorbereitung einer Knochennagelung
EP2160477B1 (de) 2007-05-23 2013-08-07 Dharmacon, Inc. Mikro-RNA-Grundstrukturen und nichtnatürlich auftretende mikro-RNAs
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
WO2008148304A1 (en) * 2007-05-31 2008-12-11 Xiamen University Rna interference target for treating aids
WO2008148862A1 (en) * 2007-06-05 2008-12-11 Melica Hb Methods and materials related to hair pigmentation and cancer
AR066984A1 (es) * 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
US20100273854A1 (en) * 2007-06-15 2010-10-28 Hagar Kalinski Compositions and methods for inhibiting nadph oxidase expression
US20090054366A1 (en) * 2007-06-15 2009-02-26 Reliance Life Sciences Pvt. Ltd. RNAi MEDIATED KNOCKDOWN OF NUMA FOR CANCER THERAPY
AU2012203780B2 (en) * 2007-06-15 2014-06-26 Arrowhead Pharmaceuticals, Inc. RNAi inhibition of alpha-ENaC expression
US8900307B2 (en) 2007-06-26 2014-12-02 DePuy Synthes Products, LLC Highly lordosed fusion cage
AU2008269689A1 (en) * 2007-06-27 2008-12-31 Auckland Uniservices Limited Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof
HRP20140522T1 (hr) * 2007-06-27 2014-08-15 Quark Pharmaceuticals, Inc. Pripravci i metode za inhibiranje izražaja proapoptotiäśkih gena
US8043343B2 (en) 2007-06-28 2011-10-25 Zimmer Spine, Inc. Stabilization system and method
US8198256B2 (en) * 2007-07-03 2012-06-12 Kyorin Pharmaceutical Co., Ltd. Treatment of influenza
CN103215269B (zh) 2007-07-05 2015-01-21 诺瓦提斯公司 用于治疗病毒感染的dsRNA
CA2693742A1 (en) * 2007-07-12 2009-01-15 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs, tissues or tumor cells
CN103212085A (zh) * 2007-07-12 2013-07-24 普罗森那技术公司 用于使化合物靶向多种选定器官或组织的分子
EP2017340A1 (de) * 2007-07-16 2009-01-21 Qiagen GmbH Positive Kontrollen für expressionsmodulierende Experimente
AR071146A1 (es) * 2007-08-03 2010-06-02 Alcon Res Ltd Inhibicion relacionada con arni de la via de senales tnf alfa para el tratamiento de angiogenesis ocular, uso de una molecula de arn de interferencia y molecula de arn de interferencia
TW200914052A (en) * 2007-08-03 2009-04-01 Alcon Res Ltd RNAi-related inhibition of TNFα signaling pathway for treatment of glaucoma
WO2009021150A2 (en) * 2007-08-08 2009-02-12 California Pacific Medical Center Platelet derived growth factor receptor supports cytomegalovirus infectivity
US8263571B2 (en) * 2007-08-10 2012-09-11 Vendevia Group, Llc Gene silencing of the brother of the regulator of imprinted sites (BORIS)
JP2010536380A (ja) * 2007-08-21 2010-12-02 スコット アンド ホワイト メモリアル ホスピタル アンド スコット，シェルウッド アンド ブリンドリー ファンデーション 転写後遺伝子サイレンシングのための方法及び組成物
US20110160280A1 (en) * 2007-08-24 2011-06-30 Oncotherapy Science, Inc. Cancer-related genes, cdca5, epha7, stk31 and wdhd1
EP2193140B1 (de) * 2007-08-27 2016-11-02 1Globe Health Institute LLC aiRNA-ZUSAMMENSETZUNGEN UND IHRE VERWENDUNG
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
EP2190995A2 (de) * 2007-09-18 2010-06-02 Intradigm Corporation Zusammensetzungen mit k-ras-sirna und verwendungsverfahren
CN101849008A (zh) 2007-09-19 2010-09-29 应用生物系统有限公司 用于减少RNAi中的脱靶表型效应的siRNA的不依赖于序列的修饰形式和其稳定形式
US20090088789A1 (en) 2007-09-28 2009-04-02 O'neil Michael J Balloon With Shape Control For Spinal Procedures
AU2008308691B2 (en) * 2007-10-01 2013-11-07 Isis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
CN103898110A (zh) * 2007-10-03 2014-07-02 夸克制药公司 新siRNA结构
JP5250632B2 (ja) 2007-10-05 2013-07-31 ジンテス ゲゼルシャフト ミット ベシュレンクテル ハフツング 拡張システム
CA2702180A1 (en) * 2007-10-12 2009-04-16 Peter Humphries Method for opening tight junctions
EP2203173B1 (de) * 2007-10-26 2015-12-23 Academisch Ziekenhuis Leiden Mittel und verfahren zur bekämpfung von muskelleiden
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
EP2222283A2 (de) * 2007-10-29 2010-09-01 University of Massachusetts Zur freisetzung von nukleinsäuren (sirna) mit hefe-zellwandproteinen verkapselte mehrlagige nanopatikel
US8097712B2 (en) 2007-11-07 2012-01-17 Beelogics Inc. Compositions for conferring tolerance to viral disease in social insects, and the use thereof
MX2010005055A (es) 2007-11-09 2010-06-25 Isis Pharmaceuticals Inc Modulacion de la expresion del factor 7.
CN101984759A (zh) * 2007-11-09 2011-03-09 Isis药物公司 因子9表达的调节
EP2848688A1 (de) 2007-12-10 2015-03-18 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und Verfahren zur Hemmung der Faktor VII-Genexpression
US20100204305A1 (en) * 2007-12-11 2010-08-12 Lorus Therapeutics Inc. Small interfering rna molecules against ribonucleotide reductase and uses thereof
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof
US20110105584A1 (en) * 2007-12-12 2011-05-05 Elena Feinstein Rtp80il sirna compounds and methods of use thereof
EP2229459B1 (de) 2007-12-13 2014-08-27 Alnylam Pharmaceuticals, Inc. Verfahren und Zusammensetzungen zur Vorbeugung oder Behandlung einer RSV-Infektion
WO2009079399A2 (en) * 2007-12-14 2009-06-25 Alnylam Pharmaceuticals, Inc. Method of treating neurodegenerative disease
JP2011506483A (ja) 2007-12-14 2011-03-03 アムジエン・インコーポレーテツド 抗スクレロスチン抗体を用いた骨折の治療方法
KR100949791B1 (ko) * 2007-12-18 2010-03-30 이동기 오프-타겟 효과를 최소화하고 ＲＮＡｉ 기구를 포화시키지않는 신규한 ｓｉＲＮＡ 구조 및 그 용도
MX2010006925A (es) * 2007-12-20 2011-05-02 Angiochem Inc Conjugados de polipeptido-acido nucleico y sus usos.
EP2077335A1 (de) * 2007-12-22 2009-07-08 Universitätsklinikum Schleswig-Holstein EXO1-Promoter-Polymorphismus im Zusammenhang mit außergewöhnlich hoher Lebenserwartung beim Menschen
KR100942807B1 (ko) * 2007-12-26 2010-02-18 재단법인서울대학교산학협력재단 폐암의 예방 또는 치료용 유전자 치료제 및 약제 조성물
JP5697988B2 (ja) * 2007-12-27 2015-04-08 プロチバ バイオセラピューティクス インコーポレイティッド 干渉ｒｎａを使用したポロ様キナーゼ発現のサイレンシング方法
EP2075333A1 (de) * 2007-12-28 2009-07-01 Qiagen GmbH Positive Kontrollen für expressionsmodulierende Experimente
EP2242854A4 (de) * 2008-01-15 2012-08-15 Quark Pharmaceuticals Inc Sirna-verbindungen und verfahren zur verwendung davon
AU2009205896A1 (en) 2008-01-17 2009-07-23 Synthes Gmbh An expandable intervertebral implant and associated method of manufacturing the same
JPWO2009093384A1 (ja) * 2008-01-24 2011-05-26 独立行政法人産業技術総合研究所 ポリヌクレオチド及びポリヌクレオチド類似体並びにこれらを用いた遺伝子発現制御方法
WO2009096612A1 (en) * 2008-01-30 2009-08-06 Korea Institute Of Science And Technology Regulation of neutrotransmittter release through anion channels
BRPI0907008A2 (pt) * 2008-01-31 2015-07-07 Alnylam Pharmaceuticals Inc Métodos otimizados para liberação de dsrna alvejando o gene pcsk9
WO2009099326A1 (en) * 2008-02-08 2009-08-13 Prosensa Holding Bv Methods and means for treating dna repeat instability associated genetic disorders
US8188060B2 (en) 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
EP2247729B1 (de) 2008-02-11 2019-05-01 Phio Pharmaceuticals Corp. Modifizierte rnai-polynukleotide und verwendungen davon
WO2009137128A2 (en) 2008-02-12 2009-11-12 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of cd45 gene
WO2009103067A2 (en) * 2008-02-14 2009-08-20 The Children's Hospital Of Philadelphia Compositions and methods to treat asthma
KR100870314B1 (ko) * 2008-02-19 2008-11-25 고려대학교 산학협력단 암 치료용 핵산 의약 조성물
EP2254910A1 (de) * 2008-02-20 2010-12-01 Technische Universität Dresden Verwendung von substanzen zur sensibilisierung von tumorzellen gegen bestrahlung und/oder chemotherapie
AU2009221775B2 (en) * 2008-03-05 2015-05-07 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of Eg5 and VEGF genes
KR101123130B1 (ko) * 2008-03-17 2012-03-30 연세대학교 산학협력단 Ｐｔｋ７ 단백질의 기능 저해를 통한 세포의 이동, 침윤 또는 혈관신생 억제제
CA2718765A1 (en) * 2008-03-20 2009-09-24 Quark Pharmaceuticals, Inc. Novel sirna compounds for inhibiting rtp801
EP2105145A1 (de) * 2008-03-27 2009-09-30 ETH Zürich Verfahren zur muskelspezifischen Abgabe lipidkonjugierter Oligonukleotide
US20110097335A1 (en) * 2008-03-31 2011-04-28 Yoshikazu Sugimoto Abc transporter protein expression inhibitor
RU2501859C2 (ru) * 2008-03-31 2013-12-20 Нэшнл Инститьют Оф Эдванст Индастриал Сайенс Энд Текнолоджи Модифицированная липидами двухцепочечная рнк, обладающая мощным эффектом рнк-интерференции
US8198255B2 (en) * 2008-05-16 2012-06-12 The Board Of Regents Of The University Of Oklahoma SiRNA-mediated inhibition of doublecortin and Ca2+/calmodulin-dependent kinase-like-1
US7902166B2 (en) * 2008-04-03 2011-03-08 The Board Of Regents Of The University Of Oklahoma Compositions comprising inhibitors of RNA binding proteins and methods of producing and using same
TWI348916B (en) * 2008-04-03 2011-09-21 Univ Nat Taiwan A novel treatment tool for cancer: rna interference of bcas2
US7956044B1 (en) 2008-04-03 2011-06-07 The Board Of Regents Of The University Of Oklahoma Compositions comprising inhibitors of RNA binding proteins and methods of producing and using same
US8936941B2 (en) 2008-04-03 2015-01-20 The Board Of Regents Of The University Of Oklahoma Compositions useful for cancer detection and treatment, a cancer stem cell model, and methods of production and use thereof
WO2009123764A2 (en) * 2008-04-04 2009-10-08 Calando Pharmaceuticals, Inc. Compositions and use of epas1 inhibitors
BRPI0910325A8 (pt) 2008-04-05 2019-01-29 Synthes Gmbh implante intervertebral expansível
EP2268812A1 (de) * 2008-04-09 2011-01-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Stim1-inhibitoren zur behandlung kardiovaskulärer erkrankungen
AU2009236219B8 (en) * 2008-04-15 2015-06-25 Arbutus Biopharma Corporation Silencing of CSN5 gene expression using interfering RNA
US8278287B2 (en) * 2008-04-15 2012-10-02 Quark Pharmaceuticals Inc. siRNA compounds for inhibiting NRF2
US7875711B2 (en) 2008-04-17 2011-01-25 Alnylam Pharamaceuticals, Inc. Compositions and methods for inhibiting expression of XBP-1 gene
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
RU2518240C2 (ru) * 2008-04-18 2014-06-10 Ангиочем Инк. Композиция, на основе гидрофобных агентов и способ ее получения(варианты)
WO2009141541A2 (fr) 2008-04-22 2009-11-26 Centre National De La Recherche Scientifique Nouvelles compositions inhibant la melanogenese et leurs utilisations
US8324366B2 (en) 2008-04-29 2012-12-04 Alnylam Pharmaceuticals, Inc. Compositions and methods for delivering RNAI using lipoproteins
EP2119783A1 (de) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Verfahren für effizientes Exon (44)-Skipping bei Duchenne-Muskeldystrophie und entsprechende Mittel
US9663585B2 (en) 2008-05-16 2017-05-30 The Board Of Regents Of The University Of Oklahoma Anti-DCLK1 monoclonal antibodies and methods of production and use thereof
AU2009246134B2 (en) 2008-05-16 2016-03-03 The Children's Hospital Of Philadelphia Genetic alterations on chromosomes 21q, 6q and 15q and methods of use thereof for the diagnosis and treatment of type I diabetes
EP2297323A1 (de) 2008-05-21 2011-03-23 Hartmann, Gunther 5 -triphosphat-oligonukleotid mit stumpfem ende und verwendugen davon
WO2009143391A2 (en) * 2008-05-22 2009-11-26 Isis Pharmaceuticals, Inc Methods for modulation expression of creb
US8541388B2 (en) 2008-05-22 2013-09-24 Isis Pharmaceuticals, Inc. Methods for modulating expression of RBP4
ES2361099B1 (es) 2008-05-26 2012-05-08 Rudolf Morgenstern Lopez "prótesis intervertebral"
US20110130442A1 (en) * 2008-06-04 2011-06-02 Kyowa Hakko Kirin Co., Ltd. Nucleic acid capable of controlling degranulation of mast cell
WO2009147742A1 (ja) * 2008-06-06 2009-12-10 株式会社ジーンテクノサイエンス ヒト・オステオポンチンｓｉＲＮＡ
WO2009147684A2 (en) * 2008-06-06 2009-12-10 Quark Pharmaceuticals, Inc. Compositions and methods for treatment of ear disorders
WO2009147246A1 (en) * 2008-06-06 2009-12-10 Medizinische Universität Graz Compounds reducing or inhibiting the expression of pkd1 for diagnosis and therapy of brain tumors
CA2643886A1 (en) * 2008-06-13 2009-12-13 Oregon Health & Science University Selection of personalized cancer therapy regimens using interfering rna functional screening
WO2009150156A1 (en) * 2008-06-13 2009-12-17 Riboxx Gmbh Method for enzymatic synthesis of chemically modified rna
TWI455944B (zh) * 2008-07-01 2014-10-11 Daiichi Sankyo Co Ltd 雙股多核苷酸
WO2010005850A1 (en) * 2008-07-08 2010-01-14 The J. David Gladstone Institutes Methods and compositions for modulating angiogenesis
DK2320925T3 (en) 2008-07-10 2016-03-21 Regenesance B V Komplementantagonister and uses thereof
US20110118337A1 (en) * 2008-07-10 2011-05-19 Merck Sharp & Dohme Corp. Method of Using Compositions Comprising MIR-192 and/or MIR-215 for the Treatment of Cancer
US20110184046A1 (en) 2008-07-11 2011-07-28 Dinah Wen-Yee Sah Compositions And Methods For Inhibiting Expression Of GSK-3 Genes
EP2313506A1 (de) * 2008-07-11 2011-04-27 Medizinische Universität Innsbruck Antagonisten von nr2f6 zur verstärkung der immunantwort
US8309791B2 (en) * 2008-07-16 2012-11-13 Recombinectics, Inc. Method for producing a transgenic pig using a hyper-methylated transposon
WO2010008582A2 (en) 2008-07-18 2010-01-21 Rxi Pharmaceuticals Corporation Phagocytic cell drug delivery system
US8710022B2 (en) 2008-07-18 2014-04-29 National University Corporation Nagoya University Cell proliferation inhibitor
CN101632833B (zh) * 2008-07-25 2013-11-06 上海市计划生育科学研究所 一种前列腺癌相关的基因及其用途
CA2732343C (en) 2008-07-29 2017-05-09 The Board Of Regents Of The University Of Texas System Selective inhibition of polyglutamine protein expression
US20110237646A1 (en) * 2008-08-07 2011-09-29 Isis Pharmaceuticals, Inc. Modulation of transthyretin expression for the treatment of cns related disorders
US8669102B2 (en) 2008-08-14 2014-03-11 Isis Pharmaceuticals, Inc. Modulation of prion expression
US8946172B2 (en) * 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
SG196769A1 (en) * 2008-08-25 2014-02-13 Excaliard Pharmaceuticals Inc Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
US20130324478A1 (en) * 2008-09-08 2013-12-05 Laurence Faure Pharmacodiagnosis Test Targeting Oncology and Neurodegeneration
JP5764730B2 (ja) 2008-09-10 2015-08-19 ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー １個だけで標識された多種類のプローブを用いるｍＲＮＡ単一分子の画像化
MX345116B (es) * 2008-09-15 2017-01-17 Children's Medical Center Corp Modulacion de bcl11a para tratamiento de hemoglobinopatias.
JP2010068723A (ja) * 2008-09-16 2010-04-02 Tokyo Medical & Dental Univ アレルギー疾患の治療のための核酸医薬
EP2340309A2 (de) 2008-09-22 2011-07-06 Rxi Pharmaceuticals Corporation Neutrale nanotransporter
WO2010036962A1 (en) 2008-09-25 2010-04-01 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
US8592570B2 (en) 2008-10-06 2013-11-26 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of an RNA from West Nile virus
US20110257251A1 (en) * 2008-10-07 2011-10-20 Presidents And Fellows Of Harvard College Telomerase inhibitors and methods of use thereof
EP2355833A4 (de) * 2008-10-15 2012-12-26 Promising Future Llc Auf fas/fasl oder andere todesrezeptoren zielende verfahren und zusammensetzungen zum abtöten von tumorzellen
EP2379084B1 (de) 2008-10-15 2017-11-22 Ionis Pharmaceuticals, Inc. Modulation der expression von faktor 11
RU2531591C2 (ru) 2008-10-15 2014-10-20 Ангиокем Инк. Конъюгаты этопозида и доксорубицина для доставки лекарственных средств
US8921314B2 (en) 2008-10-15 2014-12-30 Angiochem, Inc. Conjugates of GLP-1 agonists and uses thereof
AU2009307677C1 (en) * 2008-10-20 2022-09-22 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of transthyretin
AU2015249072C1 (en) * 2008-10-20 2022-10-27 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of transthyretin
WO2010048590A1 (en) * 2008-10-23 2010-04-29 Alnylam Pharmaceuticals, Inc. Methods and compositions for prevention or treatment of rsv infection using modified duplex rna molecules
CN105779453A (zh) 2008-10-24 2016-07-20 萨雷普塔治疗公司 用于dmd的多外显子跳跃组合物
EP2350656B1 (de) * 2008-10-30 2015-01-07 The Translational Genomics Research Institute Verfahren und Kits zur Identifikation invasiver Glioblastome
US20100267803A1 (en) * 2008-11-07 2010-10-21 The Research Foundation Of State University Of New York Regulators Of Fat Metabolism As Anti-Cancer Targets
US9095592B2 (en) * 2008-11-07 2015-08-04 The Research Foundation For The State University Of New York Bruton's tyrosine kinase as anti-cancer drug target
HUE027027T2 (en) * 2008-11-13 2016-08-29 Modgene Llc Reduction of amyloid beta load in non-brain tissue
US9074211B2 (en) * 2008-11-19 2015-07-07 Rxi Pharmaceuticals Corporation Inhibition of MAP4K4 through RNAI
EP2373308A2 (de) 2008-11-21 2011-10-12 Isis Pharmaceuticals, Inc. Kombinationstherapie zur behandlung von krebs
WO2010064851A2 (ko) * 2008-12-02 2010-06-10 울산대학교 산학협력단 종간 교차활성을 지닌 ｍＴＯＲ을 표적으로 하는 ｓｉＲＮＡ, 이를 포함하는 재조합벡터 및 이를 함유하는 약학조성물
SG171914A1 (en) 2008-12-02 2011-07-28 Chiralgen Ltd Method for the synthesis of phosphorus atom modified nucleic acids
CN102307997B (zh) * 2008-12-04 2018-03-30 库尔纳公司 通过抑制针对沉默调节蛋白1的天然反义转录物来治疗沉默调节蛋白1(sirt1)相关的疾病
US8470792B2 (en) 2008-12-04 2013-06-25 Opko Pharmaceuticals, Llc. Compositions and methods for selective inhibition of VEGF
KR101866152B1 (ko) * 2008-12-04 2018-06-08 큐알엔에이, 인크. 종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
MX2011005963A (es) 2008-12-05 2011-09-01 Angiochem Inc Conjugados de neurotensina o analogos de neurotensina y sus usos.
US20110144687A1 (en) * 2009-12-10 2011-06-16 Kleiner Jeffrey Lateral Based Retractor System
CA2746514C (en) * 2008-12-10 2018-11-27 Alnylam Pharmaceuticals, Inc. Gnaq targeted dsrna compositions and methods for inhibiting expression
EP2376641A4 (de) * 2008-12-17 2013-01-09 Commw Scient Ind Res Org Verfahren zur geschlechtsmodulation bei geflügel
WO2010079084A2 (en) * 2008-12-18 2010-07-15 Centre National De La Recherche Scientifique - Cnrs - Method for identifying genes involved in trail-induced apoptosis and therapeutic applications thereof
US11414664B2 (en) 2008-12-18 2022-08-16 Dicerna Pharmaceuticals, Inc. Extended dicer substrate agents and methods for the specific inhibition of gene expression
EP2379083B1 (de) 2008-12-18 2017-08-16 Dicerna Pharmaceuticals, Inc. Verlängerte dicer-substratstoffe und verfahren für spezifische genexpressionshemmung
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
JPWO2010079819A1 (ja) * 2009-01-08 2012-06-28 塩野義製薬株式会社 肥満または糖尿病治療用医薬組成物
US9127273B2 (en) * 2009-01-13 2015-09-08 The Board Of Regents Of The University Of Texas System UNC-45A splice variants based cancer diagnostics and therapeutics
WO2010093263A1 (en) * 2009-02-03 2010-08-19 Solilrna Biosciences Limited Compositions and methods for the treatment and prevention of neoplastic disorders
BRPI1008109A2 (pt) * 2009-02-03 2015-08-25 Hoffmann La Roche "composições e métodos para a inibição de expressão de genes de ptp1b".
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
WO2010091396A2 (en) * 2009-02-09 2010-08-12 Archemix Corp. Aptamers to von willerbrand factor and their use as thrombotic, hematologic and cardiovascular disease therapeutics
WO2010093788A2 (en) * 2009-02-11 2010-08-19 Dicerna Pharmaceuticals, Inc. Multiplex dicer substrate rna interference molecules having joining sequences
WO2010093904A2 (en) * 2009-02-12 2010-08-19 Curna, Inc. Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
WO2010091878A2 (en) * 2009-02-13 2010-08-19 Silence Therapeutics Ag Means for inhibiting the expression of opa1
CN102333869A (zh) * 2009-02-24 2012-01-25 里博克斯艾克斯有限公司 小干扰rna的改进设计
GB2468477A (en) * 2009-03-02 2010-09-15 Mina Therapeutics Ltd Double stranded RNA molecule comprising siRNA and miRNA precursors
US20110319317A1 (en) * 2009-03-04 2011-12-29 Opko Curna, Llc Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt1
CN102428179A (zh) 2009-03-06 2012-04-25 国立大学法人三重大学 用于增强t细胞功能的方法
AU2010223967B2 (en) * 2009-03-12 2015-07-30 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
US9107933B2 (en) 2009-03-16 2015-08-18 Isis Pharmaceuticals, Inc. Compositions and methods of targeting apolipoprotein B for the reduction of apolipoprotein C-III
EP2408919B1 (de) * 2009-03-16 2017-10-18 CuRNA, Inc. Behandlung von erkrankungen im zusammenhang mit dem nuklearfaktor (erythroid-derived)-like 2 (nrf2) mittels hemmung des natürlichen antisense-transkripts gegen nrf2
WO2010107958A1 (en) * 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
CA2755773A1 (en) * 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of btb and cnc homology 1, basic leucine zipper transcription factor 1 (bach 1) gene expression using short interfering nucleic acid (sina)
US20100239632A1 (en) 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
CA2753388C (en) 2009-03-23 2016-11-29 Quark Pharmaceuticals, Inc. Endo180 antibody to treat cancer and fibrotic disease
EP2411520A2 (de) * 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. Rna-interferenz-vermittelte hemmung der genexpression von tslp (thymic stromal lymphopoietin) unter verwendung von sina (short interfering nucleic acid)
US20120010272A1 (en) * 2009-03-27 2012-01-12 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Apoptosis Signal-Regulating Kinase 1 (ASK1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
WO2010111468A2 (en) * 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
US9526620B2 (en) 2009-03-30 2016-12-27 DePuy Synthes Products, Inc. Zero profile spinal fusion cage
US20120088814A1 (en) 2009-03-31 2012-04-12 Isis Pharmaceuticals, Inc. Methods of modulating an immune response to a viral infection
PL2415870T3 (pl) * 2009-03-31 2017-01-31 Delta-Fly Pharma, Inc. Cząsteczka RNAi dla syntazy tymidylanowej i jej zastosowanie
ES2628144T3 (es) * 2009-04-03 2017-08-01 Dicerna Pharmaceuticals, Inc. Métodos y composiciones para la inhibición específica de KRAS por RNA bicatenario asimétrico
WO2010115202A2 (en) * 2009-04-03 2010-10-07 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of kras by blunt ended double-stranded rna
ES2393583T3 (es) * 2009-04-07 2012-12-26 Biedermann Technologies Gmbh & Co. Kg Herramienta utilizable con un anclaje para hueso, en particular para la cirugía vertebral
AU2010239069B2 (en) 2009-04-20 2015-05-14 Angiochem Inc Treatment of ovarian cancer using an anticancer agent conjugated to an Angiopep-2 analog
EP2421971B1 (de) 2009-04-24 2016-07-06 BioMarin Technologies B.V. Oligonukleotid mit einem inosin zur behandlung von dmd
US9340592B2 (en) 2009-05-05 2016-05-17 Boehringer Ingelheim International Gmbh CHO/CERT cell lines
US8349808B2 (en) * 2009-05-05 2013-01-08 Medical Diagnostic Laboratories, Llc Identification of a novel repressor on IFN-lambda promoter and siRNA against ZEB1 and BLIMP-1 to increase IFN-lambda gene activity
CN102459596B (zh) * 2009-05-06 2016-09-07 库尔纳公司 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
KR101224828B1 (ko) 2009-05-14 2013-01-22 (주)바이오니아 ｓｉＲＮＡ 접합체 및 그 제조방법
GB0908467D0 (en) * 2009-05-15 2009-06-24 Univ Gent Use of the gtpase rab27b as biomarker to stratify patients with estrogen-receptor-positive breast cancer and to monitor their disease progression
WO2011005363A2 (en) * 2009-05-18 2011-01-13 Ensysce Biosciences, Inc. Carbon nanotubes complexed with multiple bioactive agents and methods related thereto
CN102549158B (zh) * 2009-05-22 2017-09-26 库尔纳公司 通过抑制针对转录因子e3(tfe3)的天然反义转录物来治疗tfe3和胰岛素受体底物蛋白2(irs2)相关的疾病
WO2010136417A1 (en) * 2009-05-25 2010-12-02 Università Degli Studi Di Roma "La Sapienza" miR-31 IN DUCHENNE MUSCULAR DYSTROPHY THERAPY
EP2435920B1 (de) * 2009-05-27 2019-05-15 Oracle Israel Ltd. Bereitstellung von diensten auf sitzungsbasis für netzwerke auf ereignisbasis
GB2471065A (en) * 2009-06-10 2010-12-22 Univ Sheffield Modulator of claspin for treatment of cell proliferative disorder
AU2010260148A1 (en) * 2009-06-15 2012-02-02 Alnylam Pharmaceuticals, Inc. Lipid formulated dsRNA targeting the PCSK9 gene
US9051567B2 (en) 2009-06-15 2015-06-09 Tekmira Pharmaceuticals Corporation Methods for increasing efficacy of lipid formulated siRNA
CN115227709A (zh) 2009-06-17 2022-10-25 冷泉港实验室 用于在对象中调节smn2剪接的组合物和方法
CA2765815A1 (en) * 2009-06-26 2010-12-29 Opko Curna, Llc Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
US8283333B2 (en) 2009-07-01 2012-10-09 Protiva Biotherapeutics, Inc. Lipid formulations for nucleic acid delivery
MX2012000016A (es) 2009-07-02 2012-03-26 Angiochem Inc Conjugados de peptidos multimericos y sus usos.
EP2451461A4 (de) 2009-07-06 2013-05-29 Ontorii Inc Neuartige nukleinsäure-prodrugs und verwendungsverfahren dafür
US9849146B2 (en) 2009-07-20 2017-12-26 Rutgers, The State University Of New Jersey Inhibition of nonsense mediated mRNA decay by drugs that prevent hypusination of eukaryotic initiation factor 5A
US8603814B2 (en) 2009-07-20 2013-12-10 Rutgers The State University Of New Jersey Method of inhibiting nonsense-mediated mRNA decay
US20120252869A1 (en) * 2009-07-24 2012-10-04 Opko Curna, Llc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
WO2011019763A2 (en) * 2009-08-10 2011-02-17 The Board Of Trustees Of The University Of Illinois Compositions and methods for the treatment of krabbe and other neurodegenerative diseases
CA2770104C (en) * 2009-08-11 2019-03-19 Opko Curna, Llc Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
AU2010282340B2 (en) 2009-08-13 2016-12-22 The Johns Hopkins University Methods of modulating immune function
EP2464336A4 (de) 2009-08-14 2013-11-20 Alnylam Pharmaceuticals Inc Zusammensetzungen aus lipidformulierungen und verfahren zur hemmung der expression eines gens aus dem ebolavirus
US8598327B2 (en) * 2009-08-18 2013-12-03 Baxter International Inc. Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
WO2011022606A2 (en) * 2009-08-21 2011-02-24 Curna, Inc. Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
US9821094B2 (en) 2014-06-11 2017-11-21 Silver Bullet Therapeutics, Inc. Coatings for the controllable release of antimicrobial metal ions
US8221396B2 (en) 2009-08-27 2012-07-17 Silver Bullet Therapeutics, Inc. Bone implants for the treatment of infection
US10265435B2 (en) 2009-08-27 2019-04-23 Silver Bullet Therapeutics, Inc. Bone implant and systems and coatings for the controllable release of antimicrobial metal ions
US9114197B1 (en) 2014-06-11 2015-08-25 Silver Bullett Therapeutics, Inc. Coatings for the controllable release of antimicrobial metal ions
US8927004B1 (en) 2014-06-11 2015-01-06 Silver Bullet Therapeutics, Inc. Bioabsorbable substrates and systems that controllably release antimicrobial metal ions
WO2011030329A1 (en) * 2009-09-10 2011-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of treating tumors
RU2562861C2 (ru) 2009-09-11 2015-09-10 Айсис Фармасьютикалс, Инк. Модуляция экспрессии гентингтина
CN102639115A (zh) 2009-09-15 2012-08-15 阿尔尼拉姆医药品有限公司 脂质配制的组合物及抑制eg5和vegf基因的表达的方法
US9187746B2 (en) 2009-09-22 2015-11-17 Alnylam Pharmaceuticals, Inc. Dual targeting siRNA agents
CA2775092A1 (en) * 2009-09-23 2011-03-31 Protiva Biotherapeutics, Inc. Compositions and methods for silencing genes expressed in cancer
CN102028947B (zh) * 2009-09-29 2014-02-05 苏州瑞博生物技术有限公司 Fam3b基因的抑制剂和组合物及抑制方法以及脂肪肝的疗法和抑制剂的制药用途
KR20120082906A (ko) 2009-09-30 2012-07-24 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 자가포식현상-향상 유전자 생성물의 조절을 통한 자가포식현상의 조절 방법
US8394778B1 (en) 2009-10-08 2013-03-12 Immune Disease Institute, Inc. Regulators of NFAT and/or store-operated calcium entry
US8962584B2 (en) 2009-10-14 2015-02-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Compositions for controlling Varroa mites in bees
US20110104154A1 (en) * 2009-10-30 2011-05-05 Alcon Research, Ltd. Single nucleotide polymorphisms and genes associated with age-related macular degeneration
US9101643B2 (en) 2009-11-03 2015-08-11 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR)
US20120277144A1 (en) * 2009-11-04 2012-11-01 Henricus Johannes Duckers Novel compounds for modulating neovascularisation and methods of treatment using these compounds
US9799416B2 (en) * 2009-11-06 2017-10-24 Terrapower, Llc Methods and systems for migrating fuel assemblies in a nuclear fission reactor
CN101708328A (zh) * 2009-11-06 2010-05-19 上海市免疫学研究所 Cyr61蛋白在制药中的应用
US8901097B2 (en) 2009-11-08 2014-12-02 Quark Pharmaceuticals, Inc. Methods for delivery of siRNA to the spinal cord and therapies arising therefrom
BR122023023194A2 (pt) 2009-11-12 2023-12-26 The University Of Western Australia Oligonucleotídeo antissentido, composição e respectivo uso
EP2322927A1 (de) * 2009-11-16 2011-05-18 Deutsches Krebsforschungszentrum Verbindungen zum Hemmen der CD95-Signalisierung bei der Behandlung von Pankreaskrebs
DK2504435T3 (da) 2009-11-26 2019-12-09 Quark Pharmaceuticals Inc Sirna-forbindelser omfattende terminale substitutioner
KR101168726B1 (ko) * 2009-11-30 2012-07-30 한국생명공학연구원 암 치료용 약학 조성물
JP5685267B2 (ja) 2009-12-09 2015-03-18 日東電工株式会社 Ｈｓｐ４７発現の調節
US9393129B2 (en) 2009-12-10 2016-07-19 DePuy Synthes Products, Inc. Bellows-like expandable interbody fusion cage
AU2014280918B2 (en) * 2009-12-18 2016-11-17 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat HSF1-related diseases
KR101605932B1 (ko) 2009-12-18 2016-03-24 노파르티스 아게 Ｈｓｆ1-관련 질환을 치료하기 위한 유기 조성물
GB0922332D0 (en) 2009-12-22 2010-02-03 Isis Innovation Method of treatment and screening method
ES2661387T3 (es) * 2009-12-23 2018-03-28 Curna, Inc. Tratamiento de enfermedades relacionadas con el factor de crecimiento de hepatocitos (hgf) mediante inhibición del transcrito antisentido natural a hgf
JP6031356B2 (ja) * 2009-12-23 2016-11-24 カッパーアールエヌエー，インコーポレイテッド Ｕｃｐ２に対する天然アンチセンス転写産物の阻害による脱共役タンパク質２（ｕｃｐ２）関連疾患の治療
EP2516647B1 (de) 2009-12-24 2016-12-14 BioMarin Technologies B.V. Molekül zur Behandlung einer entzündlichen Erkrankung
WO2011084193A1 (en) 2010-01-07 2011-07-14 Quark Pharmaceuticals, Inc. Oligonucleotide compounds comprising non-nucleotide overhangs
CN111700901A (zh) 2010-01-08 2020-09-25 Ionis制药公司 血管生成素样3表达的调节
US9200277B2 (en) * 2010-01-11 2015-12-01 Curna, Inc. Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG
EP2524038A4 (de) * 2010-01-12 2013-11-20 Isis Pharmaceuticals Inc Modulation der transformierung einer wachstumsfaktor-beta-1-expression
US9198983B2 (en) * 2010-01-25 2015-12-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of Mylip/Idol gene
EP3561060A1 (de) 2010-02-08 2019-10-30 Ionis Pharmaceuticals, Inc. Selektive reduktion von allelvarianten
EP2534262B1 (de) 2010-02-08 2016-12-14 Ionis Pharmaceuticals, Inc. Selektive reduktion von allelvarianten
EP2539356A4 (de) * 2010-02-26 2014-03-05 Isis Pharmaceuticals Inc Modulation der smad3-expression
PE20130649A1 (es) 2010-03-08 2013-07-13 Monsanto Technology Llc Moleculas polinucleotidicas para regulacion genetica en plantas
EP2550000A4 (de) 2010-03-24 2014-03-26 Advirna Inc Selbstfreisetzende rnai-verbindungen von reduzierter grösse
BR112012024049A2 (pt) 2010-03-24 2017-03-01 Rxi Pharmaceuticals Corp interferência de rna em indicações dérmicas e fibróticas
CN106074591B (zh) 2010-03-24 2020-01-14 菲奥医药公司 眼部症候中的rna干扰
US8853182B2 (en) * 2010-03-26 2014-10-07 The University Of Tokyo Cell growth inhibitor and screening method thereof
JP5645171B2 (ja) 2010-03-26 2014-12-24 国立大学法人 東京大学 細胞増殖抑制剤及びそのスクリーニング方法
CA2792291A1 (en) 2010-03-29 2011-10-06 Kumamoto University Sirna therapy for transthyretin (ttr) related ocular amyloidosis
AU2015268740B2 (en) * 2010-04-06 2017-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of cd274/pd-l1 gene
AU2011237630B2 (en) 2010-04-06 2016-01-21 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of CD274/PD-L1 gene
CN107929306B (zh) * 2010-04-23 2022-11-15 箭头制药公司 治疗β-ENaC-相关疾病的有机组合物
HRP20170737T1 (hr) 2010-04-29 2017-07-28 Ionis Pharmaceuticals, Inc. Modulacija ekspresije transtiretina
WO2011139387A1 (en) * 2010-05-03 2011-11-10 Opko Curna, Llc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
WO2011140365A1 (en) * 2010-05-05 2011-11-10 Auburn University Targeted particles comprising landscape phage fusion proteins and heterologous nucleic acid
CA2800065A1 (en) * 2010-05-21 2011-11-24 Peptimed, Inc. Reagents and methods for treating cancer
US9944671B2 (en) 2010-06-02 2018-04-17 Alnylam Pharmaceuticals, Inc. Compositions and methods directed to treating liver fibrosis
KR101914309B1 (ko) * 2010-06-23 2018-11-02 큐알엔에이, 인크. 전압 작동 나트륨 통로, 알파 소단위(scna)에 대한 자연 안티센스 전사체의 저해에 의한 전압 작동 나트륨 통로, 알파 소단위(scna) 관련된 질환의 치료
US8979860B2 (en) 2010-06-24 2015-03-17 DePuy Synthes Products. LLC Enhanced cage insertion device
US9763678B2 (en) 2010-06-24 2017-09-19 DePuy Synthes Products, Inc. Multi-segment lateral cage adapted to flex substantially in the coronal plane
AU2011271465B2 (en) 2010-06-29 2015-03-19 Synthes Gmbh Distractible intervertebral implant
FR2962041B1 (fr) * 2010-07-01 2012-07-27 Genethon Inhibiteurs de la calpaine 3 pour le traitement de dystrophies musculaires et de cardiomyopathies
CA2804210A1 (en) 2010-07-06 2012-01-12 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of androgen receptor by double-stranded rna
EP3489360A3 (de) 2010-07-19 2019-08-28 Ionis Pharmaceuticals, Inc. Modulation einer kern-rna
JP2013539456A (ja) 2010-07-28 2013-10-24 アルコン リサーチ，リミテッド ＶＥＧＦＡをターゲティングするｓｉＲＮＡ及びｉｎｖｉｖｏ治療のための方法
US8455304B2 (en) 2010-07-30 2013-06-04 Atmel Corporation Routable array metal integrated circuit package fabricated using partial etching process
WO2012023288A1 (en) * 2010-08-20 2012-02-23 Oncotherapy Science, Inc. Fam161a as a target gene for cancer therapy and diagnosis
US9233997B2 (en) * 2010-08-26 2016-01-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (siNA)
EP2426203B1 (de) 2010-09-02 2016-07-13 Université de Mons Zur Behandlung von fazioskapulohumeraler Muskeldystrophie nützliche Wirkstoffe
SG10201912092VA (en) 2010-09-09 2020-02-27 Pfizer 4-1bb binding molecules
US8217163B2 (en) * 2010-09-20 2012-07-10 Biomics Biotechnologies Co., Ltd. Application of highly conserved domain sequences from viral genome as template to design therapeutic slirnas
US20140141015A1 (en) * 2010-09-20 2014-05-22 Douglas Lake QSOX1 as an Anti-Neoplastic Drug Target
US8946186B2 (en) * 2010-09-20 2015-02-03 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University QSOX1 as an anti-neoplastic drug target
JP5860038B2 (ja) * 2010-09-22 2016-02-16 国立大学法人北海道大学 抗メタボリックシンドローム効果を持つ核酸
DK2620428T3 (da) 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
RU2013107129A (ru) * 2010-09-30 2014-11-10 Нитто Денко Корпорейшн Модуляция экспрессии timp1 и timp2
US20120083035A1 (en) 2010-09-30 2012-04-05 Dharmacon, Inc. Modified Cell Lines for Increasing Lentiviral Titers
JP5996431B2 (ja) * 2010-09-30 2016-09-21 Ｌｓｉｐファンド運営合同会社 優性変異遺伝子発現抑制剤
WO2012048316A2 (en) * 2010-10-08 2012-04-12 Immune Disease Institute, Inc. Regulators of nfat and/or store-operated calcium entry
US9402732B2 (en) 2010-10-11 2016-08-02 DePuy Synthes Products, Inc. Expandable interspinous process spacer implant
EP2631291B1 (de) 2010-10-22 2019-05-15 OliX Pharmaceuticals, Inc. Nukleinsäuremoleküle zur induzierung einer rna-interferenz und verwendungen davon
EP2633048B1 (de) 2010-10-27 2019-07-31 Devgen NV Herunterregulierung der genexpression bei insektenschädlingen
WO2012056441A1 (en) * 2010-10-28 2012-05-03 Nanodoc Ltd. Compositions and methods for specific cleavage of exogenous rna in a cell
CA2816321A1 (en) * 2010-10-29 2012-05-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibition of pcsk9 genes
US9150864B2 (en) 2010-11-08 2015-10-06 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
EP3037066B1 (de) 2010-11-12 2017-08-16 Silver Bullet Therapeutics Inc. Knochenimplantat zur kontrollierten freisetzung von silber
US9920317B2 (en) 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
AU2011325956B2 (en) 2010-11-12 2016-07-14 The General Hospital Corporation Polycomb-associated non-coding RNAs
WO2012068405A2 (en) 2010-11-17 2012-05-24 Isis Pharmaceuticals, Inc. Modulation of alpha synuclein expression
WO2012071238A2 (en) * 2010-11-23 2012-05-31 Opko Curna Llc Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
WO2012075114A2 (en) * 2010-12-01 2012-06-07 Ablitech, Inc. Nucleic acid-polymer conjugates and uses thereof
US20130324591A1 (en) * 2010-12-06 2013-12-05 Quark Pharmaceuticals, Inc. Double stranded oligonucleotide compounds comprising positional modifications
US9193973B2 (en) * 2010-12-10 2015-11-24 Alynylam Pharmaceuticals, Inc. Compositions and methods for increasing erythropoietin (EPO) production
EP2648763A4 (de) * 2010-12-10 2014-05-14 Alnylam Pharmaceuticals Inc Zusammensetzungen und verfahren zur expressionshemmung der gene klf-1 und bcl11a
EP2652136B1 (de) * 2010-12-17 2018-11-07 INSERM - Institut National de la Santé et de la Recherche Médicale Auf tctp gerichtete nukleinsäuren zur behandlung von chemotherapie- oder hormonresistentem krebs
US9644042B2 (en) 2010-12-17 2017-05-09 Carnegie Mellon University Electrochemically mediated atom transfer radical polymerization
WO2012094115A1 (en) * 2010-12-17 2012-07-12 Arrowhead Research Corporation Compositions and methods for inhibiting expression of flt3 genes
EP2652135A1 (de) * 2010-12-17 2013-10-23 Université Pierre et Marie Curie (Paris 6) Abcg1-gen als marker und zielgen zur behandlung von adipositas
WO2012083363A1 (en) * 2010-12-22 2012-06-28 Murdoch Childrens Research Institute A method of treatment
KR101390966B1 (ko) * 2010-12-30 2014-06-30 주식회사 삼양바이오팜 Ｈｉｆｌａ의 발현을 저해하는 ｓｉＲＮＡ 및 이를 포함하는 항암 조성물
BR112013018924A2 (en) * 2011-01-25 2018-05-08 Almac Diagnostics Limited Colon cancer gene expression signatures and methods of use
US20120197320A1 (en) * 2011-01-28 2012-08-02 Laser Spine Surgical Center, LLC Foraminoplasty Device
SI2670411T1 (sl) 2011-02-02 2019-06-28 Excaliard Pharmaceuticals, Inc. Protismiselne spojine, ki so usmerjene na rastni faktor veznega tkiva (CTGF), za uporabo v postopku zdravljenja keloidov ali hipertrofnih brazgotin
WO2012106175A1 (en) * 2011-02-02 2012-08-09 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Trrap and grin2a mutations and use thereof for the diagnosis and treatment of melanoma
US8518087B2 (en) * 2011-03-10 2013-08-27 Interventional Spine, Inc. Method and apparatus for minimally invasive insertion of intervertebral implants
US8394129B2 (en) * 2011-03-10 2013-03-12 Interventional Spine, Inc. Method and apparatus for minimally invasive insertion of intervertebral implants
EP2683825B1 (de) * 2011-03-11 2017-01-04 Sarissa Inc. Verfahren zur behandlung von krebs durch hemmung von dna-reparaturproteinen
EP2508530A1 (de) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Reinigung von triphosphorylierten Oligonucleotiden mit Einfang-Tags
MX360349B (es) 2011-03-29 2018-10-30 Alnylam Pharmaceuticals Inc Composiciones y metodos para inhibir la expresion del gen de proteasa transmembrana, serina 6 (tmprss6).
RS58489B1 (sr) 2011-04-01 2019-04-30 Ionis Pharmaceuticals Inc Modulacija eksprimiranja transduktora signala i aktivatora transkripcije 3 (stat3)
CN105886506A (zh) 2011-04-13 2016-08-24 Isis制药公司 Ptp1b 表达的反义调节
US10941399B2 (en) * 2011-04-14 2021-03-09 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for gene-specific demethylation by DNA methyltransferase (DNMT)-RNA interaction
US8642752B2 (en) 2011-04-21 2014-02-04 Isis Pharmaceuticals, Inc. Modulation of Hepatitis B virus (HBV) expression
TW201243330A (en) * 2011-04-22 2012-11-01 Univ Nat Cheng Kung Method for analyzing sectretome, biomarker for lung cancer metastasis, and siRNA compound for inhibiting lung cancer metastasis
DK2717883T3 (en) 2011-05-02 2017-04-24 Stichting Vumc PROTECTION AGAINST ENDOTELIAL BARRIER DYSFUNCTION BY INHIBITION OF THE TYROSINKINASE ABL RELATED GENES (ARG)
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
AU2012268619B2 (en) * 2011-06-06 2017-08-17 Sirna Therapeutics, Inc. RNA interference mediated inhibition of isocitrate dehydrogenase (IDH1) gene expression
RU2620980C2 (ru) * 2011-06-09 2017-05-30 Курна, Инк. Лечение заболеваний, связанных с фратаксином (fxn), путем ингибирования природного антисмыслового транскрипта fxn
US9187749B2 (en) 2011-06-10 2015-11-17 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
US9315811B2 (en) 2011-06-10 2016-04-19 Ionis Pharmaceuticals, Inc. Methods for modulating kallikrein (KLKB1) expression
CA2839437A1 (en) 2011-06-16 2012-12-20 Isis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
KR20230084331A (ko) 2011-06-21 2023-06-12 알닐람 파마슈티칼스 인코포레이티드 아포리포단백질 c-iii(apoc3) 유전자의 발현 억제를 위한 조성물 및 방법
KR102039315B1 (ko) 2011-06-21 2019-11-04 미나 테라퓨틱스 리미티드 알부민 생산 및 세포 증식
EP3444348A1 (de) 2011-06-21 2019-02-20 Alnylam Pharmaceuticals, Inc. Angiopoietin-3 (angptl3)-irna-zusammensetzungen und verfahren zur verwendung davon
US9228188B2 (en) * 2011-06-21 2016-01-05 Alnylam Pharmaceuticals, Inc. Compositions and method for inhibiting hepcidin antimicrobial peptide (HAMP) or HAMP-related gene expression
EP3388068A1 (de) * 2011-06-21 2018-10-17 Alnylam Pharmaceuticals, Inc. Zusammensetzung und verfahren zur hemmung der expression von protein-c (proc)-genen
FI20115640A0 (fi) 2011-06-22 2011-06-22 Turun Yliopisto Yhdistelmähoito
WO2012178033A2 (en) * 2011-06-23 2012-12-27 Alnylam Pharmaceuticals, Inc. Serpina1 sirnas: compositions of matter and methods of treatment
AU2012275096B2 (en) 2011-06-29 2016-02-04 Ionis Pharmaceuticals, Inc. Methods for modulating kallikrein (KLKB1) expression
WO2013010045A1 (en) 2011-07-12 2013-01-17 Biotime Inc. Novel methods and formulations for orthopedic cell therapy
ES2907620T3 (es) 2011-07-18 2022-04-25 Univ Kentucky Res Found Protección de células de la degeneración inducida por ARN Alu e inhibidores para proteger células
US9605019B2 (en) 2011-07-19 2017-03-28 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
WO2013019857A2 (en) * 2011-08-01 2013-02-07 Alnylam Pharmaceuticals, Inc. Method for improving the success rate of hematopoietic stem cell transplants
US10202599B2 (en) 2011-08-11 2019-02-12 Ionis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
US20140275420A1 (en) 2011-08-22 2014-09-18 Carnegie Mellon University Atom transfer radical polymerization under biologically compatible conditions
KR101275264B1 (ko) 2011-08-24 2013-06-17 포항공과대학교 산학협력단 샤프로닌 단백질의 조절 물질 탐색 방법
EP3640332A1 (de) 2011-08-29 2020-04-22 Ionis Pharmaceuticals, Inc. Oligomer-konjugat-komplexe und deren verwendung
WO2013031704A1 (ja) * 2011-08-29 2013-03-07 学校法人新潟科学技術学園新潟薬科大学 ヒト白血病細胞のアポトーシスを誘導するヘプタマー型スモールガイド核酸
CN103930547A (zh) * 2011-09-02 2014-07-16 诺华股份有限公司 用于治疗hsf1相关疾病的有机组合物
FI20115876A0 (fi) 2011-09-06 2011-09-06 Turun Yliopisto Yhdistelmähoito
US20130064881A1 (en) * 2011-09-08 2013-03-14 Gradalis, Inc. Compositions and methods for treating prostate cancer
US10829828B2 (en) 2011-09-13 2020-11-10 Monsanto Technology Llc Methods and compositions for weed control
EP3434779A1 (de) * 2011-09-13 2019-01-30 Monsanto Technology LLC Verfahren und zusammensetzungen zur unkrautbekämpfung
WO2013040116A1 (en) 2011-09-13 2013-03-21 Monsanto Technology Llc Methods and compositions for weed control
US10806146B2 (en) 2011-09-13 2020-10-20 Monsanto Technology Llc Methods and compositions for weed control
EP2755466A4 (de) 2011-09-13 2015-04-15 Monsanto Technology Llc Verfahren und zusammensetzungen zur unkrautbekämpfung
MX343072B (es) 2011-09-13 2016-10-21 Monsanto Technology Llc Metodos y composiciones para controlar malezas.
CN103957697B (zh) 2011-09-13 2017-10-24 孟山都技术公司 用于杂草控制的方法和组合物
US10760086B2 (en) 2011-09-13 2020-09-01 Monsanto Technology Llc Methods and compositions for weed control
US20150064710A1 (en) * 2011-09-14 2015-03-05 Nippon Kayaku Kabushiki Kaisha Method for inhibiting cell growth, nucleic acid molecule having rna interference effect on nek10 variant gene, and anticancer agent
US11058708B2 (en) * 2011-09-19 2021-07-13 Sweyshen Chen RNA interference of galectin-3 expression and methods of use thereof
US9453261B2 (en) * 2011-09-20 2016-09-27 The George Washington University Alternative splicing variants of genes associated with prostate cancer risk and survival
EP2758533B1 (de) 2011-09-20 2018-04-11 Ionis Pharmaceuticals, Inc. Antisense-modulation der gcgr-expression
US9481895B2 (en) 2011-09-23 2016-11-01 Ge Healthcare Dharmacon, Inc. Introduction of modular vector elements during production of a lentivirus
WO2013048345A1 (en) * 2011-09-28 2013-04-04 Agency For Science, Technology And Research Methods and pharmaceutical compositions for treating cancer
JP2013079210A (ja) * 2011-10-04 2013-05-02 Nagoya City Univ 治療剤、遺伝子治療剤及び好酸球の浸潤抑制方法
US9382534B2 (en) 2011-10-05 2016-07-05 Ge Healthcare Dharmacon, Inc. Optimization of vectors for effective delivery and expression of genetic content
WO2013063313A1 (en) 2011-10-25 2013-05-02 Isis Pharmaceuticals, Inc. Antisense modulation of gccr expression
US9622779B2 (en) 2011-10-27 2017-04-18 DePuy Synthes Products, Inc. Method and devices for a sub-splenius / supra-levator scapulae surgical access technique
CA2887907A1 (en) * 2011-10-31 2013-05-10 The Scripps Research Institute Systems and methods for genomic annotation and distributed variant interpretation
US9773091B2 (en) 2011-10-31 2017-09-26 The Scripps Research Institute Systems and methods for genomic annotation and distributed variant interpretation
CN102373206B (zh) * 2011-10-31 2013-02-27 暨南大学 靶向抑制PPP2R5C基因表达和肿瘤T细胞增殖的PPP2R5C-siRNA799及其应用
US9808232B2 (en) 2011-11-01 2017-11-07 DePuy Synthes Products, Inc. Dilation system
WO2013070786A1 (en) 2011-11-07 2013-05-16 Isis Pharmaceuticals, Inc. Modulation of tmprss6 expression
EP2776450B1 (de) 2011-11-10 2018-04-04 Shire Human Genetic Therapies, Inc. Antisense-oligonukleotidmodulatoren des serotoninrezeptors 2c und verwendungen davon
EP2592146A3 (de) * 2011-11-14 2013-07-24 Silenseed Ltd Verfahren und Zusammensetzungen zur Behandlung von Prostatakrebs
EP2780455B1 (de) * 2011-11-17 2017-07-05 The U.S.A. as represented by the Secretary, Department of Health and Human Services Therapeutische chimäre rna/dna-nanopartikel (np) mit automatischer erkennung
MY167390A (en) 2011-11-18 2018-08-16 Alnylam Pharmaceuticals Inc Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
WO2013075233A1 (en) * 2011-11-21 2013-05-30 The Royal Institution For The Advancement Of Learning / Mcgill University Method for treating brain cancer
US9546367B2 (en) * 2011-12-07 2017-01-17 Jenny Chee Ning Chang siRNA compositions and methods for inhibiting gene expression in tumor initiating cells of breast cancer
EP2802658A2 (de) 2012-01-09 2014-11-19 Novartis AG Rnai-wirkstoffe zur behandlung von erkrankungen im zusammenhang mit beta-catenin
US9707235B1 (en) 2012-01-13 2017-07-18 University Of Kentucky Research Foundation Protection of cells from degeneration and treatment of geographic atrophy
CN118581086A (zh) 2012-01-27 2024-09-03 比奥马林技术公司 用于治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
CN104105473B (zh) * 2012-02-13 2017-09-12 荷兰联合利华有限公司 皮肤美白组合物
DK2817287T3 (da) 2012-02-24 2019-01-02 Arbutus Biopharma Corp Trialkyl kationisk lipid og metoder til anvendelse deraf
US9139829B2 (en) * 2012-02-28 2015-09-22 Medical Diagnostic Laboratories, Llc SiRNA targeting ETS1 and ELK1 and method of using same in the inhibition of CIP2A gene in cancer treatment
WO2013138668A1 (en) * 2012-03-16 2013-09-19 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of mcl1 by double-stranded rna
WO2013142514A1 (en) * 2012-03-19 2013-09-26 Isis Pharmaceuticals, Inc. Methods and compositions for modulating alpha-1-antitrypsin expression
US9410156B2 (en) 2012-03-28 2016-08-09 Somalogic, Inc. Aptamers to PDGF and VEGF and their use in treating PDGF and VEGF mediated conditions
AU2013241099A1 (en) * 2012-03-29 2014-10-09 Aqua Therapeutics Co., Ltd. Nucleic acid molecule capable of inhibiting expression of periostin gene, method for inhibiting expression of periostin gene, and use of said nucleic acid molecule
WO2013149191A1 (en) * 2012-03-29 2013-10-03 The Trustees Of Columbia University In The City Of New York Methods for regulating hair growth disorders
WO2013148283A1 (en) 2012-03-30 2013-10-03 Isis Pharmaceuticals, Inc. Compositions and methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome
JP6482869B2 (ja) * 2012-04-03 2019-03-13 国立研究開発法人国立成育医療研究センター ｍｉＲ−１４０の発現を制御するＤＮＡ及び該ＤＮＡを利用した薬剤のスクリーニング方法
US9133461B2 (en) * 2012-04-10 2015-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the ALAS1 gene
US9265490B2 (en) 2012-04-16 2016-02-23 DePuy Synthes Products, Inc. Detachable dilator blade
SG11201406787TA (en) * 2012-04-20 2014-12-30 Agency Science Tech & Res Rnai-based therapies for cardiomyopathies, muscular dystrophies and laminopathies
US9127274B2 (en) * 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
US10407677B2 (en) * 2012-04-26 2019-09-10 Intana Bioscience Gmbh High complexity siRNA pools
TWI480043B (zh) * 2012-05-01 2015-04-11 高雄醫學大學 用以治療塑化劑引發之雌激素受體陰性型乳癌的醫藥組成物
EP3736333A1 (de) * 2012-05-02 2020-11-11 Arrowhead Pharmaceuticals, Inc. Organische zusammensetzungen zur behandlung von kras-bedingten erkrankungen
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
SG11201407486PA (en) 2012-05-16 2014-12-30 Rana Therapeutics Inc Compositions and methods for modulating utrn expression
EA201492121A1 (ru) 2012-05-16 2015-10-30 Рана Терапьютикс, Инк. Композиции и способы для модулирования экспрессии семейства генов гемоглобина
KR20150030205A (ko) 2012-05-16 2015-03-19 라나 테라퓨틱스, 인크. Smn 유전자 패밀리 발현을 조절하기 위한 조성물 및 방법
AU2013262709A1 (en) 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating MECP2 expression
JP2015523853A (ja) 2012-05-16 2015-08-20 ラナ セラピューティクス インコーポレイテッド Ａｔｐ２ａ２発現を調節するための組成物及び方法
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
WO2013173789A2 (en) 2012-05-17 2013-11-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions
US9574193B2 (en) 2012-05-17 2017-02-21 Ionis Pharmaceuticals, Inc. Methods and compositions for modulating apolipoprotein (a) expression
WO2013177248A2 (en) 2012-05-22 2013-11-28 Isis Pharmaceuticals, Inc. Modulation of enhancer rna mediated gene expression
DK2853597T3 (en) 2012-05-22 2019-04-08 Olix Pharmaceuticals Inc RNA INTERFERENCE-INducing NUCLEIC ACID MOLECULES WITH CELL PENETENING EQUIPMENT AND USE THEREOF
US10240162B2 (en) 2012-05-24 2019-03-26 A.B. Seeds Ltd. Compositions and methods for silencing gene expression
US9487780B2 (en) 2012-06-01 2016-11-08 Ionis Pharmaceuticals, Inc. Antisense compounds targeting genes associated with fibronectin
US9828602B2 (en) * 2012-06-01 2017-11-28 Ionis Pharmaceuticals, Inc. Antisense compounds targeting genes associated with fibronectin
US9201916B2 (en) * 2012-06-13 2015-12-01 Infosys Limited Method, system, and computer-readable medium for providing a scalable bio-informatics sequence search on cloud
CN102703451B (zh) * 2012-06-21 2013-04-17 浙江省医学科学院 一种抑制Bcl2基因表达的表达盒及含有该表达盒的载体
CN102703452B (zh) * 2012-06-21 2013-06-05 浙江省医学科学院 一种抑制Bcl2基因表达的siRNA双链及其应用
BR112014031789A2 (pt) * 2012-06-22 2017-08-01 Syngenta Participations Ag controle biológico de pragas de coleópteros
JP6294876B2 (ja) 2012-06-25 2018-03-14 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｕｂｅ３ａ−ａｔｓ発現の調節
SG10201610869TA (en) 2012-06-26 2017-02-27 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalacti
CN104619845A (zh) 2012-07-13 2015-05-13 图尔库大学 联合治疗iii
CN112007045B (zh) 2012-07-13 2026-01-06 波涛生命科学有限公司 手性控制
DK2872485T3 (da) 2012-07-13 2021-03-08 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
CN103540655A (zh) * 2012-07-16 2014-01-29 复旦大学 Mk5基因在筛选抗肝癌药物中的应用
WO2014018098A1 (en) 2012-07-26 2014-01-30 DePuy Synthes Products, LLC Expandable implant
US9604988B2 (en) 2012-07-27 2017-03-28 Riken Agent for treating or inhibiting recurrence of acute myeloid leukemia
WO2014022655A1 (en) * 2012-08-01 2014-02-06 The Trustees Of Columbia University In The City Of New York Methods for regulating hair growth disorders
KR101520383B1 (ko) 2012-08-02 2015-05-15 에이비온 주식회사 Ｈｐｖ 감염과 관련된 암의 치료용 조성물
WO2014028560A2 (en) 2012-08-14 2014-02-20 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
WO2014033367A1 (en) * 2012-08-30 2014-03-06 Turun Yliopisto Method of selecting individualized brain cancer therapy
US20140067069A1 (en) 2012-08-30 2014-03-06 Interventional Spine, Inc. Artificial disc
CA2883130A1 (en) * 2012-08-31 2014-03-06 The General Hospital Corporation Biotin complexes for treatment and diagnosis of alzheimer's disease
US20140066595A1 (en) * 2012-09-04 2014-03-06 Thermo Fisher Scientific Biosciences Inc. Modulators of Protein Production in a Human Cell Line and Cell-free Extracts Produced Therefrom
ES2750125T3 (es) 2012-09-05 2020-03-25 Sylentis Sau ARNip y su uso en métodos y composiciones para el tratamiento y/o la prevención de afecciones oculares
GB201215857D0 (en) 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
DK2895607T3 (da) 2012-09-12 2021-05-25 Quark Pharmaceuticals Inc Dobbeltstrengede oligonukleotidmolekyler til ddit4 og fremgangsmåder til anvendelse deraf
AU2013224684B2 (en) * 2012-09-13 2017-07-06 Plant Bioscience Limited GENETIC MARKERS FOR Myb28
US9480855B2 (en) 2012-09-26 2016-11-01 DePuy Synthes Products, Inc. NIR/red light for lateral neuroprotection
EP2712870A1 (de) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Neuartige RIG-I-Liganden und Herstellungsverfahren dafür
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
EP4052709A1 (de) 2012-10-11 2022-09-07 Ionis Pharmaceuticals, Inc. Verfahren zur behandlung der kennedy-krankheit
AR092982A1 (es) * 2012-10-11 2015-05-13 Isis Pharmaceuticals Inc Modulacion de la expresion de receptores androgenicos
RU2730677C2 (ru) 2012-10-15 2020-08-24 Ионис Фармасьютикалз, Инк. Соединение для модуляции экспрессии гена c9orf72 и его применение
WO2014062736A1 (en) 2012-10-15 2014-04-24 Isis Pharmaceuticals, Inc. Methods for monitoring c9orf72 expression
US9963699B2 (en) 2012-10-15 2018-05-08 Ionis Pharmaceuticals, Inc. Methods for modulating C9ORF72 expression
WO2014060392A1 (en) * 2012-10-16 2014-04-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Caspase-6 inhibitors for treating t cell activation and/or proliferation disorders
EP2912194B1 (de) 2012-10-26 2019-05-08 Memorial Sloan-Kettering Cancer Center Androgenrezeptorvarianten und verfahren zur herstellung und verwendung
WO2014076703A1 (en) * 2012-11-14 2014-05-22 Silenseed Ltd. Methods and compositions for treating cancer
WO2014077693A1 (en) * 2012-11-16 2014-05-22 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Means and methods for reducing an effect of aging in a mammalian cell
AU2013352156B2 (en) 2012-11-27 2018-12-06 Children's Medical Center Corporation Targeting BCL11A distal regulatory elements for fetal hemoglobin reinduction
KR102096014B1 (ko) 2012-12-05 2020-04-03 알닐람 파마슈티칼스 인코포레이티드 PCSK9 iRNA 조성물 및 그 사용 방법
US9198674B2 (en) * 2012-12-14 2015-12-01 Warsaw Orthopedic, Inc. Surgical instrument and method
WO2014093746A2 (en) * 2012-12-14 2014-06-19 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of ckap5 by double-stranded rna
US10683505B2 (en) 2013-01-01 2020-06-16 Monsanto Technology Llc Methods of introducing dsRNA to plant seeds for modulating gene expression
UA118841C2 (uk) 2013-01-01 2019-03-25 Ей.Бі. СІДС ЛТД. Спосіб формування рослини, яка має підвищену стійкість до комахи-шкідника
WO2014110291A1 (en) 2013-01-09 2014-07-17 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of smn2 splicing in a subject
US9593332B2 (en) * 2013-01-15 2017-03-14 Tufts Medical Center Methods and compositions for targeting immunoglobulins
KR101409445B1 (ko) * 2013-01-17 2014-06-24 한국과학기술연구원 ＯＴＵＢ１ 발현을 저해하는 ｓｉＲＮＡ 및 이를 포함하는 약제학적 조성물
KR101480523B1 (ko) * 2013-02-07 2015-01-08 고려대학교 산학협력단 세포 내 rpS3 발현 억제를 위한 siRNA
KR102169899B1 (ko) 2013-02-14 2020-10-26 아이오니스 파마수티컬즈, 인코포레이티드 지질단백질 리파제 결핍 (lpld) 모집단에서 아포지질단백질 c-iii (apociii) 발현의 조절
DE102013003869B4 (de) * 2013-02-27 2016-11-24 Friedrich-Schiller-Universität Jena Verfahren zur gezielten Abtötung von Zellen durch zur mRNA-Anbindung ausgerichtete Nukleotid-Moleküle sowie Nukleotid-Moleküle und Applikationskit für solche Verwendung
US9717601B2 (en) 2013-02-28 2017-08-01 DePuy Synthes Products, Inc. Expandable intervertebral implant, system, kit and method
SG10201706960TA (en) * 2013-02-28 2017-10-30 Arrowhead Res Corp Organic compositions to treat epas1-related diseases
US9522070B2 (en) 2013-03-07 2016-12-20 Interventional Spine, Inc. Intervertebral implant
US9277928B2 (en) 2013-03-11 2016-03-08 Interventional Spine, Inc. Method and apparatus for minimally invasive insertion of intervertebral implants
US9265789B2 (en) * 2013-03-12 2016-02-23 The Medical College Of Wisconsin, Inc. Targeting CLPTM1L by RNA interference for treatment and prevention of cancer
US9618510B2 (en) 2013-03-13 2017-04-11 Meso Scale Technologies, Llc. Assay methods
WO2014164761A1 (en) 2013-03-13 2014-10-09 Monsanto Technology Llc Methods and compositions for weed control
EP2967082A4 (de) 2013-03-13 2016-11-02 Monsanto Technology Llc Verfahren und zusammensetzungen zur unkrautbekämpfung
WO2014153118A1 (en) * 2013-03-14 2014-09-25 The Board Of Trustees Of The Leland Stanford Junior University Treatment of diseases and conditions associated with dysregulation of mammalian target of rapamycin complex 1 (mtorc1)
US9993353B2 (en) 2013-03-14 2018-06-12 DePuy Synthes Products, Inc. Method and apparatus for minimally invasive insertion of intervertebral implants
CN111254145A (zh) 2013-03-14 2020-06-09 Ionis制药公司 用于调节tau表达的组合物和方法
EA202090946A3 (ru) 2013-03-14 2021-07-30 Сарепта Терапьютикс, Инк. Композиции, обеспечивающие пропускание экзонов, для лечения мышечной дистрофии
ME03043B (de) 2013-03-14 2018-10-20 Alnylam Pharmaceuticals Inc Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
US9480574B2 (en) 2013-03-14 2016-11-01 Benvenue Medical, Inc. Spinal fusion implants and devices and methods for deploying such implants
WO2014144799A2 (en) 2013-03-15 2014-09-18 New York University siRNA TARGETING HSR1
US10568328B2 (en) 2013-03-15 2020-02-25 Monsanto Technology Llc Methods and compositions for weed control
US11342048B2 (en) 2013-03-15 2022-05-24 The Scripps Research Institute Systems and methods for genomic annotation and distributed variant interpretation
WO2014140856A2 (en) 2013-03-15 2014-09-18 Graham Lord Mir-142 and antagonists thereof for treating disease
US9418203B2 (en) 2013-03-15 2016-08-16 Cypher Genomics, Inc. Systems and methods for genomic variant annotation
NZ631289A (en) 2013-03-15 2017-08-25 Sarepta Therapeutics Inc Improved compositions for treating muscular dystrophy
US9909123B2 (en) * 2013-03-15 2018-03-06 Techulon Inc. Antisense molecules for treatment of Staphylococcus aureus infection
WO2014149972A1 (en) 2013-03-15 2014-09-25 The Scripps Research Institute Systems and methods for genomic annotation and distributed variant interpretation
US9132174B2 (en) 2013-03-15 2015-09-15 Anchored Rsk3 Inhibitors, Llc Treatment of heart disease by inhibition of the action of ribosomal S6 kinase 3 (RSK3)
JP5976922B2 (ja) * 2013-03-21 2016-08-24 学校法人 埼玉医科大学 二本鎖核酸分子、ｄｎａ、ベクター、癌細胞増殖抑制剤、及び医薬
US20160051693A1 (en) 2013-03-21 2016-02-25 Genisphere, Llc Cellular Delivery of DNA Intercalating Agents
CN103205400B (zh) * 2013-04-19 2014-09-17 青岛大学医学院附属医院 含有人泛素特异性蛋白酶基因USP39-shRNA的重组慢病毒及其应用
US9264644B2 (en) * 2013-04-25 2016-02-16 Forza Silicon Corporation Analog-to-digital conversion for image sensor with non-destructive read pixel
CA2921162A1 (en) 2013-05-01 2014-11-06 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
US10294480B2 (en) 2013-05-03 2019-05-21 President And Fellows Of Harvard College Foreign DNA surveillance protein
EA201592225A1 (ru) 2013-05-22 2016-04-29 Элнилэм Фармасьютикалз, Инк. КОМПОЗИЦИИ НА ОСНОВЕ iRNA TMPRSS6 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
KR102463973B1 (ko) 2013-05-22 2022-11-07 알닐람 파마슈티칼스 인코포레이티드 ＳＥＲＰＩＮＡ1 ｉＲＮＡ 조성물 및 이의 사용 방법
EP2999783A2 (de) * 2013-05-23 2016-03-30 University of Bremen Neuartige behandlung von stoffwechselkrankheiten
WO2014189996A1 (en) * 2013-05-24 2014-11-27 Nikolai Khodarev Anti-tumor therapy
JP2016524621A (ja) 2013-06-03 2016-08-18 バル−イラン ユニバーシティ ウィスコットアルドリッチ症候群タンパク質を変調するリポソーム
CA2914615C (en) 2013-06-05 2023-10-17 Biotime, Inc. Compositions and methods for induced tissue regeneration in mammalian species
KR102306656B1 (ko) * 2013-07-03 2021-09-29 삼성전자주식회사 항 c-Met 항체를 이용하는 암의 병용 치료
EP3017047A4 (de) 2013-07-03 2017-06-14 Dicerna Pharmaceuticals Inc. Verfahren und zusammensetzungen zur spezifischen alpha-1-trypsin-hemmung durch doppelsträngige rna
US9512430B2 (en) 2013-07-03 2016-12-06 Wisconsin Alumni Research Foundation Compositions and methods to promote erythropoiesis
US9522028B2 (en) 2013-07-03 2016-12-20 Interventional Spine, Inc. Method and apparatus for sacroiliac joint fixation
KR20150006743A (ko) * 2013-07-09 2015-01-19 (주)바이오니아 간암 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 암 예방 또는 치료용 조성물
KR20150006742A (ko) * 2013-07-09 2015-01-19 (주)바이오니아 간암 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 암 예방 또는 치료용 조성물
JP6668236B2 (ja) 2013-07-19 2020-03-18 モンサント テクノロジー エルエルシー Ｌｅｐｔｉｎｏｔａｒｓａ防除用組成物及びその方法
TWI657819B (zh) * 2013-07-19 2019-05-01 美商Ionis製藥公司 用於調節τ蛋白表現之組合物
US9850496B2 (en) 2013-07-19 2017-12-26 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa
TW201536329A (zh) 2013-08-09 2015-10-01 Isis Pharmaceuticals Inc 用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
US20150050738A1 (en) * 2013-08-16 2015-02-19 Rana Therapeutics, Inc. Compositions and methods for modulating rna
US10144928B2 (en) 2013-08-23 2018-12-04 Quark Pharmaceuticals, Inc. Double stranded oligonucleotide compounds comprising positional modifications
KR102365486B1 (ko) 2013-08-28 2022-02-18 아이오니스 파마수티컬즈, 인코포레이티드 프리칼리크레인 (pkk) 발현의 조절
KR102275504B1 (ko) * 2013-09-05 2021-07-09 사렙타 쎄러퓨틱스, 인코퍼레이티드 산성 알파-글루코시다제 내 안티센스-유도된 엑손2 포함
BR112016004911A2 (pt) * 2013-09-05 2017-09-05 Inis Biotech Llc Proteína secretada, acídica e rica em cisteína, um novo alvo para o tratamento e prevenção de insuficiência aguda do fígado
EP3044334B1 (de) 2013-09-09 2020-08-12 Somalogic, Inc. Pdgf- und vegf-aptamere mit erhöhter stabilität und deren verwendung bei der behandlung pdgf- und vegf-vermittelter krankheiten und leiden
JP6666250B2 (ja) * 2013-09-13 2020-03-13 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 補体ｂ因子の調節薬
EP2853596A1 (de) * 2013-09-30 2015-04-01 IKBT (Institut für Klinische Biomedizinische Forschung Thurgau) Proteinphosphatasehemmer
US9994845B2 (en) * 2013-10-02 2018-06-12 Albert Einstein College Of Medicine, Inc. Methods and compositions to inhibit metastasis and to treat fibrosis and to enhance wound healing
CA2925107A1 (en) * 2013-10-02 2015-04-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the lect2 gene
SG11201602631XA (en) * 2013-10-04 2016-05-30 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expression of the alas1 gene
SG10201808903UA (en) 2013-10-11 2018-11-29 Ionis Pharmaceuticals Inc Compositions for modulating c9orf72 expression
US11162096B2 (en) 2013-10-14 2021-11-02 Ionis Pharmaceuticals, Inc Methods for modulating expression of C9ORF72 antisense transcript
EP2865757A1 (de) * 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA und deren Verwendung in Verfahren und Zusammensetzungen zur Hemmung der Expression des PDK1-Gens
EP2865758A1 (de) * 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA und deren Verwendung in Verfahren und Zusammensetzungen zur Hemmung der Expression des ORAI1-Gens
MX390055B (es) 2013-11-04 2025-03-20 Monsanto Technology Llc Composiciones y metodos para controlar infestaciones de plagas y parasitos de los artropodos.
CA2929574A1 (en) 2013-11-11 2015-05-14 Sirna Therapeutics, Inc. Systemic delivery of myostatin short interfering nucleic acids (sina) conjugated to a lipophilic moiety
CA3236835A1 (en) 2013-11-22 2015-05-28 Mina Therapeutics Limited C/ebp alpha short activating rna compositions and methods of use
CN106061488B (zh) 2013-12-02 2021-04-09 菲奥医药公司 癌症的免疫治疗
US10150965B2 (en) 2013-12-06 2018-12-11 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA
UA119253C2 (uk) 2013-12-10 2019-05-27 Біолоджикс, Інк. Спосіб боротьби із вірусом у кліща varroa та у бджіл
CA2931090A1 (en) * 2013-12-12 2015-06-18 Alnylam Pharmaceuticals, Inc. Complement component irna compositions and methods of use thereof
HUE052243T2 (hu) 2013-12-24 2021-04-28 Ionis Pharmaceuticals Inc Az angiopoietin-szerû 3 expressziójának modulációja
US9701966B2 (en) 2013-12-27 2017-07-11 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
WO2015108048A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
CN105979770B (zh) 2014-01-15 2019-07-05 孟山都技术公司 用于使用epsps多核苷酸的杂草控制的方法和组合物
EP3095461A4 (de) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chirales nukleinsäure-adjuvans mit immunitätsinduktionswirkung und immunitätsinduktionsaktivator
KR102423317B1 (ko) 2014-01-16 2022-07-22 웨이브 라이프 사이언시스 리미티드 키랄 디자인
CN104805085A (zh) * 2014-01-29 2015-07-29 江苏命码生物科技有限公司 串联表达的siRNA及其在治疗慢性淋巴细胞白血病中的应用
AU2015217301A1 (en) 2014-02-11 2016-08-25 Alnylam Pharmaceuticals, Inc. Ketohexokinase (KHK) iRNA compositions and methods of use thereof
US11078462B2 (en) 2014-02-18 2021-08-03 ReCyte Therapeutics, Inc. Perivascular stromal cells from primate pluripotent stem cells
KR101425140B1 (ko) * 2014-02-19 2014-08-13 한국과학기술원 Lin28a 메틸화 억제제를 포함하는 줄기세포 전능화 조절용 조성물 및 lin28a 메틸화 억제제의 스크리닝 방법
JP6447933B2 (ja) 2014-02-21 2019-01-09 アイビーシー ファーマスーティカルズ，インコーポレイテッド Ｔｒｏｐ−２発現細胞に対する免疫応答を誘発することによる疾患治療
CA2935748A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
US10011837B2 (en) 2014-03-04 2018-07-03 Sylentis Sau SiRNAs and their use in methods and compositions for the treatment and/or prevention of eye conditions
CN104894223B (zh) * 2014-03-07 2019-03-26 上海吉凯基因化学技术有限公司 人copb2基因的用途及其相关药物
JPWO2015137459A1 (ja) * 2014-03-13 2017-04-06 協和発酵キリン株式会社 Ｉｒｆ５の発現を抑制する核酸
CA3276269A1 (en) 2014-03-18 2026-03-02 University Of Massachusetts Raav-based compositions and methods for treating amyotrophic lateral sclerosis
CN116970607A (zh) * 2014-03-19 2023-10-31 Ionis制药公司 用于调节共济失调蛋白2表达的组合物
WO2015143245A1 (en) 2014-03-19 2015-09-24 Isis Pharmaceuticals, Inc. Methods for modulating ataxin 2 expression
DK3119887T3 (da) * 2014-03-20 2019-05-20 Oommen Varghese Forbedrede korte interfererende ribonukleinsyremolekyler
BR112016022711A2 (pt) 2014-04-01 2017-10-31 Monsanto Technology Llc composições e métodos para controle de pragas de inseto
MY192634A (en) 2014-04-01 2022-08-29 Biogen Ma Inc Compositions for modulating sod-1 expression
US10208309B2 (en) * 2014-04-04 2019-02-19 Bioneer Corporation Double-stranded oligo RNA targeted to amphiregulin and pharmaceutical composition comprising same for preventing or treating fibrosis or respiratory diseases
MA39835A (fr) 2014-04-17 2017-02-22 Biogen Ma Inc Compositions et procédés de modulation de l'épissage du smn2 chez un patient
ES2744186T3 (es) 2014-04-25 2020-02-24 Childrens Medical Center Composiciones y métodos para tratar las hemoglobinopatías
US11279934B2 (en) 2014-04-28 2022-03-22 Phio Pharmaceuticals Corp. Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
MX382230B (es) 2014-05-01 2025-03-13 Ionis Pharmaceuticals Inc Composiciones y metodos para modular la expresion de similar a la angiopoyetina tipo 3.
JP6665111B2 (ja) 2014-05-01 2020-03-13 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｐｋｋ発現を調節するための組成物及び方法
US10280423B2 (en) * 2014-05-01 2019-05-07 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating complement factor B expression
AU2015252841B2 (en) 2014-05-01 2020-03-19 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating growth hormone receptor expression
US10408823B2 (en) 2014-05-15 2019-09-10 Meso Scale Technologies, Llc. Assay methods
US10450571B2 (en) * 2014-05-23 2019-10-22 Università Degli Studi Dell'aquila Small interfering RNA (siRNA) for the therapy of type 2 (ADO2) autosomal dominant osteopetrosis caused by CLCN7 (ADO2 CLCN7-dependent) gene mutation
KR20150137473A (ko) * 2014-05-29 2015-12-09 한국과학기술연구원 USP15의 발현을 저해하는 siRNA 및 이를 포함하는 약제학적 조성물
WO2015186770A1 (ja) * 2014-06-04 2015-12-10 協和発酵キリン株式会社 ＣＫＡＰ５遺伝子発現抑制ＲＮＡｉ医薬組成物
US9452242B2 (en) 2014-06-11 2016-09-27 Silver Bullet Therapeutics, Inc. Enhancement of antimicrobial silver, silver coatings, or silver platings
TW201620526A (zh) 2014-06-17 2016-06-16 愛羅海德研究公司 用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
WO2015200223A1 (en) 2014-06-23 2015-12-30 Monsanto Technology Llc Compositions and methods for regulating gene expression via rna interference
US11807857B2 (en) 2014-06-25 2023-11-07 Monsanto Technology Llc Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression
US10240127B2 (en) 2014-07-03 2019-03-26 ReCyte Therapeutics, Inc. Exosomes from clonal progenitor cells
US10314605B2 (en) 2014-07-08 2019-06-11 Benvenue Medical, Inc. Apparatus and methods for disrupting intervertebral disc tissue
AU2015296700B2 (en) 2014-07-29 2021-10-21 Monsanto Technology Llc Compositions and methods for controlling insect pests
US9752144B2 (en) * 2014-08-04 2017-09-05 MiRagen Therapeutics, Inc. Inhibitors of MYH7B and uses thereof
US9980737B2 (en) 2014-08-04 2018-05-29 Medos International Sarl Flexible transport auger
US20170137820A1 (en) * 2014-08-06 2017-05-18 Bavarian Nordic A/S Agonists and antagonists of toll-like receptor (tlr) 13
GB2547586A (en) * 2014-08-20 2017-08-23 Lifesplice Pharma Llc Splice modulating oligonucleotides and methods of use thereof(In the PCT request)
ES2985036T3 (es) * 2014-08-29 2024-11-04 Childrens Medical Ct Corp Métodos y composiciones para el tratamiento del cáncer
EP4137138A1 (de) 2014-08-29 2023-02-22 Alnylam Pharmaceuticals, Inc. Verfahren zum behandeln von transthyretin (ttr)-vermittelter amyloidose
US10731163B2 (en) * 2014-09-02 2020-08-04 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Oligonucleotide targeted to the A20-3′ untranslated region
KR102506169B1 (ko) 2014-09-05 2023-03-08 피오 파마슈티칼스 코프. Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
WO2016040167A1 (en) * 2014-09-08 2016-03-17 Brandon Higgs Compositions and methods for detecting and treating small cell lung cancer
US10111712B2 (en) 2014-09-09 2018-10-30 Medos International Sarl Proximal-end securement of a minimally invasive working channel
US9924979B2 (en) 2014-09-09 2018-03-27 Medos International Sarl Proximal-end securement of a minimally invasive working channel
US10264959B2 (en) 2014-09-09 2019-04-23 Medos International Sarl Proximal-end securement of a minimally invasive working channel
WO2016040748A1 (en) 2014-09-12 2016-03-17 Ionis Pharmaceuticals, Inc. Compositions and methods for detection of smn protein in a subject and treatment of a subject
EP3191591A1 (de) 2014-09-12 2017-07-19 Alnylam Pharmaceuticals, Inc. Gegen komplementkomponente c5 gerichtete polynukleotidwirkstoffe und verfahren zur verwendung davon
CA2960728C (en) * 2014-09-18 2023-06-06 The University Of British Columbia Allele-specific therapy for huntington disease haplotypes
US9777279B2 (en) 2014-09-24 2017-10-03 University Of Cincinnati Methods and compositions for treating autoimmune disorders by targeting Kv1.3 ion channels with functionalized lipid-derived nanovesicles
TWI864340B (zh) 2014-10-10 2024-12-01 美商艾爾妮蘭製藥公司 用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法
EP3207138B1 (de) * 2014-10-17 2020-07-15 Alnylam Pharmaceuticals, Inc. Gegen aminolävulinsäuresynthase-1 (alas1) gerichtete polynukleotidmittel und verwendungen davon
KR101646609B1 (ko) * 2014-10-24 2016-08-08 한국원자력의학원 후두암 또는 후두암의 방사선 저항성의 진단을 위한 조성물 및 진단 방법
EP3904519A1 (de) 2014-10-30 2021-11-03 Genzyme Corporation Polynukleotidwirkstoffe mit abzielung auf serpinc1 (at3) und verfahren zur verwendung davon
US10858650B2 (en) 2014-10-30 2020-12-08 The General Hospital Corporation Methods for modulating ATRX-dependent gene repression
US10302644B2 (en) * 2014-11-04 2019-05-28 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating multiple myeloma
SG11201703638XA (en) 2014-11-10 2017-06-29 Alnylam Pharmaceuticals Inc Hepatitis b virus (hbv) irna compositions and methods of use thereof
WO2016077566A1 (en) * 2014-11-12 2016-05-19 Research Institute At Nationwide Children's Hospital Modulation of alternative mdm2 splicing
WO2016077540A1 (en) * 2014-11-12 2016-05-19 Ionis Pharmaceuticals, Inc. Compounds and methods for the modulation of comp
IL292999A (en) 2014-11-14 2022-07-01 Voyager Therapeutics Inc Compositions and methods of treating amyotrophic lateral sclerosis (als)
WO2016077704A1 (en) 2014-11-14 2016-05-19 The Regents Of The University Of California Modulation of agpat5 expression
CA2968114A1 (en) 2014-11-17 2016-05-26 Alnylam Pharmaceuticals, Inc. Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
WO2016085852A1 (en) 2014-11-24 2016-06-02 Alnylam Pharmaceuticals, Inc. Tmprss6 irna compositions and methods of use thereof
US10400243B2 (en) 2014-11-25 2019-09-03 Ionis Pharmaceuticals, Inc. Modulation of UBE3A-ATS expression
CN104450710B (zh) * 2014-11-28 2018-06-05 广州市锐博生物科技有限公司 抑制myd88基因的寡聚核酸及其应用
US9714424B1 (en) * 2014-12-16 2017-07-25 Icahn School Of Medicine At Mount Sinai RNAi inhibition of USP10 to treat ocular disorders
MX2017007904A (es) * 2014-12-23 2017-09-05 Syngenta Participations Ag Control biologico de plagas de coleopteros.
WO2016105535A2 (en) * 2014-12-24 2016-06-30 Massachusetts Institute Of Technology Compositions and methods for manipulation of adipocyte energy consumption regulatory pathway
WO2016103042A1 (en) * 2014-12-25 2016-06-30 Guangzhou Ribobio Co., Ltd. Compositions and methods for inhibiting expression of adamts-5 and adam17
US10792299B2 (en) 2014-12-26 2020-10-06 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
US20180002702A1 (en) 2014-12-26 2018-01-04 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
US10264976B2 (en) 2014-12-26 2019-04-23 The University Of Akron Biocompatible flavonoid compounds for organelle and cell imaging
US11045488B2 (en) 2014-12-26 2021-06-29 Nitto Denko Corporation RNA interference agents for GST-π gene modulation
WO2016112132A1 (en) * 2015-01-06 2016-07-14 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of c9orf72 antisense transcript
US9982070B2 (en) 2015-01-12 2018-05-29 Carnegie Mellon University Aqueous ATRP in the presence of an activator regenerator
WO2016115490A1 (en) 2015-01-16 2016-07-21 Ionis Pharmaceuticals, Inc. Compounds and methods for modulation of dux4
US9434947B2 (en) * 2015-01-20 2016-09-06 Oregon Health & Science University Modulation of KCNH2 isoform expression by oligonucleotides as a therapeutic approach for long QT syndrome
US10968449B2 (en) 2015-01-22 2021-04-06 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa
US10022243B2 (en) 2015-02-06 2018-07-17 Benvenue Medical, Inc. Graft material injector system and method
WO2016130806A2 (en) 2015-02-13 2016-08-18 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
WO2016130943A1 (en) 2015-02-13 2016-08-18 Rana Therapeutics, Inc. Hybrid oligonucleotides and uses thereof
US10036017B2 (en) 2015-02-17 2018-07-31 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of complement component 5(C5) by double-stranded RNA
US10525076B2 (en) * 2015-02-20 2020-01-07 Rosalind Franklin University Of Medicine And Science Antisense compounds targeting genes associated with cystic fibrosis
EP3259356B1 (de) * 2015-02-20 2021-12-01 Rosalind Franklin University of Medicine and Science Antisense-verbindungen mit abzielung auf gene im zusammenhang mit zystischer fibrose
US10174322B2 (en) * 2015-02-24 2019-01-08 National Cheng Kung University Short interfering RNA for treating cancer
US10426789B2 (en) 2015-02-26 2019-10-01 Ionis Pharmaceuticals, Inc. Allele specific modulators of P23H rhodopsin
US11129844B2 (en) 2015-03-03 2021-09-28 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating MECP2 expression
US11426290B2 (en) 2015-03-06 2022-08-30 DePuy Synthes Products, Inc. Expandable intervertebral implant, system, kit and method
WO2016149455A2 (en) 2015-03-17 2016-09-22 The General Hospital Corporation The rna interactome of polycomb repressive complex 1 (prc1)
AU2016236521B2 (en) 2015-03-20 2019-03-07 Unilever Global Ip Limited Antiperspirant composition
EP3072969A1 (de) * 2015-03-23 2016-09-28 DKFZ Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Oligonukleotidsequenzen mit abzielung auf den transkriptionsfaktor tsc22d4 zur behandlung von insulinresistenz
EP3273974A4 (de) 2015-03-26 2018-11-07 Women and Infants Hospital of Rhode Island Inc. Therapie für maligne erkrankungen
US10786264B2 (en) 2015-03-31 2020-09-29 Medos International Sarl Percutaneous disc clearing device
US20160289757A1 (en) * 2015-04-01 2016-10-06 Institute Of Environmental Science And Research Limited Methods and materials for detecting rna sequences
WO2016161388A1 (en) 2015-04-03 2016-10-06 University Of Massachusetts Fully stabilized asymmetric sirna
JP7009356B2 (ja) * 2015-04-03 2022-01-25 ユニバーシティ・オブ・マサチューセッツ ハンチンチンｍＲＮＡをターゲティングするオリゴヌクレオチド化合物
HK1249140A1 (zh) 2015-04-03 2018-10-26 Ionis Pharmaceuticals, Inc. 用於调节tmprss6表达的化合物和方法
EP3277815B1 (de) 2015-04-03 2021-09-22 University of Massachusetts Oligonukleotidverbindungen zur behandlung von präeklampsie und anderen angiogenen erkrankungen
MX2017012610A (es) 2015-04-08 2018-03-16 Alnylam Pharmaceuticals Inc Composiciones y metodos para inhibir la expresion del gen lect2.
KR20250005546A (ko) 2015-04-13 2025-01-09 알닐람 파마슈티칼스 인코포레이티드 안지오포이에틴-유사 3(angptl3) irna 조성물 및 이의 이용 방법
SI3283080T1 (sl) 2015-04-16 2020-06-30 Ionis Pharmaceuticals, Inc. Sestavki za moduliranje izražanja C9ORF72
WO2016168578A1 (en) * 2015-04-17 2016-10-20 Genisphere, Llc siRNA INHIBITION OF HUMAN ANTIGEN R EXPRESSION FOR TREATMENT OF CANCER
US20180305689A1 (en) * 2015-04-22 2018-10-25 Mina Therapeutics Limited Sarna compositions and methods of use
ES2835861T5 (en) 2015-05-08 2025-02-18 Childrens Medical Ct Corp Targeting bcl11a enhancer functional regions for fetal hemoglobin reinduction
MA43344A (fr) 2015-05-29 2018-04-11 Juno Therapeutics Inc Composition et procédés de régulation des interactions inhibitrices dans les cellules génétiquement modifiées
US10883103B2 (en) 2015-06-02 2021-01-05 Monsanto Technology Llc Compositions and methods for delivery of a polynucleotide into a plant
EP3302030A4 (de) 2015-06-03 2019-04-24 Monsanto Technology LLC Verfahren und zusammensetzungen zum einführen von nukleinsäuren in pflanzen
US10980892B2 (en) 2015-06-15 2021-04-20 Angiochem Inc. Methods for the treatment of leptomeningeal carcinomatosis
WO2016209862A1 (en) * 2015-06-23 2016-12-29 Alnylam Pharmaceuticals, Inc. Glucokinase (gck) irna compositions and methods of use thereof
WO2016210098A1 (en) * 2015-06-24 2016-12-29 Board Of Regents, The University Of Texas System Dual assembly nanoparticles
US9833338B2 (en) * 2015-06-30 2017-12-05 Expanding Orthopedics Inc. Tool for intervertebral cage
EP3112466A1 (de) * 2015-07-01 2017-01-04 Samsung Electronics Co., Ltd. Zusammensetzung zur verringerung des zellseneszenzwerts einschliesslich aktivitätsinhibitor mit hemmung der dcun1d3-aktivität oder expressionsinhibitor mit hemmung des dcun1d3-decodierungsgens und verwendung davon
US9913727B2 (en) 2015-07-02 2018-03-13 Medos International Sarl Expandable implant
US11001845B2 (en) 2015-07-06 2021-05-11 Phio Pharmaceuticals Corp. Nucleic acid molecules targeting superoxide dismutase 1 (SOD1)
US10808247B2 (en) 2015-07-06 2020-10-20 Phio Pharmaceuticals Corp. Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
US10494632B2 (en) * 2015-07-10 2019-12-03 Alnylam Pharmaceuticals, Inc. Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
PE20180800A1 (es) 2015-07-10 2018-05-09 Ionis Pharmaceuticals Inc Moduladores de diaciglicerol aciltransferasa 2 (dgat2)
EP3323892A4 (de) * 2015-07-13 2019-07-17 Kyowa Hakko Kirin Co., Ltd. Antisense-oligonukleotid-inhibition der 2gpi-expression
US20170051282A1 (en) * 2015-07-23 2017-02-23 Cold Spring Harbor Laboratory Extracellular vesicle methods and compositions
TW201718620A (zh) * 2015-07-27 2017-06-01 阿尼拉製藥公司 黃嘌呤脫氫酶（ＸＤＨ）ｉＲＮＡ組成物及其使用方法
EP3328878A1 (de) * 2015-07-30 2018-06-06 Bayer CropScience Aktiengesellschaft Verfahren und zusammensetzungen zur bekämpfung von rostpilzen durch hemmung der expression des hxt1-gens
JP6896703B2 (ja) 2015-07-31 2021-06-30 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ＴＴＲ関連疾患を治療または予防するためのトランスサイレチン（ＴＴＲ）ｉＲＮＡ組成物およびその使用方法
CN105063048A (zh) * 2015-08-13 2015-11-18 吉林大学 一种抑制Survivin基因表达的siRNA及其应用
WO2017030973A1 (en) 2015-08-14 2017-02-23 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
AU2016309948B2 (en) * 2015-08-14 2021-05-20 The University Of Sydney Connexin 45 inhibition for therapy
CN106467914A (zh) * 2015-08-18 2017-03-01 华东理工大学 靶向人TSPAN8基因的siRNA及其应用
WO2017029391A1 (en) * 2015-08-20 2017-02-23 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating cancer
MX2018002158A (es) 2015-08-25 2018-07-06 Alnylam Pharmaceuticals Inc Mí‰TODOS Y COMPOSICIONES PARA TRATAR UN TRASTORNO ASOCIADO A GEN DE PROPROTEINA CONVERTASA SUBTILISINA KEXINA (PCSK9).
CN108368507B (zh) 2015-09-02 2022-03-22 阿尔尼拉姆医药品有限公司 程序性细胞死亡1配体1(PD-L1)的iRNA组合物及其使用方法
US11672562B2 (en) 2015-09-04 2023-06-13 Medos International Sarl Multi-shield spinal access system
US11744447B2 (en) 2015-09-04 2023-09-05 Medos International Surgical visualization systems and related methods
US10987129B2 (en) 2015-09-04 2021-04-27 Medos International Sarl Multi-shield spinal access system
CN113143355A (zh) 2015-09-04 2021-07-23 美多斯国际有限公司 多护罩脊柱进入系统
US12150636B2 (en) 2015-09-04 2024-11-26 Medos International Sárl Surgical instrument connectors and related methods
US11439380B2 (en) 2015-09-04 2022-09-13 Medos International Sarl Surgical instrument connectors and related methods
WO2017042239A1 (en) * 2015-09-08 2017-03-16 Sylentis Sau siRNA and their use in methods and compositions for inhibiting the expression of the CHI3L1 gene
MA44908A (fr) * 2015-09-08 2018-07-18 Sylentis Sau Molécules d'arnsi et leur utilisation dans des procédés et des compositions pour inhiber l'expression du gène nrarp
GB201516685D0 (en) * 2015-09-21 2015-11-04 Varghese Oommen P And Oommen Oommen P Nucleic acid molecules with enhanced activity
WO2017053681A1 (en) 2015-09-24 2017-03-30 Wisconsin Alumni Research Foundation Methods of expanding hematopoietic stem cells, compositions, and methods of use thereof
US10533175B2 (en) 2015-09-25 2020-01-14 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating Ataxin 3 expression
CN106554962B (zh) * 2015-09-30 2021-06-04 中国科学院上海药物研究所 过表达gpr160的癌症的预防、诊断和治疗
US10543286B2 (en) 2015-10-07 2020-01-28 The Research Foundation For The State University Of New York Methods for increasing platelet count by inhibiting biliverdin IXβ reductase
EP4474389A3 (de) 2015-10-08 2025-03-19 Ionis Pharmaceuticals, Inc. Verbindungen und verfahren zur modulation der angiotensinogenexpression
WO2017066657A1 (en) * 2015-10-14 2017-04-20 Aquinnah Pharmaceuticals, Inc. Nucleic acid based tia-1 inhibitors
SG11201802718PA (en) 2015-10-14 2018-05-30 Bio Path Holdings Inc P-ethoxy nucleic acids for liposomal formulation
US10682362B2 (en) 2015-10-14 2020-06-16 Wayne State University Treatments and diagnostics for cancers
KR101842679B1 (ko) * 2015-10-15 2018-03-28 한국과학기술원 Rna 올리고뉴클레오티드 및 이를 포함하는 면역 활성제
WO2017065369A1 (ko) * 2015-10-15 2017-04-20 한국과학기술원 Rna 올리고뉴클레오티드 및 이를 포함하는 면역 활성제
CN109563509B (zh) 2015-10-19 2022-08-09 菲奥医药公司 靶向长非编码rna的减小尺寸的自递送核酸化合物
US20180228830A1 (en) * 2015-10-23 2018-08-16 Rena Therapeutics Inc. Nucleic acid complex having at least one bulge structure
US12318489B2 (en) 2015-10-26 2025-06-03 Translate Bio Ma, Inc. Nanoparticle formulations for delivery of nucleic acid complexes
US11260073B2 (en) 2015-11-02 2022-03-01 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating C90RF72
WO2017079227A1 (en) 2015-11-05 2017-05-11 University Of Connecticut Compositions and methods for the treatment of liver fibrosis
EP3370708A4 (de) 2015-11-06 2019-06-26 Ionis Pharmaceuticals, Inc. Modulation der apolipoprotein (a)-expression
EP3373939A4 (de) 2015-11-10 2019-06-26 B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University Mittel und verfahren zur verringerung der tumorigenität von krebsstammzellen
EP3377630A4 (de) 2015-11-16 2020-01-01 Olix Pharmaceuticals, Inc. Behandlung von altersbedingter makuladegeneration mit auf myd88 oder tlr3 abzielenden rna-komplexen
EP3378482B1 (de) * 2015-11-19 2024-02-21 Public University Corporation Nagoya City University Formulierung zur verabreichung eines antitumor-arzneimittel
WO2017086436A1 (ja) * 2015-11-20 2017-05-26 国立大学法人九州大学 免疫制御剤
CA3006827A1 (en) 2015-11-30 2017-06-08 The University Of British Columbia Monocarboxylate transporter 4 (mct4) antisense oligonucleotide (aso) inhibitors for use as therapeutics in the treatment of cancer
US11058709B1 (en) 2015-12-04 2021-07-13 Ionis Pharmaceuticals, Inc. Methods of treating breast cancer
SG11201804729RA (en) 2015-12-07 2018-07-30 Genzyme Corp Methods and compositions for treating a serpinc1-associated disorder
CN108779435B (zh) 2015-12-07 2022-05-03 再生疗法有限公司 用于重新衍生不同的多能干细胞衍生的褐色脂肪细胞的方法
EP3386544B1 (de) 2015-12-10 2020-11-25 Fibrogen, Inc. Verfahren zur behandlung von motoneuronenerkrankungen
JP2018536689A (ja) * 2015-12-10 2018-12-13 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ステロール調節エレメント結合タンパク質（ＳＲＥＢＰ）シャペロン（ＳＣＡＰ）ｉＲＮＡ組成物およびその使用方法
US10358647B2 (en) * 2015-12-13 2019-07-23 Nitto Denko Corporation siRNA structures for high activity and reduced off target
EP3181698A1 (de) 2015-12-16 2017-06-21 European Molecular Biology Laboratory (EMBL) Microrna mir-142 als stammzellenmarker
CA3006015A1 (en) 2015-12-31 2017-07-06 Ionis Pharmaceuticals, Inc. Methods for reducing ataxin-2 expression
AU2017205462A1 (en) 2016-01-05 2018-06-07 Ionis Pharmaceuticals, Inc. Methods for reducing LRRK2 expression
US10478503B2 (en) 2016-01-31 2019-11-19 University Of Massachusetts Branched oligonucleotides
JP6944942B2 (ja) * 2016-02-02 2021-10-06 オリックス ファーマシューティカルズ，インコーポレーテッド ＩＬ４Ｒα、ＴＲＰＡ１、またはＦ２ＲＬ１を標的とするＲＮＡ複合体を用いたアトピー性皮膚炎および喘息の治療
EP3411481A4 (de) 2016-02-02 2020-02-26 Olix Pharmaceuticals, Inc. Behandlung von angiogeneseassoziierten erkrankungen mit auf angpt2 und pdgfb abzielenden rna-komplexen
US10299838B2 (en) 2016-02-05 2019-05-28 Medos International Sarl Method and instruments for interbody fusion and posterior fixation through a single incision
US10519442B2 (en) 2016-02-11 2019-12-31 City Of Hope Twist signaling inhibitor compositions and methods of using the same
HK1257668A1 (zh) * 2016-02-19 2019-10-25 The Regents Of The University Of California 短发夹rna(shrna734)及其用於阳性选择和消除遗传修饰的细胞的用途
IL260983B (en) 2016-02-19 2022-07-01 Genisphere Llc Nucleic acid carriers and methods of medical use
US11136577B2 (en) 2016-03-09 2021-10-05 Ionis Pharmaceuticals, Inc. Methods and compositions for inhibiting PMP22 expression
WO2017161168A1 (en) 2016-03-16 2017-09-21 Ionis Pharmaceuticals, Inc. Modulation of dyrk1b expression
EP3429690A4 (de) 2016-03-16 2019-10-23 Ionis Pharmaceuticals, Inc. Verfahren zur modulation von keap1
CN105925576B (zh) * 2016-03-24 2018-04-20 嘉兴市第一医院 针对哺乳动物R‑Spondin3基因靶点的小干扰RNA、短发卡RNA及载体和应用
KR102775461B1 (ko) 2016-04-01 2025-02-28 어비디티 바이오사이언시스 인크. 핵산-폴리펩타이드 조성물 및 이의 용도
ES2640524B1 (es) * 2016-04-01 2018-09-24 Universidad Autónoma de Madrid Uso de tcfl5/cha como nuevo marcador para el pronóstico y/o diagnóstico diferencial de leucemias linfoblásticas agudas
MA45340A (fr) * 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques du récepteur des androgènes et leurs utilisations
WO2017178883A2 (en) 2016-04-11 2017-10-19 Olix Pharmaceuticals, Inc. Treatment of idiopathic pulmonary fibrosis using rna complexes that target connective tissue growth factor
CN109219659B (zh) * 2016-04-14 2022-09-09 贝尼泰克生物制药有限公司 用于治疗眼咽型肌营养不良(opmd)的试剂及其用途
MY200252A (en) 2016-04-18 2023-12-16 Sarepta Therapeutics Inc Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
CN107345230A (zh) 2016-05-05 2017-11-14 江苏命码生物科技有限公司 一种抑制K-RAS基因表达的siRNA及其前体和应用
CN105969771A (zh) * 2016-05-30 2016-09-28 东北师范大学 靶向沉默FOXG1的shRNA
US20230348911A1 (en) * 2016-06-08 2023-11-02 Aalborg Universitet Antisense oligonucleotides for modulation of long noncoding rnas
PT109454A (pt) * 2016-06-14 2017-12-14 Phyzat Biopharmaceuticals Lda Ácidos nucleicos de interferência e composições que os compreendem
WO2017218884A1 (en) 2016-06-16 2017-12-21 Ionis Pharmaceuticals, Inc. Combinations for the modulation of smn expression
CA3023514A1 (en) 2016-06-17 2017-12-21 Ionis Pharmaceuticals, Inc. Modulation of gys1 expression
AU2017285350A1 (en) 2016-06-17 2018-12-20 F. Hoffmann-La Roche Ag Nucleic acid molecules for reduction of PAPD5 or PAPD7 mRNA for treating hepatitis B infection
CN109640889B (zh) 2016-06-28 2021-07-30 Eit 新兴移植技术股份有限公司 可扩张的角度可调节式关节运动椎间保持架
JP6995789B2 (ja) 2016-06-28 2022-01-17 イーアイティー・エマージング・インプラント・テクノロジーズ・ゲーエムベーハー 拡張可能かつ角度調節可能な椎間ケージ
KR101916652B1 (ko) 2016-06-29 2018-11-08 올릭스 주식회사 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도
CN107557363B (zh) * 2016-06-30 2021-03-12 中国科学院分子细胞科学卓越创新中心 可诱导型siRNA表达载体及其制备和应用
US11655470B2 (en) * 2016-07-05 2023-05-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Diagnosing COL6-related disorders and methods for treating same
EP3484280A4 (de) 2016-07-13 2020-08-12 Indiana University Research & Technology Corporation Rnai-insektizidmaterialien und verfahren
AR109207A1 (es) * 2016-08-05 2018-11-07 Syngenta Participations Ag Control de plagas de coleópteros utilizando moléculas de arn
US11753638B2 (en) 2016-08-12 2023-09-12 University Of Massachusetts Conjugated oligonucleotides
UY37376A (es) * 2016-08-26 2018-03-23 Amgen Inc Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso
JP2019532049A (ja) 2016-09-15 2019-11-07 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． Ｄｒｐ１阻害を通じたｐｃｓｋ９およびｌｄｌｒのモジュレーション法
CN109963571A (zh) 2016-09-16 2019-07-02 拜奥-帕斯控股股份有限公司 含有脂质体反义寡核苷酸的组合疗法
EP3516062A1 (de) 2016-09-21 2019-07-31 Alnylam Pharmaceuticals, Inc. Myostatin-irna-zusammensetzungen und verfahren zur verwendung davon
ES2963428T3 (es) 2016-09-29 2024-03-27 Biogen Ma Inc Compuestos y métodos para reducir la expresión de Tau
KR20190065341A (ko) 2016-10-06 2019-06-11 아이오니스 파마수티컬즈, 인코포레이티드 올리고머 화합물들의 접합 방법
ES2939646T3 (es) 2016-10-13 2023-04-25 Juno Therapeutics Inc Métodos y composiciones de inmunoterapia que comprenden moduladores de la vía metabólica del triptófano
US10806715B2 (en) * 2016-10-25 2020-10-20 Council Of Scientific & Industrial Research Gold nanoparticle based formulation for use in cancer therapy
US10537436B2 (en) 2016-11-01 2020-01-21 DePuy Synthes Products, Inc. Curved expandable cage
JOP20190104A1 (ar) * 2016-11-10 2019-05-07 Ionis Pharmaceuticals Inc مركبات وطرق لتقليل التعبير عن atxn3
US10646540B2 (en) 2016-11-18 2020-05-12 City Of Hope Peptide inhibitors of twist
TW202313978A (zh) 2016-11-23 2023-04-01 美商阿尼拉製藥公司 絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法
CN106421790B (zh) * 2016-11-25 2018-12-25 复旦大学附属金山医院 Cmpk的抑制剂在制备治疗卵巢癌的药物中的应用
US11033570B2 (en) 2016-12-02 2021-06-15 Cold Spring Harbor Laboratory Modulation of Lnc05 expression
MA46998A (fr) 2016-12-05 2019-10-09 Juno Therapeutics Inc Production de cellules modifiées pour une thérapie cellulaire adoptive
US10888433B2 (en) 2016-12-14 2021-01-12 DePuy Synthes Products, Inc. Intervertebral implant inserter and related methods
WO2018117253A1 (ja) * 2016-12-23 2018-06-28 協和発酵キリン株式会社 補体ｂ因子の発現を抑制する核酸
CN110381980A (zh) 2017-01-06 2019-10-25 艾维迪提生物科学有限责任公司 核酸-多肽组合物以及诱导外显子跳读的方法
UY37565A (es) 2017-01-10 2018-07-31 Arrowhead Pharmaceuticals Inc Agentes de iarn alfa-1 antitripsina (aat), composiciones que incluyen agentes de iarn aat y métodos de uso
WO2018132582A1 (en) 2017-01-12 2018-07-19 Carnegie Mellon University Surfactant assisted formation of a catalyst complex for emulsion atom transfer radical polymerization processes
EP3568480A1 (de) * 2017-01-13 2019-11-20 Roche Innovation Center Copenhagen A/S Antisense-oligonukleotide zur modulierung der nfkb2-expression
EP3580339A4 (de) 2017-02-10 2020-12-23 Research & Business Foundation Sungkyunkwan University Lange doppelsträngige rna für rna-interferenz
CN106668863B (zh) * 2017-02-21 2019-04-23 南方医科大学 靶向ktn1治疗皮肤鳞状细胞癌的药物
JPWO2018164186A1 (ja) * 2017-03-09 2020-01-09 協和キリン株式会社 Ｍａｓｐ２の発現を抑制する核酸
US10758286B2 (en) 2017-03-22 2020-09-01 Benvenue Medical, Inc. Minimal impact access system to disc space
US11261441B2 (en) 2017-03-29 2022-03-01 Bluebird Bio, Inc. Vectors and compositions for treating hemoglobinopathies
JP7247167B2 (ja) * 2017-04-05 2023-03-28 サイレンス・セラピューティクス・ゲーエムベーハー 産物及び組成物
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
EA201992490A1 (ru) 2017-04-19 2020-03-03 Байо-Пат Холдингз, Инк. Р-этокси нуклеиновые кислоты для ингибирования bcl2
JP7167059B2 (ja) 2017-04-19 2022-11-08 フィオ ファーマシューティカルズ コーポレーション 核酸化合物の局所送達
AU2018255352B2 (en) * 2017-04-19 2023-11-16 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for STAT3 inhibition
NO344051B1 (en) * 2017-05-04 2019-08-26 Patogen As Novel virus in Fish and Method for detection
SG11201909870SA (en) 2017-05-05 2019-11-28 Voyager Therapeutics Inc Compositions and methods of treating amyotrophic lateral sclerosis (als)
US10398563B2 (en) 2017-05-08 2019-09-03 Medos International Sarl Expandable cage
EP3622073A4 (de) 2017-05-09 2021-01-06 University of Massachusetts Verfahren zur behandlung von amyotropher lateralsklerose (als)
US11788087B2 (en) 2017-05-25 2023-10-17 The Children's Medical Center Corporation BCL11A guide delivery
KR20200014320A (ko) * 2017-05-31 2020-02-10 쿄와 기린 가부시키가이샤 Apcs의 발현을 억제하는 핵산
KR101940061B1 (ko) * 2017-06-02 2019-01-21 김준 리보솜 단백질 S3에 대한 siRNA를 포함하는 암 세포 전이 억제용 약학 조성물
CN107177594B (zh) * 2017-06-07 2020-03-03 浙江大学 特异性抑制CA7基因表达的siRNA及其重组载体和应用
US11344424B2 (en) 2017-06-14 2022-05-31 Medos International Sarl Expandable intervertebral implant and related methods
FR3067933B1 (fr) * 2017-06-21 2020-07-17 L'oreal Modulateurs de l’opsine 3 dans la modulation de la pigmentation de la peau
CA3064590A1 (en) 2017-06-23 2018-12-27 University Of Massachusetts Two-tailed self-delivering sirna and related methods
AU2018291368B2 (en) * 2017-06-30 2024-10-03 Oregon State University Genetic variants associated with human-directed hyper-social behavior in domestic dogs
US10940016B2 (en) 2017-07-05 2021-03-09 Medos International Sarl Expandable intervertebral fusion cage
WO2019010301A1 (en) * 2017-07-06 2019-01-10 Kapiloff Michael S TREATMENT OF CARDIOPATHIES BY INHIBITING THE ACTION OF PROTEINS FROM ANCHORING TO MUSCLE PROTEIN KINASES A (MAKAP)
KR20200024793A (ko) 2017-07-06 2020-03-09 애로우헤드 파마슈티컬스 인코포레이티드 알파-ENaC의 발현을 억제하기 위한 RNAi 작용제 및 사용 방법
AU2018301829B2 (en) 2017-07-13 2024-08-01 Alnylam Pharmaceuticals, Inc. Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase) gene expression
BR112020001059A2 (pt) 2017-07-18 2020-07-14 Calimmune, Inc. composições e métodos para o tratamento de beta-hemoglobinopatias
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
EP3664817A4 (de) * 2017-08-07 2021-09-22 Phio Pharmaceuticals Corp. Chemisch modifizierte oligonukleotide
CN110020273B (zh) * 2017-08-16 2021-06-29 北京京东尚科信息技术有限公司 用于生成热力图的方法、装置以及系统
AU2018318231A1 (en) 2017-08-18 2020-02-13 Ionis Pharmaceuticals, Inc. Modulation of the notch signaling pathway for treatment of respiratory disorders
EP3678674B1 (de) * 2017-09-06 2025-02-12 Baylor College of Medicine Park2 nukleinsäure und/oder park2 polypeptid und salvador shrna zur verwendung in der behandlung von herzerkrankungen
CN117866959A (zh) * 2017-09-07 2024-04-12 北京泰德制药股份有限公司 靶向ckip-1的双链rna分子及其用途
US10517889B2 (en) 2017-09-08 2019-12-31 Ionis Pharmaceuticals, Inc. Modulators of SMAD7 expression
CA3075205A1 (en) 2017-09-08 2019-03-14 Mina Therapeutics Limited Stabilized hnf4a sarna compositions and methods of use
TN2020000039A1 (en) 2017-09-11 2021-10-04 Arrowhead Pharmaceuticals Inc Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
PE20201287A1 (es) 2017-09-14 2020-11-24 Arrowhead Pharmaceuticals Inc Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso
KR20200089656A (ko) 2017-09-19 2020-07-27 알닐람 파마슈티칼스 인코포레이티드 트랜스타이레틴(ttr) 매개 아밀로이드증을 치료하기 위한 조성물 및 방법
US11739330B2 (en) 2017-09-22 2023-08-29 University Of Massachusetts SOD1 dual expression vectors and uses thereof
US11781136B2 (en) 2017-09-28 2023-10-10 Secarna Pharmaceuticals Gmbh & Co. Kg Oligonucleotide inhibiting the expression of Chop
EP3672579A4 (de) * 2017-10-10 2021-06-23 University of Virginia Patent Foundation Zusammensetzungen und verfahren zur behandlung altersbedingter makuladegeneration und geografischer atrophie
US11434502B2 (en) 2017-10-16 2022-09-06 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (ALS)
CN111511914B (zh) 2017-10-16 2023-11-17 豪夫迈·罗氏有限公司 减少PAPD5和PAPD7 mRNA的核酸分子用于治疗乙型肝炎感染
HRP20230023T1 (hr) 2017-10-20 2023-03-17 Dicerna Pharmaceuticals, Inc. Postupci liječenja infekcije hepatitisom b
US11866701B2 (en) 2017-11-01 2024-01-09 Alnylam Pharmaceuticals, Inc. Complement component C3 iRNA compositions and methods of use thereof
CN111527209B (zh) * 2017-11-01 2024-11-12 爱迪塔斯医药股份有限公司 Crispr-cas9编辑t细胞中的tgfbr2以用于免疫疗法的方法、组合物和组分
US20230201357A1 (en) * 2017-11-08 2023-06-29 Aptamer Diagnostic, Inc. D-dimer-specific aptamers and methods of use in diagnostics, therapeutic and theranostic purposes
TWI809004B (zh) 2017-11-09 2023-07-21 美商Ionis製藥公司 用於降低snca表現之化合物及方法
GB201718701D0 (en) * 2017-11-13 2017-12-27 Syngenta Participations Ag Improvements in or relating to gene silencing
CN109777800A (zh) * 2017-11-15 2019-05-21 信雅生物科技（苏州）有限公司 一种能够特异性抑制ZBED1基因的siRNA的构建方法及其应用
EP3714054A1 (de) * 2017-11-20 2020-09-30 Alnylam Pharmaceuticals, Inc. Serum-amyloid p-komponente (apcs) irna zusammensetzungen und verfahren zu deren verwendung
GB201719680D0 (en) * 2017-11-27 2018-01-10 Devgen Nv Improvements in or relating to gene silencing
CN110997919B (zh) 2017-12-01 2024-04-02 苏州瑞博生物技术股份有限公司 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途
CN118236391A (zh) 2017-12-01 2024-06-25 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
WO2019105435A1 (zh) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
US11660347B2 (en) 2017-12-01 2023-05-30 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing same, preparation method, and use thereof
JP7261494B2 (ja) 2017-12-01 2023-04-20 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
CN118638788A (zh) * 2017-12-06 2024-09-13 艾维迪提生物科学公司 治疗肌萎缩和强直性肌营养不良的组合物和方法
US20200385714A1 (en) * 2017-12-11 2020-12-10 Roche Innovation Center Copenhagen A/S Oligonucleotides for modulating fndc3b expression
WO2019126641A2 (en) 2017-12-21 2019-06-27 Ionis Pharmaceuticals, Inc. Modulation of frataxin expression
CN110959011B (zh) 2017-12-29 2023-03-28 苏州瑞博生物技术股份有限公司 缀合物及其制备方法和用途
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
KR102956273B1 (ko) 2018-01-08 2026-04-24 이오반스 바이오테라퓨틱스, 인크. 종양 항원-특이적 t-세포에 대해 풍부화된 til 생성물의 생성 방법
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
CN108387621B (zh) * 2018-01-10 2019-11-26 暨南大学 镉离子核酸适配体及丝网印刷电极电化学生物传感器
GB201800370D0 (en) * 2018-01-10 2018-02-21 Ucl Business Plc Anionic nanocomplexes for nucleic acid delivery
US20200392510A1 (en) 2018-01-15 2020-12-17 Ionis Pharmaceuticals, Inc. Modulators of dnm2 expression
WO2019143621A1 (en) * 2018-01-16 2019-07-25 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting aldh2 expression
US11583327B2 (en) 2018-01-29 2023-02-21 Spinal Elements, Inc. Minimally invasive interbody fusion
WO2019155387A1 (en) * 2018-02-07 2019-08-15 St. Jude Children's Research Hospital Epigenetic histone regulation mediated by cxorf67
RU2020125769A (ru) 2018-02-09 2022-03-10 Дженентек, Инк. Олигонуклеотиды для модуляции экспрессии tmem106b
AU2019227510B2 (en) * 2018-03-02 2026-02-12 Novo Nordisk A/S Compositions and methods for inhibiting GYS2 expression
US11732260B2 (en) 2018-03-02 2023-08-22 Ionis Pharmaceuticals, Inc. Compounds and methods for the modulation of amyloid-β precursor protein
TWI840345B (zh) 2018-03-02 2024-05-01 美商Ionis製藥公司 Irf4表現之調節劑
US20190284553A1 (en) 2018-03-15 2019-09-19 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
WO2019178575A1 (en) 2018-03-16 2019-09-19 Benvenue Medical, Inc. Articulated instrumentation and methods of using the same
CN112020556A (zh) * 2018-03-21 2020-12-01 瑞泽恩制药公司 第13型17β羟基类固醇脱氢酶(HSD17B13)iRNA组成物及其使用方法
EP3768694A4 (de) 2018-03-22 2021-12-29 Ionis Pharmaceuticals, Inc. Verfahren zur modulierung der fmr1-expression
IL314908A (en) * 2018-03-29 2024-10-01 Technion Res & Dev Foundation Vesicles comprising a pten inhibitor and uses of same
CA3094020A1 (en) 2018-04-11 2019-10-17 Ionis Pharmaceuticals, Inc. Modulators of ezh2 expression
US12522811B2 (en) 2018-05-01 2026-01-13 The Children's Medical Center Corporation Enhanced BCL11A RNP / CRISPR delivery and editing using a 3XNLS-CAS9
WO2019213013A1 (en) 2018-05-02 2019-11-07 The Children's Medical Center Corporation Improved bcl11a micrornas for treating hemoglobinopathies
SG11202010215TA (en) 2018-05-09 2020-11-27 Ionis Pharmaceuticals Inc Compounds and methods for reducing atxn3 expression
JP7438135B2 (ja) 2018-05-09 2024-02-26 アイオーニス ファーマシューティカルズ， インコーポレーテッド Ｆｘｉの発現を低下させるための化合物及び方法
US11833168B2 (en) 2018-06-14 2023-12-05 Ionis Pharmaceuticals, Inc. Compounds and methods for increasing STMN2 expression
NO344698B1 (en) * 2018-06-15 2020-03-09 Patogen As Novel fish virus
AU2019291050A1 (en) 2018-06-22 2020-12-24 F. Hoffmann-La Roche Ag Oligonucleotides for modulating SCN9A expression
TWI833770B (zh) 2018-06-27 2024-03-01 美商Ionis製藥公司 用於減少 lrrk2 表現之化合物及方法
WO2020007892A1 (en) 2018-07-03 2020-01-09 F. Hoffmann-La Roche Ag Oligonucleotides for modulating tau expression
WO2020011653A1 (en) * 2018-07-09 2020-01-16 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting kynu
WO2020011744A2 (en) * 2018-07-11 2020-01-16 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting cers5
EP3823725A4 (de) 2018-07-17 2023-05-10 Aronora, Inc. Verfahren zur sicheren reduzierung von thrombopoietin
CA3106986A1 (en) 2018-07-25 2020-01-30 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing atxn2 expression
EP3598995A1 (de) * 2018-07-26 2020-01-29 Silence Therapeutics GmbH Produkte und zusammensetzungen
US20220193250A1 (en) 2018-08-02 2022-06-23 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
WO2020033899A1 (en) 2018-08-10 2020-02-13 University Of Massachusetts Modified oligonucleotides targeting snps
MA70658B1 (fr) 2018-08-13 2026-04-30 Alnylam Pharmaceuticals, Inc. Compositions d'agent d'arndb du virus de l'hépatite b (vhb) et leurs méthodes d'utilisation
WO2020037076A1 (en) * 2018-08-14 2020-02-20 Emory University Inducing proliferation of cardiomyocytes and therapeutic uses related thereto
EP3842534A4 (de) 2018-08-21 2022-07-06 Suzhou Ribo Life Science Co., Ltd. Nukleinsäure, pharmazeutische zusammensetzung und konjugat mit der nukleinsäure sowie deren verwendung
JP7627042B2 (ja) 2018-08-23 2025-02-05 ユニバーシティー オブ マサチューセッツ Ｏ－メチルリッチ完全安定化オリゴヌクレオチド
JP7677628B2 (ja) * 2018-08-27 2025-05-15 ノース カロライナ ステート ユニバーシティ 肥満細胞のアポトーシスを誘導するためにスプライススイッチングオリゴヌクレオチドを用いてＫｉｔを標的とする方法
CN109085365B (zh) * 2018-08-27 2020-06-23 山东农业大学 一种抑制高致病性猪繁殖与呼吸障碍综合症病毒感染的阻断剂
CA3110563A1 (en) * 2018-08-31 2020-03-05 University Of Florida Research Foundation, Incorporated Adeno-associated viral vectors for the treatment of best disease
US20220280545A1 (en) * 2018-09-10 2022-09-08 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating cln3 expression
IL281597B1 (en) 2018-09-19 2026-05-01 Arrowhead Pharmaceuticals Inc RNAI agents for suppressing 17 beta-HSD type 13 expression, (HASD17B13), their compositions and uses
EP3862024A4 (de) 2018-09-30 2022-08-17 Suzhou Ribo Life Science Co., Ltd. Sirna-konjugat, verfahren zu seiner herstellung und seine verwendung
WO2020071392A1 (ja) * 2018-10-02 2020-04-09 小胞体ストレス研究所株式会社 予後不良のがん細胞の増殖抑制剤
US11446156B2 (en) 2018-10-25 2022-09-20 Medos International Sarl Expandable intervertebral implant, inserter instrument, and related methods
IL326747A (en) * 2018-11-02 2026-04-01 Biomarin Tech Bv Bispecific antisense oligonucleotides for dystrophin exon skipping
TW202028222A (zh) 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
EA202191342A1 (ru) 2018-11-15 2021-08-10 Айонис Фармасьютикалз, Инк. Модуляторы экспрессии irf5
US12281305B2 (en) 2018-11-21 2025-04-22 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing prion expression
JP7707065B2 (ja) * 2018-11-23 2025-07-14 サノフイ Ａｎｇｐｔｌ８を阻害するための新規のｒｎａ組成物および方法
CN111228289A (zh) * 2018-11-28 2020-06-05 中国科学院大连化学物理研究所 Plin2抑制剂的应用和治疗肿瘤药物混合物
ES2766855A1 (es) * 2018-12-14 2020-06-15 Consejo Superior Investigacion Rhoq como diana farmacéutica para trastornos neurológicos
ES2766950A1 (es) * 2018-12-14 2020-06-15 Consejo Superior Investigacion ARHGEF6 como diana farmacéutica para trastornos neurológicos
PE20211475A1 (es) 2018-12-20 2021-08-05 Amgen Inc Inhibidores de kif18a
IL319265A (en) 2018-12-21 2025-04-01 Avidity Biosciences Inc Anti-transferrin receptor antibodies and their uses
CN112423794A (zh) 2018-12-28 2021-02-26 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
WO2020142693A1 (en) * 2019-01-04 2020-07-09 Empirico Inc. Treatment of thymic stromal lymphopoietin (tslp) related diseases by inhibition of long-form tslp transcripts
EP3908288A4 (de) 2019-01-09 2023-12-20 Arrowhead Pharmaceuticals, Inc. Rnai-mittel zur hemmung der expression von hif-2 typ (epas1), zusammensetzungen davon und verwendungsverfahren
WO2020144295A1 (en) 2019-01-10 2020-07-16 Biontech Rna Pharmaceuticals Gmbh Localized administration of rna molecules for therapy
WO2020149644A1 (ko) * 2019-01-15 2020-07-23 (주)바이오니아 Dkk1 유전자를 표적으로 하는 이중나선 올리고뉴클레오티드, 이를 포함하는 구조체 및 이를 포함하는 탈모 예방 또는 발모용 조성물
WO2020150636A1 (en) * 2019-01-18 2020-07-23 University Of Massachusetts Dynamic pharmacokinetic-modifying anchors
MX2021008918A (es) 2019-01-31 2021-08-24 Ionis Pharmaceuticals Inc Moduladores de expresion yap1.
WO2020176771A1 (en) * 2019-02-27 2020-09-03 Ionis Pharmaceuticals, Inc. Modulators of malat1 expression
KR20210134003A (ko) 2019-02-27 2021-11-08 스톡 테라퓨틱스, 인크. 병태 및 질환의 치료를 위한 안티센스 올리고머
KR20260021093A (ko) 2019-03-01 2026-02-12 메소 스케일 테크놀러지즈, 엘엘시 면역검정 방법에서 사용을 위한 전기화학발광성 표지화된 프로브, 이의 사용 방법 및 이를 포함하는 키트
US11013530B2 (en) 2019-03-08 2021-05-25 Medos International Sarl Surface features for device retention
AU2020241251A1 (en) * 2019-03-15 2021-10-07 University Of Washington Improved survival of human cells differentiated in vitro by PRPF31 gene expression knockdown
AU2020239987A1 (en) * 2019-03-15 2021-11-04 University Of Massachusetts Oligonucleotides for tissue specific ApoE modulation
US11241252B2 (en) 2019-03-22 2022-02-08 Medos International Sarl Skin foundation access portal
CA3135180A1 (en) 2019-03-29 2020-10-08 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating ube3a-ats
US11129727B2 (en) 2019-03-29 2021-09-28 Medos International Sari Inflatable non-distracting intervertebral implants and related methods
US11813026B2 (en) 2019-04-05 2023-11-14 Medos International Sarl Systems, devices, and methods for providing surgical trajectory guidance
US12357695B2 (en) 2019-04-17 2025-07-15 Aadigen, Llc Peptides and nanoparticles for intracellular delivery of molecules
EP3956448A4 (de) * 2019-04-18 2022-10-19 University of Massachusetts Aim2-inhibitoren und verwendungen davon
CA3137715A1 (en) 2019-04-25 2020-10-29 Avidity Biosciences, Inc. Nucleic acid compositions and methods of multi-exon skipping
CN111849968A (zh) * 2019-04-30 2020-10-30 中美瑞康核酸技术(南通)研究院有限公司 寡核苷酸分子及其在急性间歇性卟啉症治疗中的应用
US20220213479A1 (en) 2019-05-05 2022-07-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Restoration of the cftr function by splicing modulation
US11938198B2 (en) 2019-05-15 2024-03-26 University Of Miami Treatment of heart disease by disruption of the anchoring of PP2A
AU2020280439B2 (en) 2019-05-22 2025-08-14 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
JP7663951B2 (ja) 2019-05-22 2025-04-17 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、薬物組成物及び複合体ならびに調製方法と使用
CN113811613B (zh) 2019-05-22 2024-04-05 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
US20200369759A1 (en) 2019-05-23 2020-11-26 Fibrogen, Inc. Methods of treatment of muscular dystrophies
WO2020238766A1 (zh) * 2019-05-24 2020-12-03 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
US20220315929A1 (en) * 2019-05-24 2022-10-06 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition and conjugate, preparation method therefor and use thereof
CA3140917A1 (en) * 2019-05-24 2020-12-03 Empirico Inc. Treatment of angiopoietin like 7 (angptl7) related diseases
EP3980540A4 (de) 2019-06-06 2023-11-01 Arrowhead Pharmaceuticals, Inc. Verfahren zur behandlung von alpha-1-antitrypsin-mangel (aatd)
CA3143996A1 (en) 2019-06-21 2020-12-24 The Children's Medical Center Corporation Methods and compositions for the treatment of cancer
EP3997225A1 (de) * 2019-07-10 2022-05-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur behandlung von epilepsie
ES3048358T3 (en) 2019-07-26 2025-12-10 Ionis Pharmaceuticals Inc Compounds and methods for modulating gfap
WO2021020412A1 (ja) 2019-07-30 2021-02-04 塩野義製薬株式会社 Ｍｕｒｆ１を標的とする核酸医薬
CA3149835A1 (en) 2019-08-09 2021-02-18 University Of Massachusetts Chemically modified oligonucleotides targeting snps
CN120866510A (zh) 2019-08-12 2025-10-31 雷杰纳荣制药公司 巨噬细胞刺激1受体(mst1r)变体及其用途
WO2021041317A1 (en) * 2019-08-23 2021-03-04 University Of Virginia Patent Foundation Ddx17 and nlrc4 targeting for inflammatory diseases
US12195772B2 (en) 2019-08-30 2025-01-14 Inari Agriculture Technology, Inc. RNA-guided nucleases and DNA binding proteins
CN114173783A (zh) * 2019-08-30 2022-03-11 新加坡科技研究局 促进运动神经元的存活和/或功能的方法及相关试剂、用途和方法
US20220290147A1 (en) * 2019-08-30 2022-09-15 Baylor College Of Medicine System for regulating gene expression
EP3791930A1 (de) * 2019-09-13 2021-03-17 Secarna Pharmaceuticals GmbH & Co. KG Inhibitor der metadherin-expression
US12365894B2 (en) 2019-09-16 2025-07-22 University Of Massachusetts Branched lipid conjugates of siRNA for specific tissue delivery
KR102100163B1 (ko) 2019-09-24 2020-04-13 테고사이언스 (주) 켈로이드 또는 비후성 반흔 예방 또는 치료용 조성물
JP2022551970A (ja) * 2019-10-16 2022-12-14 ブラウン ユニバーシティ 筋再生および筋成長
BR112022007540A2 (pt) 2019-10-22 2022-07-12 Alnylam Pharmaceuticals Inc Composições de irna de componente complementar c3 e métodos de uso das mesmas
TW202130809A (zh) * 2019-10-29 2021-08-16 美商愛羅海德製藥公司 用於抑制β-ENaC表現之RNAi藥劑、其組合物及使用方法
WO2021087325A1 (en) * 2019-11-01 2021-05-06 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing dnajb1-prkaca fusion gene expression
JP2023501352A (ja) * 2019-11-08 2023-01-18 アイオーニス ファーマシューティカルズ， インコーポレーテッド Ｓｐｄｅｆ発現を低減するための化合物及び方法
CN110859960B (zh) * 2019-11-26 2022-03-04 深圳先进技术研究院 靶向AMPK的抑制剂/siRNA与蛋白酶体抑制剂组合在制备抗肿瘤药物中的应用
AU2020399633A1 (en) * 2019-12-09 2022-07-07 Empirico Inc. Oligonucleotides for treatment of Angiopoietin like 4 (ANGPTL4) related diseases
KR20220116520A (ko) 2019-12-16 2022-08-23 알닐람 파마슈티칼스 인코포레이티드 파타틴-유사 포스포리파제 도메인 함유 3 (PNPLA3) iRNA 조성물 및 이의 사용 방법
TW202136510A (zh) * 2019-12-20 2021-10-01 瑞士商赫孚孟拉羅股份公司 用於抑制ｓｃｎ９ａ表現之增強型寡核苷酸
JP2023507501A (ja) * 2019-12-23 2023-02-22 ヴェルサメブ アーゲー 遺伝子の発現を同時に調節するための組成物及び方法
EP4081302A4 (de) * 2019-12-23 2025-01-29 University Of Massachusetts Oligonukleotide zur gewebespezifischen genexpressionsmodulation
WO2021137506A1 (ko) * 2019-12-31 2021-07-08 한국원자력연구원 Wdr34 억제제를 포함하는 암줄기세포 성장 억제용 조성물 및 그 용도
WO2021160937A1 (en) 2020-02-11 2021-08-19 Turun Yliopisto Therapy of ras-dependent cancers
WO2021167841A1 (en) 2020-02-18 2021-08-26 Alnylam Pharmaceuticals, Inc. Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
BR112022014717A2 (pt) * 2020-02-21 2022-10-11 Replicor Inc Métodos e composições para a inibição das infecções por vírus da hepatite b e da hepatite d
PH12022552258A1 (en) 2020-02-28 2023-11-20 Ionis Pharmaceuticals Inc Compounds and methods for modulating smn2
US12258566B2 (en) * 2020-02-28 2025-03-25 University Of Massachusetts Oligonucleotides for PRNP modulation
WO2021178769A1 (en) * 2020-03-06 2021-09-10 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating kcnq2
WO2021178736A1 (en) * 2020-03-06 2021-09-10 Alnylam Pharmaceuticals, Inc. KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
US11426286B2 (en) 2020-03-06 2022-08-30 Eit Emerging Implant Technologies Gmbh Expandable intervertebral implant
WO2021188390A1 (en) * 2020-03-19 2021-09-23 Avidity Biosciences, Inc. Compositions and methods of treating facioscapulohumeral muscular dystrophy
EP4127173A4 (de) * 2020-03-27 2024-07-17 Alnylam Pharmaceuticals, Inc. Fc-fragment von igg-rezeptor- und transporter-irna-zusammensetzungen und verfahren zur verwendung davon
CN113444723A (zh) * 2020-03-27 2021-09-28 北京键凯科技股份有限公司 一种抑制血管内皮生长因子受体2基因表达的干扰rna及其应用
WO2021195469A1 (en) 2020-03-27 2021-09-30 Avidity Biosciences, Inc. Compositions and methods of treating muscle dystrophy
IL297130A (en) * 2020-04-07 2022-12-01 Alnylam Pharmaceuticals Inc Compositions and methods for silencing scn9a expression
TW202203919A (zh) * 2020-04-14 2022-02-01 美商安進公司 用於治療贅生性疾病之ｋｉｆ１８ａ抑制劑
KR20230002814A (ko) * 2020-04-17 2023-01-05 더 유니버시티 오브 브리티쉬 콜롬비아 Tdp-43 및 fus 응집을 억제하기 위한 조성물 및 방법
KR20230005933A (ko) 2020-05-01 2023-01-10 아이오니스 파마수티컬즈, 인코포레이티드 Atxn1을 조정하는 화합물 및 방법
BR112022022889A2 (pt) 2020-05-11 2023-04-04 Stoke Therapeutics Inc Oligômeros antissentido de opa1 para tratamento de condições e doenças
TW202208628A (zh) * 2020-05-13 2022-03-01 瑞士商赫孚孟拉羅股份公司 靶向顆粒蛋白前體之寡核苷酸促效劑
CN116113421A (zh) 2020-05-14 2023-05-12 阿莱兹精准医疗公司 使用siRNA调节PRDM2/RIZ蛋白表达的癌症治疗
CN111714510B (zh) * 2020-05-18 2021-07-06 北京航空航天大学 长链非编码rna snhg12抑制剂在制备对抗骨质疏松药物中的应用
EP4153746A1 (de) * 2020-05-21 2023-03-29 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur hemmung der marc1-genexpression
EP4157289A4 (de) 2020-05-26 2024-06-26 University Of Massachusetts Synthetische oligonukleotide mit block- und cluster-modifikationsregionen
US20230203496A1 (en) * 2020-06-09 2023-06-29 Alnylam Pharmaceuticals, Inc. Sirna compositions and methods for silencing gpam (glycerol-3-phosphate acyltransferase 1, mitochondrial) expression
EP4161532A4 (de) * 2020-06-09 2025-09-17 Alnylam Pharmaceuticals Inc Irna-zusammensetzungen aus tumornekrosefaktorrezeptorassoziiertem faktor 6 (traf6) und verfahren zur verwendung davon
WO2021252903A2 (en) * 2020-06-11 2021-12-16 Genetic Intelligence, Inc, New York, Ny Compositions for flcn gene modulation and methods thereof
US11459567B2 (en) 2020-06-24 2022-10-04 Patricia Virginia Elizalde Specific siRNA molecules, composition and use thereof for the treatment of triple negative breast cancer
IL298530A (en) 2020-06-29 2023-01-01 Ionis Pharmaceuticals Inc Compounds and methods for modulating plp1
CA3186853A1 (en) * 2020-07-23 2022-01-27 John Mansell Compositions and methods for treating pain and anxiety disorders
EP4201484A4 (de) * 2020-07-28 2024-10-02 KNC Laboratories Co., Ltd. Antisense-nukleinsäure zur induktion von exon-skipping des angiotensin-konvertierenden enzym-2-gens
KR20230043914A (ko) 2020-07-28 2023-03-31 아이오니스 파마수티컬즈, 인코포레이티드 App 발현을 감소시키기 위한 화합물 및 방법
WO2022031591A2 (en) * 2020-08-03 2022-02-10 University Of Massachusetts Oligonucleotides for htt-1a modulation
AU2021321430A1 (en) * 2020-08-04 2023-03-02 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting PLP1 expression
TW202221123A (zh) 2020-08-07 2022-06-01 美商Ionis製藥公司 調節ｓｃｎ２ａ之化合物及方法
EP4196587A4 (de) * 2020-08-13 2025-07-23 Nevada Res & Innovation Corporation Klf11-sirna zur behandlung von diabetes und adipositas
CA3189861A1 (en) * 2020-09-01 2022-03-10 Sean Christopher DAUGHERTY Dux4 inhibitors and methods of use thereof
WO2022054801A1 (ja) * 2020-09-09 2022-03-17 大原薬品工業株式会社 ｓｉＲＮＡおよびその用途
AU2021342155A1 (en) 2020-09-11 2023-04-13 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use
CA3195722A1 (en) 2020-09-17 2022-03-24 Q-State Biosciences, Inc. Therapeutic compositions for treating pain via multiple targets
EP4223876A4 (de) * 2020-09-30 2025-12-10 Fujifilm Corp Doppelsträngige rna zur hemmung der produktion von hepatitis-b-virusprotein und pharmazeutische zusammensetzung
WO2022089486A1 (zh) * 2020-10-28 2022-05-05 江苏柯菲平医药股份有限公司 抑制PCSK9基因表达的siRNA及其修饰物与应用
WO2022103999A1 (en) 2020-11-13 2022-05-19 Alnylam Pharmaceuticals, Inc. COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2022104141A1 (en) * 2020-11-13 2022-05-19 The George Washington University, A Congressionally Chartered Not-For -Profit Corporation B-spectrin (sptbn1) deficiency protects mice from high-fat diet-induced liver disease and cancer development
JP7820374B2 (ja) 2020-11-18 2026-02-25 アイオーニス ファーマシューティカルズ， インコーポレーテッド アンジオテンシノーゲン発現を調節するための化合物及び方法
EP4257686A4 (de) * 2020-12-07 2026-02-18 Olix Pharmaceuticals Inc Nukleinsäuremolekül zur induktion von asymmetrischer rnai zur hemmung der expression von ror-beta
US12018261B2 (en) 2020-12-18 2024-06-25 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating factor XII
KR20230154026A (ko) * 2021-02-08 2023-11-07 락티젠 세러퓨틱스 다가 올리고뉴클레오티드 작용제 및 이의 사용 방법
AU2022231003A1 (en) 2021-03-04 2023-09-14 Alnylam Pharmaceuticals, Inc. Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
US11771517B2 (en) 2021-03-12 2023-10-03 Medos International Sarl Camera position indication systems and methods
US20220411802A1 (en) * 2021-03-17 2022-12-29 Sirnaomics, Inc. METHODS OF CANCER TREATMENT BY DELIVERY OF siRNAs AGAINST NSD3
US11850160B2 (en) 2021-03-26 2023-12-26 Medos International Sarl Expandable lordotic intervertebral fusion cage
WO2022204440A1 (en) * 2021-03-26 2022-09-29 Alnylam Pharmaceuticals, Inc. ELONGATION OF VERY LONG CHAIN FATTY ACIDS PROTEIN 1 (ELOVL1) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
WO2022212208A1 (en) * 2021-03-29 2022-10-06 University Of Massachusetts Oligonucleotides for syngr-3 modulation
US11752009B2 (en) 2021-04-06 2023-09-12 Medos International Sarl Expandable intervertebral fusion cage
BR112023020626A2 (pt) 2021-04-08 2023-12-19 Arrowhead Pharmaceuticals Inc Agentes de rnai para inibir a expressão do receptor para produtos finais de glicação avançada, composições dos mesmos e métodos de uso
US12239710B2 (en) * 2021-04-14 2025-03-04 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
CA3215478A1 (en) * 2021-04-16 2022-10-20 Adeline VANDERVER Compositions and methods useful for the treatment of h-abc leukodystrophy
MX2023012086A (es) * 2021-04-19 2023-10-25 Novo Nordisk As Composiciones y metodos para inhibir la expresion del miembro 3 del grupo h de la subfamilia 1 de receptores nucleares (nr1h3).
IL307721A (en) * 2021-04-20 2023-12-01 Astrazeneca Ireland Ltd Compounds and methods for inhibiting expression of component 3
US20240182894A1 (en) * 2021-04-22 2024-06-06 Molecular Axiom, Llc Compositions and methods for modulating sos gene expressions
BR112023022284A2 (pt) 2021-04-26 2023-12-26 Alnylam Pharmaceuticals Inc Composições de irna de protease transmembrana, serina 6 (tmprss6) e métodos de uso da mesma
NZ804423A (en) 2021-04-27 2026-01-30 4D Molecular Therapeutics Inc Compositions and methods for treatment of ocular disease associated with angiogenesis
CA3217456A1 (en) * 2021-05-06 2022-11-10 Spyro Mousses Multitargeting rna compositions
US20240301415A1 (en) * 2021-05-21 2024-09-12 Ionis Pharmaceuticals, Inc. Compounds for modulating unc13a expression
WO2022251629A2 (en) * 2021-05-27 2022-12-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing carbonic anhydrase 2 expression
MX2023013504A (es) 2021-05-28 2024-02-23 Novo Nordisk As Composiciones y métodos para inhibir la expresión del componente 1 de reducción de amidoxima mitocondrial (marc1).
KR20240014067A (ko) * 2021-05-28 2024-01-31 애로우헤드 파마슈티컬스 인코포레이티드 뮤신 5AC (MUC5AC)의 발현을 억제하기 위한 RNAi 작용제, 그의 조성물, 및 사용 방법
WO2022256824A1 (en) * 2021-06-03 2022-12-08 The University Of Chicago Methods and compositions for treating fibrosis
EP4355430A4 (de) * 2021-06-16 2025-04-09 Empirico Inc. Behandlung von mst1r-bedingten erkrankungen und störungen
EP4355759A4 (de) 2021-06-18 2026-05-13 Ionis Pharmaceuticals Inc Verbindungen und verfahren zur reduzierung der ifnar1-expression
US11549112B1 (en) 2021-06-21 2023-01-10 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use
CA3224904A1 (en) * 2021-06-21 2022-12-29 Shanghai Junshi Biosciences Co., Ltd. Sirna inhibiting angptl3 gene expression and use thereof
CN113416776B (zh) * 2021-06-21 2022-04-01 深圳市儿童医院 一种用于检测室间隔缺损的生物标记物及其应用
AR126207A1 (es) 2021-06-23 2023-09-27 Univ Massachusetts Compuestos de oligonucleotidos anti-flt1 optimizados para el tratamiento de la preeclampsia y otros desordenes angiogénicos
EP4359526A1 (de) * 2021-06-25 2024-05-01 Stichting Radboud universitair medisch centrum Allelspezifische silencing-therapie für dfna21 mit antisense-oligonukleotiden
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
JP2024525868A (ja) * 2021-07-17 2024-07-12 サーナオミクス インコーポレイテッド 産物及び組成物
TW202328445A (zh) 2021-08-03 2023-07-16 美商艾拉倫製藥股份有限公司 甲狀腺素運載蛋白（ＴＴＲ）ｉＲＮＡ組成物及其使用方法
IL310407A (en) * 2021-08-13 2024-03-01 Alnylam Pharmaceuticals Inc Factor XII (F12) IRNA compositions and methods of using them
WO2023028564A1 (en) 2021-08-26 2023-03-02 Volastra Therapeutics, Inc. Spiro indoline inhibitors of kif18a
MX2024002440A (es) 2021-08-31 2024-03-08 Alnylam Pharmaceuticals Inc Composiciones de acido ribonucleico de interferencia (arni) del efector b similar al factor de fragmentacion de adn subunidad alfa (dffa) que induce la muerte celular (cideb) y metodos de uso de estas.
US11833221B2 (en) 2021-09-01 2023-12-05 Ionis Pharmaceuticals, Inc. Oligomeric compounds for reducing DMPK expression
MX2024003266A (es) 2021-09-16 2024-04-03 Avidity Biosciences Inc Composiciones y metodos de tratamiento de la distrofia muscular facioescapulohumeral.
US12043832B2 (en) * 2021-09-16 2024-07-23 Washington University Methods and compositions for reducing pathogenic isoforms
EP4408468A4 (de) 2021-09-28 2025-07-02 Frontaim Biomedicines Inc Mehrere formate molekularer komplexe
CA3233755A1 (en) 2021-10-01 2023-04-06 Adarx Pharmaceuticals, Inc. Prekallikrein-modulating compositions and methods of use thereof
CA3234636A1 (en) 2021-10-29 2023-05-04 Alnylam Pharmaceuticals, Inc. Complement factor b (cfb) irna compositions and methods of use thereof
TW202334418A (zh) * 2021-10-29 2023-09-01 美商艾拉倫製藥股份有限公司 杭丁頓（ＨＴＴ）ｉＲＮＡ劑組成物及其使用方法
WO2023088227A1 (zh) 2021-11-16 2023-05-25 上海舶望制药有限公司 抑制血管紧张素原(agt)蛋白表达的组合物和方法
EP4437104A4 (de) 2021-11-24 2026-01-21 Adarx Pharmaceuticals Inc Komplementfaktor-b-modulierende zusammensetzungen und verfahren zur verwendung davon
US20230167447A1 (en) * 2021-11-30 2023-06-01 Genetic Intelligence, Inc Compositions for FNIP1/FNIP2 Gene Modulation and Methods Thereof
WO2023108020A2 (en) * 2021-12-07 2023-06-15 Alnylam Pharmaceuticals, Inc. iRNA COMPOSITIONS AND METHODS FOR SILENCING MYLIP
WO2023122805A1 (en) 2021-12-20 2023-06-29 Vestaron Corporation Sorbitol driven selection pressure method
KR20240126870A (ko) 2021-12-22 2024-08-21 캠프4 테라퓨틱스 코포레이션 조절 rna들을 표적으로 하는 안티센스 올리고뉴클레오티드를 사용한 유전자 전사의 조절
US20250075209A1 (en) * 2021-12-27 2025-03-06 Apellis Pharmaceuticals, Inc. Rnas for complement inhibition
EP4473477A4 (de) * 2022-02-01 2026-01-14 4D Path Inc Systeme und verfahren zur bildbasierten krankheitscharakterisierung
US12090064B2 (en) 2022-03-01 2024-09-17 Medos International Sarl Stabilization members for expandable intervertebral implants, and related systems and methods
IL315546A (en) 2022-03-16 2024-11-01 Empirico Inc GALNAC compositions to improve siRNA bioavailability
US12258563B2 (en) 2022-03-28 2025-03-25 Empirico Inc. Modified oligonucleotides
US12071621B2 (en) 2022-04-05 2024-08-27 Avidity Biosciences, Inc. Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
WO2023215370A2 (en) * 2022-05-04 2023-11-09 University Of Massachusetts Oligonucleotides for pms2 modulation
WO2023220566A1 (en) * 2022-05-09 2023-11-16 The Regents Of The University Of California Crispr-cas effector polypeptides and methods of use thereof
CA3251926A1 (en) * 2022-05-10 2023-11-16 Amylyx Pharmaceuticals, Inc. OLIGONUCLEOTIDE COMPOSITIONS AND ASSOCIATED PROCESSES
JP2025524468A (ja) * 2022-06-24 2025-07-30 イーライ リリー アンド カンパニー Ａｔｘｎ２ ｒｎａ干渉剤
CA3262515A1 (en) * 2022-07-25 2024-02-01 Amgen Inc. ARNI CONSTRUCTIONS AND METHODS FOR INHIBITING FAM13A EXPRESSION
CN116042822A (zh) * 2022-09-16 2023-05-02 湖南灵康医疗科技有限公司 Znf32调控ccnd1基因的表达在抗结直肠癌化疗耐药中的应用
CN120239607A (zh) 2022-09-23 2025-07-01 Ionis制药公司 用于降低mecp2表达的化合物和方法
CN116004543B (zh) * 2022-09-26 2025-03-11 南通大学 Traf6抑制剂在制备人恶性黑色素瘤治疗药物中的应用
CN115844919B (zh) * 2022-09-28 2025-09-09 李永 一种抑制黑色素瘤生长的双核酸序列及应用
EP4598531A2 (de) * 2022-10-03 2025-08-13 Cystic Fibrosis Foundation Zusammensetzungen und verfahren zur cftr-modulation
WO2024104663A1 (en) 2022-11-16 2024-05-23 Unilever Ip Holdings B.V. Method of reducing malodour
JP2026500230A (ja) * 2022-12-07 2026-01-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 阻害性核酸およびその使用方法
EP4634391A2 (de) 2022-12-15 2025-10-22 Empirico Inc. Behandlung von mst1-bedingten erkrankungen und störungen
AU2023417630A1 (en) * 2022-12-29 2025-05-15 Voyager Therapeutics, Inc. Compositions and methods for regulating mapt
WO2024159113A1 (en) * 2023-01-27 2024-08-02 The Methodist Hospital Modulators of alternative polyadenylation and methods of use thereof
WO2024175586A2 (en) * 2023-02-21 2024-08-29 Vib Vzw Inhibitors of synaptogyrin-3 expression
WO2024187102A2 (en) * 2023-03-09 2024-09-12 Leal Therapeutics, Inc. Compositions and methods for modulating c3
CN121219020A (zh) * 2023-03-22 2025-12-26 圣拉斐尔医院有限责任公司 基因疗法
UY40699A (es) 2023-04-05 2024-08-30 Ionis Pharmaceuticals Inc Compuestos y métodos para reducir la expresión de pln
WO2024215825A1 (en) * 2023-04-14 2024-10-17 Avicenna Biotech Research, Llc Rna-based compositions and methods for treating breast cancer
EP4704859A1 (de) * 2023-05-05 2026-03-11 Children's Medical Research Institute Verfahren zur behandlung von alt-abhängigen krebsarten
WO2024233966A2 (en) * 2023-05-10 2024-11-14 The General Hospital Corporation Modulating stromal and immune cells in atrial disease
KR20260029506A (ko) * 2023-05-26 2026-03-04 탱그램 테라퓨틱스 피엘씨 발현 및/또는 기능의 억제제
CN118272371B (zh) * 2023-05-30 2026-02-06 北京大学 靶向plin2基因的小干扰核酸、短反义寡核苷酸及其用途
WO2024259134A1 (en) 2023-06-13 2024-12-19 Arnatar Therapeutics, Inc Advanced rna targeting (arnatar) for angiotensinogen
CN116794325B (zh) * 2023-06-15 2024-05-10 中山大学 敲低或抑制slc35f6的试剂在制备激活ampk的药物中的应用
EP4735602A2 (de) 2023-06-27 2026-05-06 Atrium Therapeutics, Inc. Zusammensetzungen und verfahren zur verwendung eines auf prkag2 abzielenden antikörper-oligonukleotid-konjugat-abstrahs
CN121793987A (zh) 2023-06-30 2026-04-03 艾维迪提生物科学公司 使用pln靶向性抗体-寡核苷酸缀合物的组合物和方法
CN116898975B (zh) * 2023-08-21 2026-04-14 中国福利会国际和平妇幼保健院 Ythdc1抑制剂在制备防治早产的药物中的应用
CN117323435A (zh) * 2023-09-15 2024-01-02 湖北工业大学 Styk1在制备预测、诊断或治疗胰腺癌产品中的应用
IL327100A (en) 2023-09-15 2026-05-01 Praxis Prec Medicines Inc Alsonarsen/PRAX-22 for use in the treatment of SCN2A-related disorders
TW202530408A (zh) * 2023-09-29 2025-08-01 美商英西特羅公司 用於治療非酒精性脂肪肝病的組合物與方法
CN117070583B (zh) * 2023-10-16 2024-05-14 吉林凯莱英制药有限公司 抑制PCSK9基因表达的siRNA的制备方法
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
WO2025107242A1 (zh) * 2023-11-23 2025-05-30 成都福实生物科技有限公司 机械力响应型巨噬细胞亚群在胰腺癌诊断或预后评估中的应用
CN117959445B (zh) * 2024-02-04 2025-06-27 北京大学 Rna结合蛋白抑制剂在用于制备抑制慢性乙型肝炎病毒复制的药物中的用途
EP4603586A1 (de) * 2024-02-16 2025-08-20 Universität zu Lübeck Inhibitorische oligonukleotide gegen adamts7
US12553050B2 (en) * 2024-03-22 2026-02-17 Takeda Pharmaceutical Company Limited Compositions and methods for inhibiting cytochrome P450 family 7 subfamily a member 1 (CYP7A1) expression
WO2025212467A1 (en) 2024-03-31 2025-10-09 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of microtubule associated protein tau (mapt), compositions thereof, and methods of use
WO2025226343A1 (en) * 2024-04-26 2025-10-30 Research Institute At Nationwide Children's Hospital Products and methods to inhibit expression of dynamin-1 variants and replace dynamin-1
WO2025231449A1 (en) * 2024-05-02 2025-11-06 Institute For Myeloma & Bone Cancer Research Prediction, diagnosis, and treatment of multiple myeloma
CN118624918B (zh) * 2024-08-08 2024-11-15 中国医学科学院医药生物技术研究所 宿主细胞cxcr6基因作为抗黄病毒靶点在制备抗黄病毒药物中的应用
WO2026037289A1 (zh) * 2024-08-12 2026-02-19 广州必贝特医药股份有限公司 用于抑制尿酸盐转运体1基因表达的siRNA、药物及其应用
WO2026044017A2 (en) * 2024-08-21 2026-02-26 Insitro, Inc. Compositions and methods for treating nonalcoholic fatty liver disease
WO2026083309A1 (en) * 2024-10-17 2026-04-23 Astrazeneca Ab Use of inhibitors or modulators of artemis in gene editing
CN120775978A (zh) * 2025-03-14 2025-10-14 浙江省肿瘤医院 乳头状甲状腺癌早期预测标志物的筛选方法及应用
CN120241773B (zh) * 2025-04-07 2026-01-30 深圳市华元生物技术股份有限公司 一种抑制人PPP1R3B基因表达的siRNA试剂、组合物及其应用
CN120290720B (zh) * 2025-04-11 2025-12-23 新疆医科大学第三附属医院 靶向RPS4X基因的siRNA、LAMB3-PI3K-AKT信号通路抑制剂、卵巢癌药物及应用
CN120514724B (zh) * 2025-07-24 2025-10-10 济南瑞隆安生物技术有限公司 一种siRNA在制备餐后高血糖治疗制剂中的应用

Family Cites Families (342)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US647526A (en) * 1899-06-26 1900-04-17 William Allen Runyan Freight-car door.
US1541453A (en) * 1922-12-20 1925-06-09 Watkins Clayton Stuart Demountable rim and wheell for automobiles and other vehicles
US3260656A (en) * 1962-09-27 1966-07-12 Corning Glass Works Method and apparatus for electrolytically determining a species in a fluid
EG10142A (en) * 1968-01-29 1976-06-30 Bayer Ag N-tritylimidazolium salts
US3653841A (en) * 1969-12-19 1972-04-04 Hoffmann La Roche Methods and compositions for determining glucose in blood
US3719564A (en) * 1971-05-10 1973-03-06 Philip Morris Inc Method of determining a reducible gas concentration and sensor therefor
US3837339A (en) * 1972-02-03 1974-09-24 Whittaker Corp Blood glucose level monitoring-alarm system and method therefor
US4184429A (en) * 1972-02-09 1980-01-22 Max Datwyler & Co. Constant bevel doctor blade and method and apparatus using same
US3811449A (en) * 1972-03-08 1974-05-21 Becton Dickinson Co Dilating apparatus and method
US3908657A (en) * 1973-01-15 1975-09-30 Univ Johns Hopkins System for continuous withdrawal of blood
US4100048A (en) * 1973-09-20 1978-07-11 U.S. Philips Corporation Polarographic cell
US3911901A (en) * 1974-07-24 1975-10-14 Gen Electric In vivo hydrogen ion sensor
US3972320A (en) * 1974-08-12 1976-08-03 Gabor Ujhelyi Kalman Patient monitoring system
US3979274A (en) * 1975-09-24 1976-09-07 The Yellow Springs Instrument Company, Inc. Membrane for enzyme electrodes
US4016866A (en) * 1975-12-18 1977-04-12 General Electric Company Implantable electrochemical sensor
US4055175A (en) * 1976-05-07 1977-10-25 Miles Laboratories, Inc. Blood glucose control apparatus
DE2625834B2 (de) * 1976-06-09 1978-10-12 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur Bestimmung von Substraten oder Enzymaktivitäten
US4076596A (en) * 1976-10-07 1978-02-28 Leeds & Northrup Company Apparatus for electrolytically determining a species in a fluid and method of use
FR2387659A1 (fr) * 1977-04-21 1978-11-17 Armines Dispositif de controle et regulation de la glycemie
US4098574A (en) * 1977-08-01 1978-07-04 Eastman Kodak Company Glucose detection system free from fluoride-ion interference
JPS5912135B2 (ja) * 1977-09-28 1984-03-21 松下電器産業株式会社 酵素電極
US4151845A (en) * 1977-11-25 1979-05-01 Miles Laboratories, Inc. Blood glucose control apparatus
DK151000C (da) * 1978-02-17 1988-06-13 Radiometer As Fremgangsmaade og apparat til bestemmelse af en patients in vivo plasma-ph-vaerdi
US4172770A (en) * 1978-03-27 1979-10-30 Technicon Instruments Corporation Flow-through electrochemical system analytical method
HU177369B (en) * 1978-09-08 1981-09-28 Radelkis Electrokemiai Industrial molecule-selective sensing device and method for producing same
US4247297A (en) * 1979-02-23 1981-01-27 Miles Laboratories, Inc. Test means and method for interference resistant determination of oxidizing substances
US4573994A (en) * 1979-04-27 1986-03-04 The Johns Hopkins University Refillable medication infusion apparatus
US4401122A (en) * 1979-08-02 1983-08-30 Children's Hospital Medical Center Cutaneous methods of measuring body substances
US4458686A (en) * 1979-08-02 1984-07-10 Children's Hospital Medical Center Cutaneous methods of measuring body substances
US4450842A (en) * 1980-04-25 1984-05-29 Cordis Corporation Solid state reference electrode
US4340458A (en) * 1980-06-02 1982-07-20 Joslin Diabetes Center, Inc. Glucose sensor
US4401433A (en) * 1980-06-13 1983-08-30 Luther Ronald B Apparatus for advancing oversized catheter through cannula, and the like
DE3025785C2 (de) * 1980-07-08 1984-08-16 Storz, Karl, 7200 Tuttlingen Dilatator, Verfahren zu seiner Verwendung und Vorrichtung zur Durchführung des Verfahrens
US4356074A (en) * 1980-08-25 1982-10-26 The Yellow Springs Instrument Company, Inc. Substrate specific galactose oxidase enzyme electrodes
US4404066A (en) * 1980-08-25 1983-09-13 The Yellow Springs Instrument Company Method for quantitatively determining a particular substrate catalyzed by a multisubstrate enzyme
US4352960A (en) * 1980-09-30 1982-10-05 Baptist Medical Center Of Oklahoma, Inc. Magnetic transcutaneous mount for external device of an associated implant
US4390621A (en) * 1980-12-15 1983-06-28 Miles Laboratories, Inc. Method and device for detecting glucose concentration
US4369790A (en) * 1981-03-05 1983-01-25 Mccarthy John M Catheter
US4436094A (en) * 1981-03-09 1984-03-13 Evreka, Inc. Monitor for continuous in vivo measurement of glucose concentration
US4350151A (en) * 1981-03-12 1982-09-21 Lone Star Medical Products, Inc. Expanding dilator
DE3117802A1 (de) * 1981-05-06 1982-11-25 Max Dr. 8520 Erlangen Hubmann Katheterbesteck
AT369254B (de) * 1981-05-07 1982-12-27 Otto Dipl Ing Dr Tech Prohaska Medizinische sonde
FR2508305B1 (fr) * 1981-06-25 1986-04-11 Slama Gerard Dispositif pour provoquer une petite piqure en vue de recueillir une goutte de sang
US4440175A (en) * 1981-08-10 1984-04-03 University Patents, Inc. Membrane electrode for non-ionic species
DE3278334D1 (en) * 1981-10-23 1988-05-19 Genetics Int Inc Sensor for components of a liquid mixture
US4431004A (en) * 1981-10-27 1984-02-14 Bessman Samuel P Implantable glucose sensor
JPS58153154A (ja) * 1982-03-09 1983-09-12 Ajinomoto Co Inc 修飾電極
US4581336A (en) * 1982-04-26 1986-04-08 Uop Inc. Surface-modified electrodes
DE3221339A1 (de) * 1982-06-05 1983-12-08 Basf Ag, 6700 Ludwigshafen Verfahren zur elektrochemischen hydrierung von nicotinamidadenin-dinucleotid
US4427770A (en) * 1982-06-14 1984-01-24 Miles Laboratories, Inc. High glucose-determining analytical element
DE3228551A1 (de) * 1982-07-30 1984-02-02 Siemens AG, 1000 Berlin und 8000 München Verfahren zur bestimmung der zuckerkonzentration
US4534356A (en) * 1982-07-30 1985-08-13 Diamond Shamrock Chemicals Company Solid state transcutaneous blood gas sensors
US4571292A (en) * 1982-08-12 1986-02-18 Case Western Reserve University Apparatus for electrochemical measurements
US4461691A (en) * 1983-02-10 1984-07-24 The United States Of America As Represented By The United States Department Of Energy Organic conductive films for semiconductor electrodes
US4679562A (en) * 1983-02-16 1987-07-14 Cardiac Pacemakers, Inc. Glucose sensor
IT1170375B (it) * 1983-04-19 1987-06-03 Giuseppe Bombardieri Apparecchio che infonde insulina o glucosio nel soggetto diabetico sulla base di determinazioni di concentrazioni di glucosio ottenute senza bisogno di prelievi del sangue del paziente
CA1218704A (en) * 1983-05-05 1987-03-03 Graham Davis Assay systems using more than one enzyme
US4650547A (en) * 1983-05-19 1987-03-17 The Regents Of The University Of California Method and membrane applicable to implantable sensor
US4524114A (en) * 1983-07-05 1985-06-18 Allied Corporation Bifunctional air electrode
US4538616A (en) * 1983-07-25 1985-09-03 Robert Rogoff Blood sugar level sensing and monitoring transducer
US4543955A (en) * 1983-08-01 1985-10-01 Cordis Corporation System for controlling body implantable action device
US4655880A (en) * 1983-08-01 1987-04-07 Case Western Reserve University Apparatus and method for sensing species, substances and substrates using oxidase
US4601710B1 (en) * 1983-08-24 1998-05-05 United States Surgical Corp Trocar assembly
US4573448A (en) * 1983-10-05 1986-03-04 Pilling Co. Method for decompressing herniated intervertebral discs
US4522690A (en) * 1983-12-01 1985-06-11 Honeywell Inc. Electrochemical sensing of carbon monoxide
US4840893A (en) * 1983-12-16 1989-06-20 Medisense, Inc. Electrochemical assay for nucleic acids and nucleic acid probes
JPS60135756A (ja) * 1983-12-24 1985-07-19 Ngk Insulators Ltd 電気化学的セルの製造方法
DE8407894U1 (de) * 1984-03-15 1984-09-06 Richard Wolf Gmbh, 7134 Knittlingen Dilatator zum aufweiten von einstichkanaelen der niere
WO1985005119A1 (fr) * 1984-04-30 1985-11-21 Stiftung, R., E. Procede de sensibilisation d'un photo-catalyseur d'oxydo-reduction et photo-catalyseur ainsi obtenu
DK8601218A (de) * 1984-07-18 1986-03-17
US4820399A (en) * 1984-08-31 1989-04-11 Shimadzu Corporation Enzyme electrodes
CA1254091A (en) * 1984-09-28 1989-05-16 Vladimir Feingold Implantable medication infusion system
US4717673A (en) * 1984-11-23 1988-01-05 Massachusetts Institute Of Technology Microelectrochemical devices
US4721601A (en) * 1984-11-23 1988-01-26 Massachusetts Institute Of Technology Molecule-based microelectronic devices
JPH0617889B2 (ja) * 1984-11-27 1994-03-09 株式会社日立製作所 生物化学センサ
GB8500729D0 (en) * 1985-01-11 1985-02-13 Hill H A O Surface-modified electrode
US4627445A (en) * 1985-04-08 1986-12-09 Garid, Inc. Glucose medical monitoring system
US4671288A (en) * 1985-06-13 1987-06-09 The Regents Of The University Of California Electrochemical cell sensor for continuous short-term use in tissues and blood
DE3687646T3 (de) * 1985-06-21 2001-05-31 Matsushita Electric Industrial Co., Ltd. Biosensor und dessen herstellung.
US4796634A (en) * 1985-08-09 1989-01-10 Lawrence Medical Systems, Inc. Methods and apparatus for monitoring cardiac output
US4805624A (en) * 1985-09-09 1989-02-21 The Montefiore Hospital Association Of Western Pa Low-potential electrochemical redox sensors
US4680268A (en) * 1985-09-18 1987-07-14 Children's Hospital Medical Center Implantable gas-containing biosensor and method for measuring an analyte such as glucose
US4890620A (en) * 1985-09-20 1990-01-02 The Regents Of The University Of California Two-dimensional diffusion glucose substrate sensing electrode
US4830959A (en) * 1985-11-11 1989-05-16 Medisense, Inc. Electrochemical enzymic assay procedures
GB8529300D0 (en) * 1985-11-28 1986-01-02 Ici Plc Membrane
US4776944A (en) * 1986-03-20 1988-10-11 Jiri Janata Chemical selective sensors utilizing admittance modulated membranes
US4685463A (en) * 1986-04-03 1987-08-11 Williams R Bruce Device for continuous in vivo measurement of blood glucose concentrations
US4726378A (en) * 1986-04-11 1988-02-23 Minnesota Mining And Manufacturing Company Adjustable magnetic supercutaneous device and transcutaneous coupling apparatus
US4757022A (en) * 1986-04-15 1988-07-12 Markwell Medical Institute, Inc. Biological fluid measuring device
US4909908A (en) * 1986-04-24 1990-03-20 Pepi Ross Electrochemical cncentration detector method
US4795542A (en) * 1986-04-24 1989-01-03 St. Jude Medical, Inc. Electrochemical concentration detector device
DE3614821A1 (de) * 1986-05-02 1987-11-05 Siemens Ag Implantierbare, eichbare messvorrichtung fuer eine koerpersubstanz sowie eichverfahren
US4911794A (en) * 1986-06-20 1990-03-27 Molecular Devices Corporation Measuring with zero volume cell
US4764416A (en) * 1986-07-01 1988-08-16 Mitsubishi Denki Kabushiki Kaisha Electric element circuit using oxidation-reduction substances
US4917800A (en) * 1986-07-07 1990-04-17 Bend Research, Inc. Functional, photochemically active, and chemically asymmetric membranes by interfacial polymerization of derivatized multifunctional prepolymers
US4726716A (en) * 1986-07-21 1988-02-23 Mcguire Thomas V Fastener for catheter
US4894137A (en) * 1986-09-12 1990-01-16 Omron Tateisi Electronics Co. Enzyme electrode
US4802479A (en) * 1986-10-31 1989-02-07 C. R. Bard, Inc. Hand-held instrument for implanting, dispensing, and inflating an inflatable membrane
DE3700119A1 (de) * 1987-01-03 1988-07-14 Inst Diabetestechnologie Gemei Implantierbarer elektrochemischer sensor
US4848351A (en) * 1987-03-04 1989-07-18 Sentry Medical Products, Inc. Medical electrode assembly
US4759828A (en) * 1987-04-09 1988-07-26 Nova Biomedical Corporation Glucose electrode and method of determining glucose
US4822337A (en) * 1987-06-22 1989-04-18 Stanley Newhouse Insulin delivery method and apparatus
JPH07122624B2 (ja) * 1987-07-06 1995-12-25 ダイキン工業株式会社 バイオセンサ
US4874500A (en) * 1987-07-15 1989-10-17 Sri International Microelectrochemical sensor and sensor array
GB8718430D0 (en) * 1987-08-04 1987-09-09 Ici Plc Sensor
JPS6431701U (de) * 1987-08-20 1989-02-27
US4815469A (en) * 1987-10-08 1989-03-28 Siemens-Pacesetter, Inc. Implantable blood oxygen sensor and method of use
US4813424A (en) * 1987-12-23 1989-03-21 University Of New Mexico Long-life membrane electrode for non-ionic species
US4862891A (en) * 1988-03-14 1989-09-05 Canyon Medical Products Device for sequential percutaneous dilation
US4923442A (en) * 1988-05-02 1990-05-08 Cryomedical Sciences Inc. Blood substitute
US4994027A (en) * 1988-06-08 1991-02-19 Farrell Edward M Percutaneous femoral bypass system
US5224952A (en) * 1988-07-06 1993-07-06 Ethicon, Inc. Safety trocar
US5613950A (en) * 1988-07-22 1997-03-25 Yoon; Inbae Multifunctional manipulating instrument for various surgical procedures
US5514091A (en) * 1988-07-22 1996-05-07 Yoon; Inbae Expandable multifunctional manipulating instruments for various medical procedures
US5831066A (en) 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US5002557A (en) * 1989-04-06 1991-03-26 Hasson Harrith M Laparoscopic cannula
US5176697A (en) * 1989-04-06 1993-01-05 Hasson Harrith M Laparoscopic cannula
WO1991004753A1 (en) * 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof
US5114407A (en) * 1990-08-30 1992-05-19 Ethicon, Inc. Safety mechanism for trocar
US5188118A (en) * 1990-11-07 1993-02-23 Terwilliger Richard A Automatic biopsy instrument with independently actuated stylet and cannula
US5324261A (en) * 1991-01-04 1994-06-28 Medtronic, Inc. Drug delivery balloon catheter with line of weakness
AU648135B2 (en) * 1991-01-15 1994-04-14 Ethicon Inc. Knife for surgical trocar
US5176651A (en) * 1991-04-01 1993-01-05 Dexide, Inc. Combination surgical trocar housing and selective reducer sleeve assembly
US5295993A (en) * 1991-04-30 1994-03-22 United States Surgical Corporation Safety trocar
US5241972A (en) * 1991-05-03 1993-09-07 Meditron Devices, Inc. Method for debulking tissue to remove pressure on a nerve
US5183464A (en) * 1991-05-17 1993-02-02 Interventional Thermodynamics, Inc. Radially expandable dilator
CA2069060C (en) * 1991-06-26 2003-07-29 Daniel Shichman Powered trocar
US5195506A (en) * 1991-10-18 1993-03-23 Life Medical Products, Inc. Surgical retractor for puncture operation
GB9123947D0 (en) * 1991-11-12 1992-01-02 Imp Cancer Res Tech Therapeutic compounds
US5267554A (en) * 1991-11-15 1993-12-07 Wilk Peter J Spreadable laparoscopic retractor and associated method of use
AU671266B2 (en) * 1991-11-27 1996-08-22 Inbae Yoon Retractable safety penetrating instrument for portal sleeve introduction
US5713870A (en) * 1991-11-27 1998-02-03 Yoon; Inbae Retractable safety penetrating instrument with laterally extendable spring strip
US5171279A (en) * 1992-03-17 1992-12-15 Danek Medical Method for subcutaneous suprafascial pedicular internal fixation
US5290243A (en) * 1992-07-16 1994-03-01 Technalytics, Inc. Trocar system
EP1251170A3 (de) * 1992-07-17 2002-10-30 Ribozyme Pharmaceuticals, Inc. Vergahren und Reagenz zur Behandlung von NF-kappaB abhängiger Tierischen Krankheiten
US5312417A (en) * 1992-07-29 1994-05-17 Wilk Peter J Laparoscopic cannula assembly and associated method
US7060077B2 (en) * 1992-09-04 2006-06-13 Boston Scientific Scimed, Inc. Suturing instruments and methods of use
US20040204380A1 (en) 1999-01-07 2004-10-14 Ackermann Elizabeth J Antisense modulation of novel anti-apoptotic bcl-2-related proteins
US6001992A (en) 1999-01-07 1999-12-14 Isis Pharmaceuticals Inc. Antisense modulation of novel anti-apoptotic bcl-2-related proteins
US20020086321A1 (en) 1993-02-02 2002-07-04 Craig Ruth W. Myeloid cell leukemia associated gene MCL-1
US5814073A (en) * 1996-12-13 1998-09-29 Bonutti; Peter M. Method and apparatus for positioning a suture anchor
FR2706309B1 (fr) * 1993-06-17 1995-10-06 Sofamor Instrument de traitement chirurgical d'un disque intervertébral par voie antérieure.
US6410322B1 (en) * 1993-07-27 2002-06-25 Hybridon Inc Antisense oligonucleotide inhibition of vascular endothelial growth factor expression
US5641756A (en) * 1993-07-27 1997-06-24 Hybridon, Inc. Modified VEGF oligonucleotides
US5731294A (en) * 1993-07-27 1998-03-24 Hybridon, Inc. Inhibition of neovasularization using VEGF-specific oligonucleotides
DE69503038T2 (de) 1994-02-14 1999-03-25 Amgen Inc., Thousand Oaks, Calif. Zellzyklusprotein in Säugetieren
US5407430A (en) * 1994-03-21 1995-04-18 Peters; Michael J. Intravenous catheter
US5512037A (en) * 1994-05-12 1996-04-30 United States Surgical Corporation Percutaneous surgical retractor
EP0769552A4 (de) * 1994-06-27 1997-06-18 Toagosei Co Ltd 'antisense'nukleinsäure-zusammensetzung
US5505710A (en) * 1994-08-22 1996-04-09 C. R. Bard, Inc. Telescoping probe
US5647857A (en) * 1995-03-16 1997-07-15 Endotex Interventional Systems, Inc. Protective intraluminal sheath
US5624447A (en) * 1995-03-20 1997-04-29 Othy, Inc. Surgical tool guide and entry hole positioner
US6206922B1 (en) * 1995-03-27 2001-03-27 Sdgi Holdings, Inc. Methods and instruments for interbody fusion
US5776156A (en) * 1995-09-05 1998-07-07 United States Surgical Corporation Endoscopic cutting instrument
US5817034A (en) * 1995-09-08 1998-10-06 United States Surgical Corporation Apparatus and method for removing tissue
US5830879A (en) * 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
US5772678A (en) * 1995-10-20 1998-06-30 Inlet Medical, Inc. Retractable disposable tip reusable trocar obturator
US6346398B1 (en) 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
US5743881A (en) * 1995-11-03 1998-04-28 Aptec Medical Corporation Laparoscopic surgical instrument and method of using same
US5707359A (en) * 1995-11-14 1998-01-13 Bufalini; Bruno Expanding trocar assembly
WO1997020925A1 (en) * 1995-12-08 1997-06-12 Hybridon, Inc. Modified vegf antisense oligonucleotides for treatment of skin disorders
CA2239991A1 (en) * 1995-12-08 1997-06-19 Hybridon, Inc. Modified vegf antisense oligonucleotides
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US6048309A (en) * 1996-03-04 2000-04-11 Heartport, Inc. Soft tissue retractor and delivery device therefor
US5810721A (en) * 1996-03-04 1998-09-22 Heartport, Inc. Soft tissue retractor and method for providing surgical access
US6679833B2 (en) * 1996-03-22 2004-01-20 Sdgi Holdings, Inc. Devices and methods for percutaneous surgery
US5792044A (en) * 1996-03-22 1998-08-11 Danek Medical, Inc. Devices and methods for percutaneous surgery
JP2000511788A (ja) * 1996-03-22 2000-09-12 エスディージーアイ・ホールディングス・インコーポレーテッド 経皮的外科手術用装置及び方法
AU2733697A (en) * 1996-04-17 1997-11-07 Aronex Pharmaceuticals, Inc. Antisense inhibitors of vascular endothelial growth factor (vegf/vpf) expression
US20050261485A1 (en) 1996-05-23 2005-11-24 Toagosei Co., Ltd., A Japan Corporation Method of producing antisense oligonucleotide
CA2259123C (en) 1996-07-01 2003-10-21 Lorus Therapeutics Inc. Oligonucleotides from the untranslated regions of ribonucleotide reductase and their use to modulate cell growth
US6053935A (en) * 1996-11-08 2000-04-25 Boston Scientific Corporation Transvaginal anchor implantation device
US6264676B1 (en) * 1996-11-08 2001-07-24 Scimed Life Systems, Inc. Protective sheath for transvaginal anchor implantation devices
US5893850A (en) * 1996-11-12 1999-04-13 Cachia; Victor V. Bone fixation device
JP2001504017A (ja) * 1996-11-15 2001-03-27 クック インコーポレーティッド． 分離可能なスリーブ，ステント配備装置
WO1998027425A1 (en) * 1996-12-19 1998-06-25 Isis Pharmaceuticals, Inc. Large-scale purification of full length oligonucleotides by solid-liquid affinity extraction
US6228058B1 (en) * 1997-04-03 2001-05-08 Core Dynamics, Inc. Sleeve trocar with penetration indicator
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
JPH1142091A (ja) * 1997-07-25 1999-02-16 Toagosei Co Ltd アンチセンス核酸化合物
US6293952B1 (en) * 1997-07-31 2001-09-25 Circon Corporation Medical instrument system for piercing through tissue
EP1007092B1 (de) * 1997-08-26 2006-08-09 Amgen Fremont Inc. Ein verfahren zur inhibierung der komplementaktivierung über einen alternativen weg
DE69837611T2 (de) * 1997-10-01 2007-12-27 Boston Scientific Ltd., St. Michael Dilatationssysteme
US6030364A (en) * 1997-10-03 2000-02-29 Boston Scientific Corporation Apparatus and method for percutaneous placement of gastro-intestinal tubes
CA2248762A1 (en) 1997-10-22 1999-04-22 University Technologies International, Inc. Antisense oligodeoxynucleotides regulating expression of tnf-.alpha.
US6206826B1 (en) * 1997-12-18 2001-03-27 Sdgi Holdings, Inc. Devices and methods for percutaneous surgery
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AU2572499A (en) 1998-01-29 1999-08-16 Trustees Of Columbia University In The City Of New York, The Human hairless gene, protein and uses thereof
US6111086A (en) 1998-02-27 2000-08-29 Scaringe; Stephen A. Orthoester protecting groups
JP2002510487A (ja) * 1998-04-03 2002-04-09 ウイスコンシン アラムニ リサーチ ファンデーション 哺乳類のｔｏｌｌｏｉｄ様遺伝子及びタンパク質
US6428541B1 (en) * 1998-04-09 2002-08-06 Sdgi Holdings, Inc. Method and instrumentation for vertebral interbody fusion
US20030228597A1 (en) 1998-04-13 2003-12-11 Cowsert Lex M. Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
US6447527B1 (en) * 1998-04-23 2002-09-10 Ronald J. Thompson Apparatus and methods for the penetration of tissue
DE69919869T2 (de) * 1998-06-10 2005-09-29 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH Stimulierung des immunsystems
JP2000010376A (ja) * 1998-06-26 2000-01-14 Fujitsu Ltd 画像形成装置
US20030096775A1 (en) * 2001-10-23 2003-05-22 Isis Pharmaceuticals Inc. Antisense modulation of complement component C3 expression
US6007995A (en) * 1998-06-26 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of TNFR1 expression
WO2000001393A2 (en) 1998-07-02 2000-01-13 The Trustees Of Columbia University In The City Of New York OLIGONUCLEOTIDE INHIBITORS OF bcl-xL
US5916145A (en) * 1998-08-07 1999-06-29 Scimed Life Systems, Inc. Device and method of using a surgical assembly with mesh sheath
US6093173A (en) * 1998-09-09 2000-07-25 Embol-X, Inc. Introducer/dilator with balloon protection and methods of use
US6117174A (en) * 1998-09-16 2000-09-12 Nolan; Wesley A. Spinal implant device
US5957902A (en) * 1998-09-28 1999-09-28 Teves; Leonides Y. Surgical tool for enlarging puncture opening made by trocar
US6228642B1 (en) * 1998-10-05 2001-05-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression
US6172216B1 (en) 1998-10-07 2001-01-09 Isis Pharmaceuticals Inc. Antisense modulation of BCL-X expression
WO2000021559A2 (en) 1998-10-09 2000-04-20 Musc Foundation For Research Development Blocking factor b to treat complement-mediated immune disease
US6365577B1 (en) * 1998-10-26 2002-04-02 Avi Biopharma, Inc. p53 antisense agent and method
CN1342077A (zh) * 1998-11-06 2002-03-27 诺尔股份公司 抑制血管渗透性过高的形成
US5958773A (en) 1998-12-17 1999-09-28 Isis Pharmaceuticals Inc. Antisense modulation of AKT-1 expression
DE50008326D1 (de) * 1999-02-12 2004-11-25 Storz Karl Gmbh & Co Vorrichtung zum einführen eines intubationstubus in die trachea
DE60012485T2 (de) * 1999-02-18 2005-08-18 The Regents Of The University Of California, Oakland Salicylamid-lanthanid komplexe zur verwendung als lumineszenzmarker
DE60038011T2 (de) 1999-04-08 2009-02-12 Novartis Vaccines and Diagnostics, Inc., Emeryville Verbesserung der immunantwort als anwendung in impfstoff und gentherapie
US6607530B1 (en) * 1999-05-10 2003-08-19 Highgate Orthopedics, Inc. Systems and methods for spinal fixation
EP1189611B1 (de) 1999-06-14 2006-05-03 Cancer Research Technology Limited Krebstherapie
US6607547B1 (en) * 1999-08-25 2003-08-19 Origin Medsystems, Inc. Longitudinal dilator and method
US6200322B1 (en) * 1999-08-13 2001-03-13 Sdgi Holdings, Inc. Minimal exposure posterior spinal interbody instrumentation and technique
WO2001013807A2 (en) * 1999-08-26 2001-03-01 Sdgi Holdings, Inc. Devices and methods for implanting fusion cages
US6770633B1 (en) * 1999-10-26 2004-08-03 Immusol, Inc. Ribozyme therapy for the treatment of proliferative skin and eye diseases
US6287313B1 (en) * 1999-11-23 2001-09-11 Sdgi Holdings, Inc. Screw delivery system and method
US7179796B2 (en) 2000-01-18 2007-02-20 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
US20070026394A1 (en) 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US6582441B1 (en) * 2000-02-24 2003-06-24 Advanced Bionics Corporation Surgical insertion tool
US6562049B1 (en) * 2000-03-01 2003-05-13 Cook Vascular Incorporated Medical introducer apparatus
ATE450621T2 (de) 2000-03-30 2009-12-15 Whitehead Biomedical Inst Mediatoren von rns-interferenz, die rns- sequenzspezifisch sind
US20020064856A1 (en) * 2000-06-26 2002-05-30 Gregory Plowman Novel proteases
US6592553B2 (en) * 2000-07-05 2003-07-15 Cardiac Pacemakers, Inc. Introducer assembly and method therefor
EP1325121A2 (de) * 2000-10-13 2003-07-09 Institut de Cardiologie de Montreal Antisense oligonukleotid gerichtet gegen gene von vegf rezeptoren von säugetieren und deren verwendungen
AU2002243429A1 (en) * 2000-10-24 2002-06-24 Isis Pharmaceuticals, Inc. Antisense modulation of tnfr1 expression
CA2427698A1 (en) 2000-11-01 2002-05-10 Bki Holding Corporation Cellulose ethers and method of preparing the same
KR100872437B1 (ko) 2000-12-01 2008-12-05 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
DE60143095D1 (de) * 2000-12-12 2010-10-28 Olympus Corp Trokar und trokarsystem
US20020150945A1 (en) * 2000-12-28 2002-10-17 Cell Therapeutics, Inc. Methods for making polynucleotide libraries, polynucleotide arrays, and cell libraries for high-throughput genomics analysis
US20030143597A1 (en) 2000-12-28 2003-07-31 Finney Robert E. Methods for making polynucleotide libraries, polynucleotide arrays, and cell libraries for high-throughput genomics analysis
WO2002053161A1 (en) 2000-12-29 2002-07-11 Alteon, Inc. Method for treating fibrotic diseases or other indications
US20020087152A1 (en) * 2001-01-04 2002-07-04 Endocare, Inc. Systems and methods for delivering a probe into tissue
WO2003035869A1 (de) 2001-10-26 2003-05-01 Ribopharma Ag Verwendung einer doppelsträngigen ribonukleinsäure zur gezielten hemmung der expression eines vorgegebenen zielgens
US20030087249A1 (en) * 2001-03-01 2003-05-08 Millennium Pharmaceuticals, Inc. 93870, a human G-protein coupled receptor and uses therefor
US6511481B2 (en) * 2001-03-30 2003-01-28 Triage Medical, Inc. Method and apparatus for fixation of proximal femoral fractures
WO2002085285A2 (en) 2001-04-18 2002-10-31 Wyeth Methods and reagents for regulating bone and cartilage formation
AU2002256359A1 (en) 2001-04-24 2002-11-05 Epigenesis Pharmaceuticals, Inc. Antisense and anti-inflammatory based compositions to treat respiratory disorders
WO2002085309A2 (en) * 2001-04-24 2002-10-31 Epigenesis Pharmaceuticals, Inc. Composition, formulations & kits for treatment of respiratory & lung disease with anti-sense oligonucleotides & a bronchodilating agent
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20030124513A1 (en) 2001-05-29 2003-07-03 Mcswiggen James Enzymatic nucleic acid treatment of diseases or conditions related to levels of HIV
WO2003070910A2 (en) * 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2003070969A2 (en) 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF BCL2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20050048529A1 (en) 2002-02-20 2005-03-03 Sirna Therapeutics, Inc. RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
US20040219671A1 (en) 2002-02-20 2004-11-04 Sirna Therapeutics, Inc. RNA interference mediated treatment of parkinson disease using short interfering nucleic acid (siNA)
US20050227935A1 (en) 2001-05-18 2005-10-13 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA)
WO2003072705A2 (en) 2002-02-20 2003-09-04 Sirna Therapeutics, Inc. Rna interference mediated inhibition of cyclin d1 gene expression using short interfering nucleic acid (sina)
US20050176025A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)
US20050239731A1 (en) 2001-05-18 2005-10-27 Sirna Therapeutics, Inc. RNA interference mediated inhibition of MAP kinase gene expression using short interfering nucleic acid (siNA)
US20050130181A1 (en) 2001-05-18 2005-06-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of wingless gene expression using short interfering nucleic acid (siNA)
CA2448320A1 (en) * 2001-05-29 2002-12-05 Sirna Therapeutics, Inc. Ribozyme based treatment of female reproductive diseases
US6746451B2 (en) * 2001-06-01 2004-06-08 Lance M. Middleton Tissue cavitation device and method
WO2003006424A1 (en) 2001-07-10 2003-01-23 4Sc Ag Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
US6589240B2 (en) * 2001-08-28 2003-07-08 Rex Medical, L.P. Tissue biopsy apparatus with collapsible cutter
US6734017B2 (en) * 2001-09-28 2004-05-11 Isis Pharmaceuticals, Inc. Antisense modulation of vascular endothelial growth factor receptor-2 expression
JP4917225B2 (ja) 2001-09-28 2012-04-18 ローム株式会社 半導体装置
WO2003035870A1 (de) 2001-10-26 2003-05-01 Ribopharma Ag Medikament zur behandlung eines pankreaskarzinoms
US7008431B2 (en) * 2001-10-30 2006-03-07 Depuy Spine, Inc. Configured and sized cannula
AU2002368202B2 (en) 2001-11-02 2008-06-05 Insert Therapeutics, Inc Methods and compositions for therapeutic use of RNA interference
US20040063654A1 (en) 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
FR2832154B1 (fr) 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
US6685706B2 (en) * 2001-11-19 2004-02-03 Triage Medical, Inc. Proximal anchors for bone fixation system
US20030186903A1 (en) 2001-11-23 2003-10-02 Isis Pharmaceuticals Inc. Antisense modulation of MyD88 expression
AU2002358631A1 (en) 2001-11-26 2003-06-10 Hybrigenics Protein-protein interactions in human immunodeficiency virus
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
GB0130955D0 (en) * 2001-12-24 2002-02-13 Cancer Res Ventures Expression system
ATE459388T1 (de) * 2001-12-26 2010-03-15 Univ Yale Gefäss-shuntvorrichtung
KR100441894B1 (ko) * 2002-01-26 2004-07-27 한국전자통신연구원 마이크로 집적형 근접장 광기록 헤드 및 이를 이용한광기록 장치
EP3415625A1 (de) 2002-02-01 2018-12-19 Life Technologies Corporation Doppelsträngige oligonukleotide
AU2003207708A1 (en) * 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
JP2005517433A (ja) * 2002-02-20 2005-06-16 サーナ・セラピューティクス・インコーポレイテッド 短干渉核酸（ｓｉＮＡ）を用いるＴＮＦおよびＴＮＦレセプタースーパーファミリー遺伝子発現のＲＮＡ干渉媒介性阻害
JP2005521393A (ja) 2002-03-20 2005-07-21 マサチューセッツ インスティテュート オブ テクノロジー Ｈｉｖ治療
AU2003224780A1 (en) 2002-03-29 2003-10-20 Yun Yen A human ribonucleotide reductase m2 subunit
US20030224512A1 (en) 2002-05-31 2003-12-04 Isis Pharmaceuticals Inc. Antisense modulation of beta-site APP-cleaving enzyme expression
AU2003237570A1 (en) 2002-05-13 2003-11-11 Salviac Limited Catheter system with procedural catheter and embolic proctection system
US20040101857A1 (en) 2002-11-23 2004-05-27 Isis Pharmaceuticals Inc. Modulation of cytokine-inducible kinase expression
AU2003239897A1 (en) 2002-05-23 2003-12-12 Ceptyr, Inc. Modulation of ptp1b signal transduction by rna interference
US20040102391A1 (en) 2002-11-21 2004-05-27 Isis Pharmaceuticals Inc. Modulation of Gankyrin expression
WO2003106974A2 (en) 2002-06-18 2003-12-24 Irm Llc Diagnosis and treatment of chemoresistant tumors
US7993351B2 (en) * 2002-07-24 2011-08-09 Pressure Products Medical Supplies, Inc. Telescopic introducer with a compound curvature for inducing alignment and method of using the same
US7148342B2 (en) * 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
US6906186B1 (en) 2002-07-30 2005-06-14 Isis Pharmaceuticals, Inc. Antisense modulation of polo-like kinase expression
US20040029275A1 (en) 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
WO2004027030A2 (en) 2002-09-18 2004-04-01 Isis Pharmaceuticals, Inc. Efficient reduction of target rna’s by single- and double-stranded oligomeric compounds
US7074226B2 (en) * 2002-09-19 2006-07-11 Sdgi Holdings, Inc. Oval dilator and retractor set and method
CA2500405A1 (en) 2002-09-30 2004-04-15 Oncotherapy Science, Inc. Genes and polypeptides relating to human myeloid leukemia
AU2003304386A1 (en) 2002-10-30 2005-02-25 The Center For Blood Research, Inc. Methods for treating and preventing apoptosis-related diseases using rna interfering agents
EP1562970A4 (de) 2002-11-01 2006-04-12 Univ Pennsylvania ZUSAMMENSETZUNGEN UND VERFAHREN ZUR siRNA-HEMMUNG VON HIF-1 ALPHA
ATE443764T1 (de) 2002-11-04 2009-10-15 Univ Massachusetts Allelspezifische rna-interferenz
US7612196B2 (en) 2002-11-14 2009-11-03 Dharmacon, Inc. siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
US7691998B2 (en) 2002-11-14 2010-04-06 Dharmacon, Inc. siRNA targeting nucleoporin 62kDa (Nup62)
US7592442B2 (en) 2002-11-14 2009-09-22 Dharmacon, Inc. siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)
US7582747B2 (en) 2002-11-14 2009-09-01 Dharmacon, Inc. siRNA targeting inner centromere protein antigens (INCENP)
US7951935B2 (en) 2002-11-14 2011-05-31 Dharmacon, Inc. siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US7977471B2 (en) 2002-11-14 2011-07-12 Dharmacon, Inc. siRNA targeting TNFα
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US7781575B2 (en) 2002-11-14 2010-08-24 Dharmacon, Inc. siRNA targeting tumor protein 53 (p53)
US7619081B2 (en) 2002-11-14 2009-11-17 Dharmacon, Inc. siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)
US7635770B2 (en) 2002-11-14 2009-12-22 Dharmacon, Inc. siRNA targeting protein kinase N-3 (PKN-3)
JP2006507841A (ja) 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ
WO2004046324A2 (en) 2002-11-15 2004-06-03 University Of Massachusetts Allele-targeted rna interference
US7790867B2 (en) 2002-12-05 2010-09-07 Rosetta Genomics Inc. Vaccinia virus-related nucleic acids and microRNA
WO2004052920A2 (en) 2002-12-12 2004-06-24 The Burnham Institute Conversion of apoptotic proteins
US20040248299A1 (en) * 2002-12-27 2004-12-09 Sumedha Jayasena RNA interference
US7166088B2 (en) * 2003-01-27 2007-01-23 Heuser Richard R Catheter introducer system
US20050266409A1 (en) * 2003-02-04 2005-12-01 Wyeth Compositions and methods for diagnosing, preventing, and treating cancers
FR2835838B1 (fr) * 2003-02-06 2007-11-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene codant pour un facteur de transcription
FR2835837B1 (fr) * 2003-02-06 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leurs utilisation pour reprimer specifiquement un gene codant pour un facteur de croissance
US7090680B2 (en) * 2003-02-12 2006-08-15 Bonati Alfred O Method for removing orthopaedic hardware
WO2004076639A2 (en) 2003-02-26 2004-09-10 Wyeth Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus
WO2004090105A2 (en) 2003-04-02 2004-10-21 Dharmacon, Inc. Modified polynucleotides for use in rna interference
WO2004094636A1 (en) 2003-04-24 2004-11-04 Galapagos Genomics N.V. Effective sirna knock-down constructs
US7399853B2 (en) 2003-04-28 2008-07-15 Isis Pharmaceuticals Modulation of glucagon receptor expression
EP2251039A3 (de) 2003-05-30 2010-12-08 Nippon Shinyaku Co., Ltd. Doppelsträngige Oligo-RNA zum Hemmen der Expression von BCL-2 und sie enthaltende pharmazeutische Zusammensetzung
US20070042979A1 (en) 2003-05-30 2007-02-22 Junichi Yano Oligonucleic acid-bearing composite and pharmaceutical composition containing the composite
AU2004252442B2 (en) 2003-06-02 2010-04-08 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of FNAi
US7750144B2 (en) 2003-06-02 2010-07-06 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of RNA silencing
ES2712695T3 (es) 2003-06-02 2019-05-14 Univ Massachusetts Métodos y composiciones para controlar la eficacia de la silenciación del ARN
WO2005014782A2 (en) 2003-06-13 2005-02-17 Alnylam Europe Ag., Double-stranded ribonucleic acid with increased effectiveness in an organism
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
DE10341333B4 (de) * 2003-09-08 2006-06-08 Siemens Ag Piezoaktor und Verfahren zum Herstellen eines Piezoaktors
KR100568246B1 (ko) * 2003-11-19 2006-04-05 삼성전자주식회사 컴퓨터 시스템 및 그 제어방법
US20050176045A1 (en) 2004-02-06 2005-08-11 Dharmacon, Inc. SNP discriminatory siRNA
ES2423060T3 (es) 2004-03-12 2013-09-17 Alnylam Pharmaceuticals, Inc. Agentes iRNA que tienen como diana al VEGF
KR101147147B1 (ko) 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
WO2005105157A2 (en) 2004-04-23 2005-11-10 The Trustees Of Columbia University In The City Ofnew York INHIBITION OF HAIRLESS PROTEIN mRNA
EP1750775A2 (de) 2004-05-04 2007-02-14 Nastech Pharmaceutical Company Inc. Zusammensetzungen und verfahren zur effizienteren abgabe von nukleinsäuren in zellen und zur änderung der zielgenexpression in zellen
EP1752536A4 (de) 2004-05-11 2008-04-16 Alphagen Co Ltd Rna-störung verursachendes polynukleotid sowie verfahren zur regulation der genexpression unter verwendung davon
US7605250B2 (en) 2004-05-12 2009-10-20 Dharmacon, Inc. siRNA targeting cAMP-specific phosphodiesterase 4D
JP2006013252A (ja) * 2004-06-28 2006-01-12 Hitachi Cable Ltd レーザダイオードの制御方法、制御回路、および光送信器
AU2005288522B2 (en) 2004-09-28 2012-06-28 Quark Pharmaceuticals, Inc. Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
US20060134189A1 (en) 2004-11-17 2006-06-22 Protiva Biotherapeutics, Inc siRNA silencing of apolipoprotein B
MX2007012766A (es) 2005-04-12 2008-10-01 Intradigm Corp Composición y métodos de terapéuticos de arni para el tratamiento de cáncer y otras enfermedades de neovascularización.
US20060286575A1 (en) 2005-04-16 2006-12-21 Cylene Pharmaceuticals, Inc. MCL-1 quadruplex nucleic acids and uses thereof
US7825099B2 (en) 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
US7910566B2 (en) 2006-03-09 2011-03-22 Quark Pharmaceuticals Inc. Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
CA2650416A1 (en) 2006-05-19 2007-11-29 Alcon Research, Ltd. Rnai-mediated inhibition of tumor necrosis factor .alpha.-related conditions
US8523707B2 (en) * 2006-05-31 2013-09-03 Bridgestone Sports Co., Ltd. Multi-piece solid golf ball
US8138160B2 (en) 2006-08-03 2012-03-20 Warsaw Orthopedic, Inc. Reagents, methods and systems to suppress pro-inflammatory cytokines
CN101640467B (zh) 2008-07-28 2012-05-30 鸿富锦精密工业（深圳）有限公司 弹片及音圈马达

Also Published As

Publication number Publication date
US20090082556A1 (en) 2009-03-26
US20080091003A1 (en) 2008-04-17
EP2305812A2 (de) 2011-04-06
EP1560931B1 (de) 2011-07-27
US20100331214A1 (en) 2010-12-30
JP2010187668A (ja) 2010-09-02
US8008474B2 (en) 2011-08-30
US8093370B2 (en) 2012-01-10
US7745611B2 (en) 2010-06-29
EP1560931A2 (de) 2005-08-10
US20050255487A1 (en) 2005-11-17
US7514550B2 (en) 2009-04-07
US20190345573A1 (en) 2019-11-14
US20080300395A1 (en) 2008-12-04
EP2305812A3 (de) 2012-06-06
US20090149644A1 (en) 2009-06-11
US20100075869A1 (en) 2010-03-25
EP2284266A3 (de) 2012-01-25
US7691997B2 (en) 2010-04-06
US7834170B2 (en) 2010-11-16
US20080139798A1 (en) 2008-06-12
US20070093653A1 (en) 2007-04-26
AU2003295600A1 (en) 2004-06-15
US20090203895A1 (en) 2009-08-13
US20090163701A1 (en) 2009-06-25
US7507811B2 (en) 2009-03-24
DK2284266T3 (da) 2014-01-13
EP2305813A3 (de) 2012-03-28
US20050256525A1 (en) 2005-11-17
US20080188647A1 (en) 2008-08-07
US20070031844A1 (en) 2007-02-08
US7579457B2 (en) 2009-08-25
US20080293595A1 (en) 2008-11-27
US20070072823A1 (en) 2007-03-29
EP2213738A3 (de) 2010-11-17
US20080293593A1 (en) 2008-11-27
US20100323922A1 (en) 2010-12-23
EP2284266B1 (de) 2013-11-06
EP2305813A2 (de) 2011-04-06
AU2003295600A8 (en) 2004-06-15
WO2004045543A3 (en) 2005-04-21
US20100087335A1 (en) 2010-04-08
US20070039072A1 (en) 2007-02-15
US7655788B2 (en) 2010-02-02
US20080221317A1 (en) 2008-09-11
PT2284266E (pt) 2013-12-17
US7893247B2 (en) 2011-02-22
US20100004142A1 (en) 2010-01-07
US20080114162A1 (en) 2008-05-15
EP2314691A2 (de) 2011-04-27
US20070088154A1 (en) 2007-04-19
US20050246794A1 (en) 2005-11-03
US7511132B2 (en) 2009-03-31
US20110111983A1 (en) 2011-05-12
ES2440284T3 (es) 2014-01-28
US20080108803A1 (en) 2008-05-08
US20080091004A1 (en) 2008-04-17
US7592444B2 (en) 2009-09-22
US20050245475A1 (en) 2005-11-03
US7820809B2 (en) 2010-10-26
US7576197B2 (en) 2009-08-18
EP2213738A2 (de) 2010-08-04
US7642349B2 (en) 2010-01-05
US7696344B2 (en) 2010-04-13
EP2213738B1 (de) 2012-10-10
US20100029510A1 (en) 2010-02-04
US20070088153A1 (en) 2007-04-19
US20070099862A1 (en) 2007-05-03
US20080108802A1 (en) 2008-05-08
US20080097090A1 (en) 2008-04-24
US20070141611A1 (en) 2007-06-21
US20120052487A9 (en) 2012-03-01
US20090163702A1 (en) 2009-06-25
US20080091002A1 (en) 2008-04-17
US8000902B2 (en) 2011-08-16
EP2278005A3 (de) 2012-05-23
US20100152064A1 (en) 2010-06-17
US7608707B2 (en) 2009-10-27
US20080188648A1 (en) 2008-08-07
WO2004045543A2 (en) 2004-06-03
EP2314691A3 (de) 2012-01-18
US8090542B2 (en) 2012-01-03
US20100267586A1 (en) 2010-10-21
US7595389B2 (en) 2009-09-29
US20080091001A1 (en) 2008-04-17
EP2278005A2 (de) 2011-01-26
US7645869B2 (en) 2010-01-12
US20120135892A1 (en) 2012-05-31
US8030474B2 (en) 2011-10-04
EP2284266A2 (de) 2011-02-16
US20070088152A1 (en) 2007-04-19
JP2006507841A (ja) 2006-03-09
US20100291681A1 (en) 2010-11-18
US20090088563A1 (en) 2009-04-02
US7807819B2 (en) 2010-10-05
US20070088155A1 (en) 2007-04-19
US7674896B2 (en) 2010-03-09
US7803933B2 (en) 2010-09-28
US20090291497A1 (en) 2009-11-26
US7795420B2 (en) 2010-09-14
US20110319474A1 (en) 2011-12-29
US7576196B2 (en) 2009-08-18
US20090298176A1 (en) 2009-12-03
US20070207974A1 (en) 2007-09-06
US20080306015A1 (en) 2008-12-11
EP1560931A4 (de) 2006-08-02
US7985854B2 (en) 2011-07-26

Similar Documents

Publication Publication Date Title
AU2003295600A8 (en) Functional and hyperfunctional sirna
WO2006006948A3 (en) METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
ATE539170T1 (de) Abschätzung und verringerung des risikos von graft-versus-host-reaktion
WO2004058940A3 (en) Sirna-mediated gene silencing
ATE544774T1 (de) Rnai-modulation von mll-af4 und verwendungen dafür
DE602005015994D1 (de) siRNA-VERMITTELTES GEN-SILENCING VON ALPHA-SYNUKLEIN
ATE330038T1 (de) Nukleinsäure-biosensor
NO20054079D0 (no) Hydrokarbongassprosess.
DK1399590T3 (da) Happier kortlægning
WO2006083800A3 (en) Nucleic acid silencing of huntington's disease gene
WO2004065613A3 (en) Inducible small interfering rna (sirna) expression constructs for targeted gene silencing
NO20082783L (no) Induserbare ekspresjonssystemer
CY1111151T1 (el) Αναστολεις φωσφολιπασης α2 του κυτταροδιαλυματος
DE602004021836D1 (de) Meg1-endospermspezifische promotoren und gene
ATE506436T1 (de) Auf trans-splicing basierende amplifikationsvectoren
DE602008006254D1 (de) Doppel-oligonukleotid-nukleinsäurenachweisverfahren
CY1116649T1 (el) Τεχνητη dna αλληλουχια με βελτιστοποιημενη λειτουργια οδηγου σε 5' (5-utr) για βελτιωμενη εκφραση ετερολογων πρωτεϊνων σε φυτα
ITMO20030081A0 (it) Bioreattore,particolarmente per organi bioartificiali.
ATE460667T1 (de) Mikroarray-vorrichtungen mit steuerbarem reaktionsvolumen
ATE428783T1 (de) Expressionssystem für sirna
MXPA05005120A (es) Secuencias de adn de la region genomica tcd de photorhabdus luminescens.
DE60333101D1 (de) Ierten organismen
DE602006010187D1 (de) Einzelsequenzhybridisierungssonden
ATE382062T1 (de) Antikörper gegen allgegenwärtige mitochondriale kreatinkinase und dessen verwendung
ATE426046T1 (de) Stoffliche nutzung von biogas

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties